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General introduction
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Infection and inflammation throughout history
The immune system is our main line of defense against pathogens. Throughout history, the human 
race has been challenged by infectious diseases. Approximately 4000 years ago, the ancient 
Egyptians already postulated the principle of -in essence- infection from the gut.1 It were the 
Greek who first used the term ‘sepsis’ in the Hippocratic books, mainly translated now as the 
process of putrification or rotting of the flesh and, in that time, mainly attributed to a poisonous 
substance.2 The spread of disease by either miasma (bad air) or contagion (derived from the Latin 
term ‘contigere’ which means ‘to touch’) was the subject of debate for scientists in the centuries 
thereafter.2 The Romans developed theories about the transmission of infections, recognizing 
the dangers of swamps and the breading of mosquitos. The postulation of the idea that animals, 
too small to see for the human eye, could cause ‘difficult diseases’ was already born in the time 
of Julius Caesar.1,2 The invention of the microscope in the late 16th century and the first glance 
at bacteria and other microorganisms by Antonie van Leeuwenhoek was the start of a new era 
in scientific research and medicine.1 In the 19th century, Louis Pasteur finally proved the theory 
that infectious diseases were in fact spread by microbes and this initiated the discovery of 
sterilization, vaccination, the importance of hygiene in medical treatments and finally, antibiotics 
which remain the cornerstone of treatment of the septic patient today.2–4 However, the under-
standing of the complex responses of the human body to an infection remains incomplete to 
this date. Furthermore, it was recognized that the immune response is not only the hallmark of 
our defense against pathogens but that (chronic) inflammation is at the basis of main causes of 
death in the present time such as atherosclerosis and cancer.5,6
Sepsis
Sepsis, defined as the systemic response after an infection, is considered a major challenge for 
today’s intensive care physicians. Despite advances in treatment in recent years, it remains a 
major health care burden with an estimated worldwide incidence of 19 million patients a year.7 
Furthermore, approximately a third of all intensive care unit (ICU) patients suffer from an epi-
sode of sepsis either at admission or during their ICU stay and its presence is associated with 
an increased risk of mortality.8,9 Infection of the respiratory tract is the most common cause 
and in recent years, incidence of Gram-positive microorganisms has been rising to an approx-
imately equal share compared to Gram-negatives in 2006.8 After reaching a case definition in 
199210 and after implementation of the surviving sepsis campaign as well as other improvements 
in intensive care treatment, mortality rates have been declining over the years and are now 
approximately 25-35%, but still around 40-50% if shock is present, while great variations exist 
between different regions of the world.8,9 The pathogenesis of this complex clinical syndrome is 
still not fully understood. Excessive inflammation, production of reactive oxygen species (ROS) 
and vascular injury are considered main contributors to organ dysfunction and responsible for 
the poor outcome of sepsis patients.11 However, next to the damage caused by an overwhelm-
ing pro-inflammatory response, we have come to realize that the concomitant mounting of 
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an anti-inflammatory response, leading to an immunosuppressive state after the initial insult, 
might be of great importance and could also be a target for novel therapeutic measures.3,12,13 It 
must be acknowledged that, since the beginning of the 1980s, over 60 clinical trials have been 
performed in sepsis patients using a wide range of substances targeting mainly to dampen the 
pro-inflammatory response in general, or to inhibit specific substances such as endotoxin, the 
Toll-like receptor 4, specific cytokines, the coagulation cascade, etc. Disappointingly, besides 
still debated results on steroids, none have reached broad clinical application due to a lack of 
effect.14 Next to methodological concerns that can be raised regarding these studies, it is most 
likely that the search for a ‘magic bullet’ for this very complex immunological syndrome is not 
going to be successful and that a much more tailored approach will be necessary in the future 
to benefit the sepsis patient.
Sepsis research: animal models for inflammatory disorders
The very disappointing results of pharmacological interventions in sepsis patients were almost 
unanimously preceded by studies demonstrating beneficial effects in preclinical models. This 
illustrates the lack of a good research model for sepsis.14 In in vitro experiments, whole blood 
or isolated cells are stimulated with various substances such as cytokines or lipopolysaccharide 
(LPS) while in vivo animal models frequently utilize the infusion of endotoxin (i.e. LPS) or the 
ligation and puncture of the coecum (CLP) creating bacterial peritonitis. One of the possible 
explanations for the lack of positive studies in sepsis patients is the fact that these models only 
mimic a limited part of the body’s response to an infection and that the immune response in 
animals differs greatly from the human response. For instance, in mice, a dose of 1-25 mg/kg of 
endotoxin is considered lethal while in humans, a dose that is 1.000 to 10.000 times smaller can 
already cause signs of septic shock.14–17 Second, the temporal response differs greatly between 
humans and rodents. Correlations were sought between the genomic response of the immune 
system for different models and in human disease. Interestingly, mice models did not correlate 
with their human disease counterparts.17 Even more so, the immunologic response in humans 
after endotoxin did not correlate with the rodent response after endotoxin. Interestingly, the 
human genomic response to trauma, sepsis, ARDS and burns demonstrated higher levels of 
similarity and correlations with the human experimental endotoxemia model (in which bacte-
rial endotoxin is infused to healthy volunteers).17 Finally, the animal experiments performed are 
usually performed in young, healthy animals raised under highly controlled conditions. Usually, 
the treatment under investigation is given prior to, or at the same time as the inflammatory 
stimulus used. 
Naturally, this approach will be impossible to achieve in most patient categories where the 
infection is unexpected. Here, activation of the immune system already occurs well before 
patients even reach the hospital, so we are always one (or more) steps behind compared to 
these animal experiments. Furthermore, the comorbid diseases of our patients will naturally 
also influence outcome.
Chapter 1
14
Human experimental endotoxemia
In the early 1900s, doctors started to consider fever as a possible therapeutic measure in infec-
tious diseases. In 1942, endotoxin (or lipopolysaccharide/LPS) was first isolated as a compound 
of Salmonella and the first humans were infused with a low dose. The rise of antibiotics in the 
following years replaced the role of endotoxin as a therapeutic measure, but its role in the 
research of the immune response has been established ever since.18
Today, infusion of healthy volunteers with a low dose (usually 2 or 4 ng/kg) of Escherichia coli LPS 
is used as a model for acute systemic inflammatory states. As a stimulator of Toll-like receptor 
4, endotoxin evokes a well predictable immune response and flu-like syndrome with fever, chills, 
headache and hemodynamic changes, such as a (modest) increase in heart rate and decrease in 
blood pressure. However, the response is short-lived with most cytokines only elevated for 2-4 
hours and symptoms resolving within 4-6 hours after administration. Temperature and hemo-
dynamic changes return to baseline values within approximately 8-12 hours.19 No long-term 
sequelae have been observed after human experimental endotoxemia while it has been applied 
in thousands of subjects over the last 30 years. The innate immune response is characterized by 
an increase of pivotal cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-6 and 
IL-10 as well as transient leukopenia (due to sequestration) followed by leukocytosis and an 
increase in C-reactive protein. Furthermore, endothelial dysfunction and a decreased vascular 
sensitivity to the vasopressor noradrenaline occur after endotoxin infusion.20,21 The model mimics 
the early innate immune response after an infection, but is also correlated to the response in 
trauma and burns patients.17,19 The great advantage is the fact that it provides a safe manner to 
elicit a controlled and reproducible inflammatory response in humans and therefore creates 
possibilities to test pharmacological interventions for proof of principle purposes. However, the 
differences between the very complex immune response in sepsis patients and human experi-
mental endotoxemia must be considered in the interpretation of the data.
Heme oxygenase: an introduction to a potential therapeutic target for inflammatory disorders
Heme (iron protoporphyrin IX) is an omnipresent molecule that is crucial for oxygen transport, 
oxygen delivery and cell signaling and therefore the survival of all aerobic cells.22,23 Although 
of great importance in the human body, free heme also carries toxic effects when present in 
excess concentrations. If released, in for instance hemolysis or during blood transfusion, heme can 
amplify oxidative stress and inflammation by catalyzing the formation of ROS, such as oxidized 
LDL and therefore activate endothelial cells and increase vascular permeability and leukocyte 
infiltration.24–27 Therefore, tight regulation of the free heme concentration is of utmost impor-
tance to maintain homeostasis. 
Heme oxygenase (HO) is the rate limiting enzyme in the catabolism of heme. First described in 
1968, HO cleaves heme to form Fe2+, biliverdin and carbon monoxide (CO).28 (Figure 1) The 
end-product biliverdin is then converted to bilirubin by biliverdin reductase and the potentially 
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toxic free iron is sequestered to ferritin. (Figure 1) Not only does HO contribute to the reduction 
of oxidative stress by the scavenging of free heme, the enzyme itself carries immunomodulatory 
effects and the bilirubin produced is considered to be one of the most powerful endogenous 
anti-oxidants of the human body.23,29 Furthermore, CO has clear vasoactive and anti-inflamma-
tory effects.23 This makes HO a promising target to prevent inflammation-induced tissue damage 
considered crucial in the development of several diseases, both chronic inflammation as observed 
in diabetes and atherosclerosis, and acute inflammation, such as observed during sepsis.11,30,31
Figure 1: The heme oxygenase pathway.
Heme is cleaved by heme oxygenase-1 (HO-1) to form Fe2+, biliverdin and carbon monoxide (CO). Biliverdin 
reductase (BVR) then converts biliverdin to bilirubin. As depicted, HO-1 is upregulated by different substances 
such as hypoxia35, cytokines32,33, hyperoxia36, nitric oxide (NO)34, reactive oxygen species (ROS)38, LPS48–51 and 
ischemia/reperfusion37.
To date, 2 functional isoforms of HO have been identified of which HO-1 is highly inducible under 
various circumstances relevant to different patients, such as hypoxia and hyperoxia, cytokine or 
endotoxin exposure, oxidative stress and ischemia/reperfusion injury.32–38 As mentioned, both 
oxidative stress and inflammation are considered to contribute to the poor outcome of sepsis 
patients11 and indeed, in animal models for sepsis, beneficial effects of HO-1 upregulation have 
been demonstrated. When rodents are subjected to otherwise lethal doses of endotoxin or to 
CLP, their survival is dramatically improved after upregulation of HO-1,39–41 an effect that is also 
observed if end-molecules CO or biliverdin/bilirubin are administered.40–45 The importance of 
HO-1 is further illustrated by a clinical case of HO-1 deficiency. A case report of a boy who 
died at the age of six describes the signs of generalized inflammation, vascular endothelial injury, 
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intravascular hemolysis and coagulation abnormalities in the absence of HO-1.46,47 Although of 
interest for human inflammatory disorders, intervention studies targeting HO-1 in humans are 
currently lacking.
Targeting HO and its end products in humans
Several possible agents are candidates for use as a pharmacological intervention in humans. 
Heme arginate, clinically applied in porphyria patients52, serves as a source of heme and therefore 
makes a logical candidate for application. However, one must consider the increase in oxidative 
stress associated with heme infusion. Many agents applied in preclinical studies are currently not 
approved for use in humans and/or lack selectivity for HO-1 induction. Inhibition of the HO-1 
system has been studied in humans. In adults and neonates suffering from hyperbilirubinemia 
tin proto- or mesophorphyrin was applied in clinical studies and proven effective in lowering 
bilirubin concentrations. However, side effects such as photo sensibility hampers its use in clinical 
practice. Furthermore, they lack HO-1 isoform selectivity.53,54
The application of HO-1s end products is another possibility for targeting this enzyme system. 
The administration of the anti-oxidant bilirubin has been applied in the past as a liver function 
test where bilirubin clearance served as a measure for function.55 Interestingly, an ancient report 
by Thompson et al. even suggests the anti-inflammatory effects of the molecule in rheumatoid 
arthritis patients.56 As mentioned, beneficial effects of bilirubin/biliverdin administration have 
been demonstrated in rodent models of sepsis.43–45 Besides its powerful anti-oxidant effects, an 
effect on downregulating TLR-4 has also been postulated illustrating its potential as a target for 
inflammation.57 However, bilirubin for infusion to humans is currently unavailable.
Although CO is available for human inhalation, the risk of CO intoxication must be considered 
since symptoms are not fully depended on the concentrations reached in the blood.58 Interest-
ingly, a human experimental endotoxemia study demonstrated that a low dose CO inhalation 
does not modulate the inflammatory response in humans.59 Furthermore, CO releasing mol-
ecules (CORMs) are used for infusion in animal experiments and could possibly be of interest 
given the fact that they can release CO more directly to the tissue , however none have been 
approved for human use as yet.23 
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outline of this thesis
This thesis is divided in four parts.
Part I consists of four studies addressing methodological issues regarding the human experimental 
endotoxemia model. In chapter 2 the effects of iso-osmolar fluid administration prior to endo-
toxin infusion in healthy volunteers are described with a focus on pro- and anti-inflammatory 
cytokines. The differences between males and females concerning the inflammatory and vascular 
response after endotoxin exposure are demonstrated in chapter 3. Chapter 4 describes the 
influence of body mass index on the inflammatory response during human experimental endo-
toxemia. Lastly, in chapter 5, an analysis of the correlation of in vitro and in vivo cytokine release 
after stimulation with endotoxin is presented.
In part II the regulation of HO-1 in humans and in particular during endotoxemia is elucidated 
(chapter 6). We investigated the response of murine and human myeloid cells on endotoxin 
as well as the response to endotoxin in vivo related to HO-1 mRNA and protein expression. 
Furthermore, we investigated the regulatory mechanism behind discrepancies found between 
species. The effects of heme arginate as a possible inducer of HO-1 in humans suffering from 
metabolic syndrome are described in chapter 7. Here, the main outcome parameters included 
endothelial function and insulin sensitivity.
Part III focuses on the effects of HO-1 end products bilirubin and CO. In chapter 8 and 9, the 
effects of an increased bilirubin concentration evoked by the HIV inhibitor atazanavir are inves-
tigated in the human experimental endotoxemia model as well as diabetes patients focusing on 
inflammation and endothelial dysfunction. In chapter 10, the reintroduction of bilirubin for human 
administration is described with specific emphasis on safety as well as pharmacokinetic aspects.
Chapter 11 constitutes a letter to the editor in which the response of CO after endotoxin 
administration to humans is presented. In chapter 12, the effects of the common ‘Gilbert-syn-
drome’, in which bilirubin levels are mildly elevated, are investigated in pneumosepsis patients in 
relationship to pneumonia susceptibility, disease severity, organ dysfunction and mortality.
The thesis is concluded in part IV and chapter 13 which includes a summary, general discussion 
and future perspectives and chapter 14 which includes a translation in Dutch.
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abstract
Clinical experience suggests that the administration of fluids in human endotoxemia reduces 
symptoms. In the present study the effects of a standardised fluid protocol on symptoms, 
inflammatory and hemodynamic parameters in human endotoxemia are determined. With 
approval of the local ethics committee, 16 healthy volunteers received 2 ng/kg of E. coli 
endotoxin (O:113). After an overnight fast, nine subjects received 1.5 L 2.5% glucose/0.45% 
saline the hour prior to the endotoxin administration and 150 mL/hr during the course of 
the experiment (‘prehydrated group’). Seven subjects only received a continuous infusion 
of 75 mL/hr during the experiment (‘non-prehydrated group’). The course of inflammatory 
parameters and symptoms were determined and mean arterial pressure, heart rate and 
forearm blood flow were measured. 
In the prehydrated group, tumor necrosis factor (TNF)-α increased to 522 ± 63 pg/mL 
(mean ± SEM) while the maximum in the non-prehydrated group was 927 ± 187 pg/mL 
(p<0.04). Interleukin (IL)-10 increased similarly in both groups (non-prehydrated 117 ± 18 
and prehydrated 99 ± 18 pg/mL, p=NS). The prehydrated group had a significantly lower 
(p<0.004) symptom score and recovered sooner (p=0.004). Endotoxin-induced changes 
in hemodynamics revealed no significant differences between groups. 
We demonstrate that prehydration in experimental human endotoxemia significantly shifts 
the cytokine balance towards a more anti-inflammatory pattern. This effect is associated 
with a reduction in symptoms, whereas the changes in hemodynamic parameters are not 
influenced by prehydration.
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introduction 
Endotoxin administration to both animals and humans is a widely used model to investigate the 
pathophysiological characteristics of sepsis. Animal experiments indicate that the inflammatory 
response to endotoxin is affected by hydration status. Experiments in rats have demonstrated 
that in a state of dehydration, endotoxin-induced fever is significantly higher, an effect that can 
be eradicated by the administration of a dose of sterilized water prior to the endotoxin.1 Both 
volume and osmolarity may play a role in the modulation of the immune system. In sepsis as well 
as in trauma patients the infusion of hypertonic solutions is an accepted method for fast volume 
resuscitation that also exerts immunomodulatory effects.2,3 Interestingly, the administration of 
iso-osmolar fluids in human endotoxemia is widely applied since the clinical impression of expe-
rienced investigators suggests that it reduces endotoxin-induced symptoms. This observation may 
indicate that besides the known immunomodulatory effects of hypertonic solutions, iso-osmolar 
fluids also exert an effect on the inflammatory response. However, the immunomodulatory 
effects of iso-osmolar solutions in humans have not been studied.
In the present study the effects of iso-osmolar prehydration on the inflammatory, clinical and 
hemodynamic response in human endotoxemia are determined. 
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methods
Subjects
After approval from the local ethics committee, 16 non-smoking subjects (8 females, 8 males) 
gave written informed consent to participate in these experiments. Subjects who were taking 
prescription drugs (except for oral contraceptives), aspirin or other non-steroid anti-inflamma-
tory drugs were excluded. Screening of the subjects within 14 days prior to the test revealed 
no abnormalities in medical history and physical examination. Routine laboratory tests and 
ECG were normal. All subjects tested HIV and Hepatitis B negative. They did not have a febrile 
illness in the 2 weeks preceding the study. Ten hours prior to the experiment, subjects refrained 
from caffeine, alcohol and food. The experiments were conducted as part of a vascular research 
investigation in which a local pharmacological intervention took place a t=4 hours (h) after 
endotoxin administration. The subjects of the non-prehydrated group were part of a previously 
published study.4
Study design and procedures
All subjects received a 20 gauge arterial catheter (Angiomat, Deseret Medical, Becton Dickinson, 
Sandy UT, U.S.A.) connected to an arterial pressure monitoring line (Viggo Spectramed, 5269-129 
connected to a Siemens S9000 monitor). This enabled continuous blood pressure monitoring 
as well as blood sampling. Mean arterial pressure (MAP) was determined by the electronically 
integrated area under the arterial pulse wave curve. Heart rate was continuously monitored 
using a 3-lead ECG. Both heart rate and blood pressure monitoring started at approximately 
two hours before endotoxin administration and continued until the end of the experiment. A 
canulla was placed in an antecubital vein to permit the infusion of glucose/saline solution and 
endotoxin administration. Forearm blood flow (FBF) was measured in both forearms using 
venous occlusion plethysmography as previously described (Filtrass Domed, Munich, Germany).5,6 
The endotoxin-induced temperature changes were determined every 30 minutes for the first 
8 h after endotoxin administration using an infrared tympanic thermometer (Sherwood Medi-
cal,’s-Hertogenbosch, the Netherlands).
At t=0 h, all subjects received a dose of purified lipopolysaccharide prepared from E. coli (O:113, 
2 ng/kg). The endotoxin was injected intravenously in 1 minute, followed by 5 mL of normal saline 
to ensure complete delivery. To monitor onset and alterations of endotoxin-induced symptoms, 
subjects were asked to score the severity of nausea, headache, shivering, muscle and back pain 
every 30 minutes until 8 hours after the endotoxin was administrated. Symptoms were scored on 
a scale ranging from 0, (symptom not present) to 5 (worst ever experienced) and these scores 
were added up to form a “total symptom score”. The duration of symtoms was determined by 
assesing at which time point the total symptom score returned to baseline.
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Laboratory tests
All blood tests were performed on blood samples taken from the arterial line. Blood samples 
were taken at various times during the test in order to determine the time course and the peak 
values per individual. Leukocyte and CRP values were measured before endotoxin administration 
and at 1 h, 6, 12 and 22 h after endotoxin. Leukocyte levels were determined in EDTA plasma 
using flow-cytometry (Sysmex XE-2100, Goffin Meyvis, Etten Leur, the Netherlands). CRP was 
measured in Lithium Heparin plasma using immunologic detection according to the instructions 
of the manufacturer (Aeroset, Abbott Laboratories, Abbot Park, IL, U.S.A.). 
To determine the concentration of the various cytokines, EDTA plasma was processed immedi-
ately by centrifugation at 2000g at 4˚C for 15 minutes and was stored at –80 ˚ C before analyses. 
Concentrations of tumor necrosis factor (TNF)-α, (interleukin)IL-1β, IL-6, IL-8 and IL-10 were 
determined in samples taken at baseline and 15, 30, 60 and 90 minutes and 2, 3, 4, 6, 8, and 22h 
after endotoxin was administrated using simultaneous Luminex Assay.7 
Protocol 1: The non-prehydrated group 
Seven subjects (four females, three males) received a continuous infusion of 75 mL/hour of 2.5% 
glucose/0.45% saline solution. Infusion started directly after cannulation (approximately two hours 
before endotoxin administration). Total volume infused before endotoxin was administrated 
therefore was 150 mL per subject. Infusion was continued until the next morning (22h after the 
administration of endotoxin, t=22h).
Protocol 2: The prehydrated group
In nine subjects (four females, five males) 2.5% glucose/0.45% saline solution was administered 
at an infusion rate of 150 mL/hour starting directly after cannulation and continued until t=6 
h. In the hour prior to the endotoxin administration an extra 1,5 L 2.5% glucose/0.45% saline 
solution was administered. Therefore, total volume infused before endotoxin administration was 
1800 mL per subject. After t=6 h the infusion rate was decreased to 75 mL/hour until the end 
of the experiment.
Drugs and Solutions
All solutions were freshly prepared on the day of the experiment. Endotoxin (US Standard 
Reference Endotoxin E. coli O:113 retrieved from United States Pharmacopia Convention, 
Rockville, MD) was dissolved in normal saline 0.9% to a concentration of 200 EU/mL, of which 
0.1 mL/kg was administrated. 
Chapter 2
30
Data analysis, Calculations and Statistics
The MAP and heart rate were sampled every five minutes throughout the experiments. To 
determine the effect of the endotoxin, the group average of the 30 minutes before the admin-
istration of the prehydration and the group average of 30 minutes at the time where endotoxin 
induced effects were most dominant, are expressed. To asses changes in FBF the flow of both 
forearms was averaged and expressed as absolute values and percentage change from baseline. 
All of the expressed peak values/concentrations are the group average of the highest value/
concentration per subject, unless otherwise stated.
Unpaired Student’s t-tests or ANOVA with repeated measures were used to compare the 
differences between the prehydrated and the non-prehydrated group, as appropriate. To deter-
mine changes over time (endotoxin induced effects) the paired Student’s t-test was used. The 
Mann-Whitney U test was used to compare peak levels of IL-1β, because of the non-parametric 
distribution as a consequence of the lower detection limits. All data are expressed as mean ± 
SEM unless otherwise stated. P<0.05 was considered statistically significant. 
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results
There were no significant differences in demographic characteristics between both groups. 
Characteristics are shown in Table 1.
Table 1: Demographic characteristics of the subjects
Non-prehydrated group Prehydrated group
N; m:f 7;3:4 9;5:4
Age (yrs) 23.9 ± 3.1 22.2 ± 1.7
Height (cm) 175 ± 14 175 ± 9
Weight (kg) 69.9 ± 13.7 71.3 ± 9.1 
BMI (kg/m2) 22.5 ± 1.8 23.2 ± 2.0
MAP (mmHg) 96 ± 6 91 ± 10
HR (bpm) 64 ± 10 61 ± 10
FAV (mL) 993 ± 281 1061 ± 216
Data are expressed as mean ± SD. N number of subjects, m male, f female; BMI body mass index; MAP mean 
arterial blood pressure, measured with i.a. pressure monitoring line, averaged for a half hour; HR heart rate, 
measured with 3 lead ECG averaged for a half hour; FAV forearm volume, measured with water displacement 
method. There were no significant differences between groups.
Inflammatory parameters
Baseline leukocyte values did not differ between the two groups (4.9 ± 0.2 vs 5.0 ± 0.4 ×109/L). 
Figure 1A demonstrates a drop in leukocyte count (due to sequestration) after which an endo-
toxin-induced leukocytosis is observed. 
ANOVA repeated measures did not demonstrate significant differences between the two groups. 
However, the peak leukocyte count was significantly lower in the prehydrated group, reaching 
a peak value of 12.7 ± 0.7 ×109/L compared to a peak of 15.8 ± 1.1 ×109/L (p<0.05) in the 
non-prehydrated group, all peak values were reached between 6 and 12 hours. 
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As illustrated in Figure 1B, CRP values started to increase approximately 6 hrs after endotoxin 
administration and reached maximum values at t=22 h. The peak CRP in the prehydrated group 
averaged 29 ± 4 mg/L. Although the rise in CRP in the non-prehydrated group tended to be 
higher (average of 39 ± 5 mg/L at t=22 h), this difference did not reach statistical significance 
(difference between peak values: p=0.14).
Figure 1: Leukocyte count and CRP in human endotoxemia with and without prehydration.
Effects of 2 ng/kg endotoxin (administered at t=0 h.) in the non-prehydrated group (○) and the prehydrated 
group (●) on leukocyte count (A) and CRP (B) over time. In both groups, endotoxin administration induced an 
increase in both leukocyte count and CRP. ANOVA repeated measures demonstrated no significant differences 
between the prehydrated and non-prehydrated group neither for leukocyte count nor for CRP. Data are 
expressed as mean ± SEM.
At baseline, cytokine levels did not differ between the prehydrated and the non-prehydrated 
group. After endotoxin administration, TNF-α increased to an average peak value of 522 ± 63 
pg/mL at t=90 min in the prehydrated group compared to 927 ± 187 pg/mL between 90 and 
120 minutes in the non-prehydrated group (p<0.04, ANOVA repeated measures: p=0.046) 
(Figure 2A). 
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In the prehydrated group IL-1β stayed below the level of detection (8 pg/mL) during the 
entire experiment whereas IL-1β concentrations in the non-prehydrated group demonstrated 
an increase from below the level of detection to an average peak value of 25.6 ± 1.9 pg/mL 
between 2 and 4 h after endotoxin administration (Figure 3A, p<0.001, ANOVA repeated 
measures: p=0.018). In addition, the concentrations of the pro-inflammatory cytokines IL-6 and 
IL-8 demonstrated an endotoxin-induced rise, in the group receiving prehydration this rise in 
cytokine-concentrations was almost halved (Figure 3B/C). 
In contrast to the pro-inflammatory cytokines, IL-10 concentrations showed a trend towards 
higher values in the prehydrated group, however differences were not significant. (prehydrated 
group 117 ± 18 pg/mL versus non-prehydrated group 99 ± 18 pg/mL, all peak times recorded 
between 2 and h after endotoxin administration, p=NS, Figure 2B). Approximately one hour 
after endotoxin administration body temperature started to rise in both groups. Subjects in 
the prehydrated group developed a significantly lower peak body temperature (average peak 
value of 38.1 ± 0.1 versus 38.8 ± 0.3 ˚ C in the non-prehydrated group, Student’s t-test: p<0.05).
Figure 2: TNF-α and IL-10 concentrations during human endotoxemia with and without prehydration.
Effects of 2 ng/kg endotoxin (administered at t=0 h.) in the prehydrated group (●) and the non-prehydrated 
group (○) on proinflammatory cytokine TNF-α (A) and anti-inflammatory cytokine IL-10 (B) over time. In both 
groups TNF-α and IL-10 demonstrated a significant rise in response to the endotoxin. TNF-α was significantly 
lower in the group receiving prehydration (ANOVA, p=0.046). IL-10 concentrations were not significantly 
different between groups (ANOVA, p=NS). The bar diagrams show the average of individual peak values per 
cytokine in the prehydrated group (■) and the non-prehydrated group (□). TNF-α peak: p<0.04, IL-10 peak: 
p=NS (Student’s t-test). Data are expressed as mean ± SEM.
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Figure 3: IL-1β, IL-6 and IL-8 concentrations during human endotoxemia with and without prehydration.
Effects of 2 ng/kg endotoxin (administered at t=0 h.) in the prehydrated group (●) and the non-prehydrated 
group (○) on IL-1β (A), IL-6 (B) and IL-8 (C) over time. In both groups all three cytokines demonstrated a 
significant rise in response to the endotoxin. IL-1β and IL-8 were significantly lower in the group receiving 
prehydration (ANOVA: p=0.018, and p=0.005 respectively). The difference between groups concerning the 
release of IL-6 did not reach statistical significance (ANOVA repeated measures p=0.095). The bar diagrams 
show the average of individual peak values per cytokine in the prehydrated group (■) and the non-prehydrated 
group (□). All three cytokines were significantly lower in the group receiving prehydration. IL-1β peak: p<0.001, 
IL-6 peak: p<0.03 and IL-8 peak: p<0.002 (Student’s t-test). Data are expressed as mean ± SEM.
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Symptomatic parameters
The first endotoxin-induced symptoms occurred after approximately one hour and usually 
started with headache and nausea. In the prehydrated group subjects scored lower on all 
symptom items, however due to variation these effects did not reach statistical significance on 
each symptom item separately. The total symptom score was significantly lower in the prehydra-
tion-group (peak values of 5.9 ± 0.5 versus 10.0 ± 1.2, p<0.004, ANOVA repeated measures: 
p=0.036) and symptoms lasted significantly shorter (p<0.005) compared to the non-prehydrated 
group (Figure 4).
Figure 4: Total symptom score during human endotoxemia with and without prehydration.
Total symptoms score after 2 ng/kg E. coli endotoxin administration in the non-prehydrated (□) and the 
prehydrated (■) group. Subjects were asked to score the severity of nausea, headache, shivering, muscle and 
back pain on a scale from 0 (symptom not present) to 5 (worst ever experienced) every 30 minutes until 8 
hours after the endotoxin was administrated. Symptoms were scored on a scale ranging from 0, (symptom not 
present) to 5 (worst ever experienced) and these scores were added up to form a “total symptom score”. 
All subjects experienced a significant rise in symptom score in response to the endotoxin. Expressed data are 
the average of the symptom score at baseline and the average of the highest score per individual. The total 
symptom score was significantly lower in the group receiving prehydration (p<0.004, Student’s t-test). Data 
expressed are mean ± SEM.
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Figure 5: The time course of mean arterial pressure and heart rate during human endotoxemia with and 
without prehydration.
Effects of 2 ng/kg E. coli endotoxin (administered at t=0 h.) on mean arterial pressure (MAP, A) and heart rate 
(HR, B) in the prehydrated (thick line) and the non-prehydrated group (thin line). MAP was determined using 
the intra-arterial catheter and an arterial pressure monitoring line, heart rate was determined by a 3-lead ECG. 
Both MAP and HR were sampled every five minutes throughout the experiments. Endotoxin administration 
induced a significant fall of MAP (non-prehydrated group: p<0.001, prehydrated group: p<0.005, Student’s 
t-test) and heart rate increased in both groups (non-prehydrated group: p<0.002, prehydrated group: p<0.0001, 
Student’s t-test). Data expressed are the group averages over time. For reasons of clarity SEM’s are omitted.
Hemodynamic parameters
As illustrated in Figure 5, endotoxin-induced changes in hemodynamic parameters reached their 
zenith at approximately 4 hrs after endotoxin was administrated. MAP declined by 15% (from 
91 ± 9 to 77 ± 3 mmHg, p<0.005) in the prehydrated group and by 15% (from 96 ± 2 to 
81 ± 4 mmHg, p<0.001) in the non-prehydrated group. Heart rate increased by 50% from an 
average of 61 ± 3 to 92 ± 4 bpm in the prehydrated group (p<0.0001) and by 47% from 64 
± 4 to 94 ± 3 bpm in de the non-prehydrated group (p<0.002). No significant differences for 
heart rate and MAP were observed between the prehydrated and the non-prehydrated group.
Forearm blood flow increased in response to the endotoxin. In the prehydrated group FBF was 
3.4 ± 0.6 at baseline and increased by 132% to 7.9 1.2 mL/min/dl at t=5hrs (over time: p<0.0005). 
In the non-prehydrated group FBF averaged 2.9 ± 0.5 at baseline and increased by 103% to 5.9 
0.9 ml/min/dl (over time: p<0.03, difference between groups: p=NS). 
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discussion
The main finding of the present study is that prehydration in human endotoxemia causes an 
attenuated endotoxin-induced response of the pro-inflammatory cytokines including TNF-α. 
In contrast, the response of the anti-inflammatory cytokine IL-10 was not significantly altered 
by the prehydration and even demonstrated a trend towards higher concentrations in the 
group receiving prehydration, indicating that prehydration significantly shifts the cytokine bal-
ance towards a more anti-inflammatory pattern. This effect is associated with a reduction and 
faster recovery of symptoms and an attenuated endotoxin-induced fever, whereas the possible 
influence of prehydration on endotoxin-induced changes in forearm blood flow, blood pressure 
and heart rate were not detected. The shift in pro/anti-inflammatory balance indicates that 
prehydration in human endotoxemia exerts immunomodulating properties. The endotoxin-in-
duced hemodynamic effects are either not influenced by hydration status or compensated by 
counterregulatory mechanisms.
Previous studies concerning immunomodulation have mainly focused on the effects of hypertonic 
saline. It has been demonstrated that apart from an efficient method of volume resuscitation in 
sepsis,8,9 hypertonic saline also exerts immunomodulatory effects. These effects include suppres-
sion of neutrophil activation and modulation of pro- and anti-inflammatory cytokines.2,10,11 In vitro 
experiments demonstrate that hypertonic saline reduces endotoxin induced TNF-α production 
whereas IL-10 production is augmented and therefore helps to restore the pro/anti-inflammatory 
balance.3 The immunomodulatory effects of hypertonic solutions show similarity to the effects 
of prehydration demonstrated in our experiments. However, the prehydration administered to 
our subjects was isotonic and it is therefore impossible that the effects on the immune response 
observed in our experiments are mediated by a change in osmolarity. This indicates that the 
increase in volume must be the main instigator of the effects found in this study. 
Animal experiments have shown that hypovolemia caused by dehydration increases Salmonella 
endotoxin-induced fever and that the administration of fluid before endotoxin reduces this 
effect.3 Angiotensin II is believed to play a role in the induction of endotoxin-induced fever and 
cytokine production since both are reduced by an ACE-inhibitor.12,13 It could be argued that 
after an overnight fast, our subjects in the non-prehydrated group are relatively hypovolemic 
resulting in an activated Renin-Angiotensin-Aldosterone System and a Angiotensin II-mediated 
pro-inflammatory response. However, in humans this effect could not be confirmed as in exper-
iments with volunteers receiving E. coli endotoxin after an overnight fast, administration of an 
ACE-inhibitor gave no significant differences in TNF-α concentrations.14 
In addition, the mild hypovolemia may cause activation of the sympathetic nervous system leading 
to increased concentrations of circulating catecholamines. Interestingly, various cytokine producing 
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cells express α- and β-adrenoreceptors and in subjects infused with adrenalin, endotoxin induces 
less TNF-α and more IL-10 compared to controls, indicating that β-adrenergic stimulation exerts 
anti-inflammatory effects.15 In contrast, in several in vitro studies, noradrenaline was demonstrated 
to exert pro-inflammatory properties. By stimulating the α-adrenoreceptors of macrophages 
and lung mononuclear cells, noradrenaline augmented TNF-α secretion in various inflamma-
tion-inducing models.16,17 It could be envisaged that, due to the limited infusion strategy after 
the overnight fast, the sympathetic activity and therefore noradrenaline concentrations in the 
non-prehydrated group are higher. The α-adrenoreceptor agonism by the increased noradren-
aline concentrations may explain the more pro-inflammatory pattern found in this study group. 
Lastly, it could be hypothesized that prehydration improves the microcirculation in organs involved 
in cytokine release during human endotoxemia. This may result in an attenuated induction of 
proinflammatory cytokines after a similar inflammatory insult, thereby leading to a change in the 
pro/anti-inflammatory balance. Rivers et al.18 have demonstrated that in septic patients, fast and 
early volume therapy positively affects outcome. Furthermore, the (preoperative) optimization 
of hemodynamic parameters has beneficial effects in high-risk surgical patients.19,20 It is thought 
that during an infection a moderate increase in pro-inflammatory cytokines is beneficial, but 
that severe induction of pro-inflammatory cytokines is deleterious and causes organ dysfunc-
tion.21 In view of our study it is tempting to speculate that the better outcome after early goal 
directed therapy and preoperative optimization are a not only a consequence of an improved 
oxygen delivery, but also a direct effect of a more balanced pro/anti-inflammatory pattern as a 
consequence of an improved microcirculation. 
At present, the human endotoxemia model is the only available in vivo human model to mimic 
Gram-negative sepsis. Future studies using human endotoxemia have to take into account that 
prehydration alters the pro/anti-inflammatory balance after the administration of endotoxin. 
Besides the decrease in symptoms, it is also believed that prehydration decreases the risk of a 
severe vagal response during human endotoxemia.22 It is advisable to administer prehydration 
in human endotoxemia experiments, but when used as a model to measure inflammation or 
the effects of therapeutic interventions on cytokine responses, a standardised protocol should 
be applied.
In conclusion, in human endotoxemia prehydration significantly attenuates the concentrations 
of pro-inflammatory cytokines, while the concentration of the anti-inflammatory cytokine IL-10 
demonstrates a trend towards higher concentrations. We conclude that prehydration results 
in a shift towards a more anti-inflammatory cytokine pattern. This effect is associated with a 
reduction of endotoxin-induced symptoms and fever, while the endotoxin-induced changes in 
hemodynamic parameters remain unchanged. Since this effect is caused by the administration 
of an iso-osmolar fluid this effect is most likely due to a volume effect. 
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abstract
Objective: To determine gender differences in the innate immune response and vascular 
reactivity during human endotoxemia.
Design: Clinical experimental study.
Setting: University Medical Centre Intensive Care Research Unit.
Subjects: Fifteen female and 15 male volunteers.
Intervention: Intravenous injection of 2ng/kg E. coli lipopolysaccharide (LPS).
Measurements and Main Results: C-reactive protein, leukocytes and cytokines were measured 
at regular time intervals as indicators of inflammation. Heart rate and blood pressure were 
continuously monitored. Forearm blood flow and the responsiveness of forearm vessels to 
the intrabrachial infusion of norepinephrine (1-3-10-30 ng/min/dL) were measured before 
and 4 hours (h) after the administration of endotoxin using venous occlusion plethysmog-
raphy. Differences were tested with ANOVA repeated measures.
Females showed a more pro-inflammatory response to LPS than males, illustrated by a 
higher rise in CRP (42±3 vs 29±3 mg/L, p=0.002) and more leukocyte sequestration 
(leukopenia 1.8±0.1x109/L vs 2.4±0.1x 109/L, p=0.003). The increase in cytokine levels 
showed a more pro-inflammatory pattern in females as reflected by a higher rise in TNF-α 
(965±193 vs 411±35 pg/mL, p<0.0001), whereas the rise of the anti-inflammatory IL-10 
was not significantly different (95±15 pg/ml in females vs 129±15 pg/mL in males, p=0.288). 
Females exhibited higher baseline levels (9.9±1.1 vs 7.0±0.8 pg/mL in males, p=0.042) and 
an augmented increase in LPS-binding protein, which may explain the more pronounced 
inflammatory response in females. The LPS-induced change in heart rate was not significantly 
different between the sexes, whereas blood pressure decreased more in females (p<0.0001). 
LPS administration significantly attenuated the norepinephrine sensitivity in males (p=0.002), 
whereas, no LPS-induced effect was observed in females (p=0.552, difference between 
groups: p=0.045)
Conclusions: During experimental human endotoxemia, females show a more pronounced 
pro-inflammatory innate immune response associated with less attenuation of the norepi-
nephrine sensitivity. These findings may be relevant in view of the profound and incompletely 
explained differences in incidence and outcome of male and female septic patients. 
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introduction
Severe sepsis and septic shock are important causes of death in intensive care units. Although our 
understanding of the pathogenesis of inflammation and sepsis has improved exponentially over 
the past decades, some very fundamental questions are still unanswered. One of the most striking 
observations that remains unexplained is the gender-based difference in mortality and morbidity 
of septic patients in the advantage of women. Although females in general mount a more pro-
found immune response following antigenic challenge, it is now well-recognized that they also 
exhibit lower susceptibility to bacterial sepsis than their male counterparts.1–3 Significantly more 
males develop severe sepsis/septic shock than females1,4 and significantly fewer female patients 
are referred to the intensive care unit.4 These differences have been mainly attributed to the 
immunomodulatory effects of sex-hormones 5–7, but human in vivo data are lacking.
Apart from the possible differences in innate immune response, the hemodynamic response 
to vasopressor therapy is of eminent importance in septic shock patients. Differences between 
males and females in vascular reactivity have been demonstrated in the absence of an inflamma-
tory stimulus,8,9 but human data during systemic inflammation are not available. For these reasons, 
it is pivotal to study gender differences during experimentally controlled systemic inflammation 
in humans in vivo. The aim of the present study was to investigate gender differences in the 
innate immune response, clinical symptoms, and vascular reactivity following the administration 
of lipopolysaccharide (LPS) to human volunteers of both sexes.
The administration of a low dose of LPS to humans is a valuable way of studying the innate 
immune response and hemodynamic sequelae during systemic inflammation.10,11 LPS administra-
tion evokes a dose-dependent12 and predictable rise in cytokines. Furthermore, it exerts several 
vascular effects reflected by a transient fall in blood pressure of 15 to 20 mmHg and a reduced 
sensitivity to vasopressor therapy with norepinephrine.11,13 
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methods
Subjects
The subjects described in the present study participated in a larger endotoxin trial.14 After 
approval from the local ethics committee, 30 non-smoking individuals (15 females, 15 males) 
gave written informed consent to participate in these experiments. Females were studied in 
the follicular phase. Nine females used oral anticonceptiva (5 used ethinylestradiol 30 μg/levo-
norgetrel 150 μg, 3 used cyproteronacetate 2 mg/ethinylestradiol 35 μg, 1 used ethinylestradiol 
30 μg/drospirenon 3 mg).
Subjects who were taking prescription drugs, aspirin or other non-steroid anti-inflammatory 
drugs were excluded. Screening of the subjects within 14 days prior to the test revealed no 
abnormalities in medical history and physical examination. Routine laboratory tests and ECG 
were normal. All subjects tested HIV and Hepatitis B negative. They did not have a febrile illness 
in the 2 weeks preceding the study. Ten hours prior to the experiment, subjects refrained from 
the consumption of caffeine, alcohol and food.
Study design and procedures
On the morning of the test, subjects were admitted to the ICU. All subjects received a 20 gauge 
arterial catheter (Angiomat, Deseret Medical, Becton Dickinson, Sandy UT, USA) in the brachial 
artery for continuous blood pressure monitoring, blood sampling, and intra-arterial infusion of 
norepinephrine. Both heart rate (3-lead ECG) and blood pressure were continuously moni-
tored. A canulla was placed in an antecubital vein to permit the infusion of 1.5 L of 2.5%/0.45% 
glucose/saline solution before, and 150 mL/hr after the administration of endotoxin to ensure 
an optimal hydration status.15,16
At t=0 hour (h), all subjects received a dose of purified lipopolysaccharide prepared from E. 
coli (O:113, 2 ng/kg). The endotoxin was injected intravenously in 1 minute, followed by 5 mL 
of normal saline to ensure complete delivery. EDTA anti coagulated blood samples were taken 
from the arterial catheter at baseline and 15, 30, 60 and 90 minutes and 2, 3 and 4 h after the 
administration of LPS in order to determine the time course and the peak values of several 
cytokines (tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-10, IFN-γ). Other parame-
ters of inflammation (CRP, leukocyte count) were measured in blood that was drawn at baseline 
and at t=3,6,12 and 22 h. For the determination of lipopolysaccharide binding protein (LBP), 
blood was sampled at baseline and at 1, 2, 3, 4, 6, 8 and 22 h. Body temperature was measured 
every 30 minutes for the first 8 hours after endotoxin administration using an infrared tympanic 
thermometer (Sherwood Medical,’s-Hertogenbosch, the Netherlands).
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Subjects were asked to score the severity of the endotoxin-induced flu-like symptoms (nausea, 
headache, shivering, muscle and back pain) every 30 minutes up untill 8 h after the administration 
of endotoxin. Symptoms were scored on a scale ranging from 0, (‘symptom not present’) to 5 
(‘worst ever experienced’) and these scores were added, forming an arbitrary “total symptom 
score”. Since 5 symptoms were scored, the maximal score is 25. Since not all symptoms occur at 
the same time (First headache and nausea, later shivering, muscle and back pain), the cumulative 
score is not very high at any give point in time. 
Forearm blood flow and the responsiveness of forearm vessels to the intra-arterial infusion of 
norepinephrine (1-3-10-30 ng/min/dL) were measured before and 4 h after the administra-
tion of endotoxin using venous occlusion plethysmography (Filtrass Domed, Munich, Germany) 
according to methods described previously.17,18
Laboratory tests
To determine the concentration of the various cytokines and LBP, plasma was processed imme-
diately by centrifugation at 2000g at 4˚C for 15 minutes and was stored at –80 ˚C before 
analyses. Concentrations of TNF-α, IL-1β, IL-6, and IL-10, and IFN-γ were determined using a 
simultaneous Luminex Assay.19 LBP levels were determined using Immulite (Diagnostic Products 
Corporations Nederland b.v., Breda, The Netherlands). Leukocyte levels were determined using 
flow-cytometry (Sysmex XE-2100, Goffin Meyvis, Etten Leur, the Netherlands) and CRP was 
measured using immunologic detection (turbidimetric method) according to the instructions of 
the manufacturer (Aeroset, Abbott Laboratories, Abbot Park, IL, U.S.A.). 
Drugs and Solutions
All solutions were freshly prepared on the day of the experiment. LPS of E. coli (O:113, lot 
G2B274) was retrieved from United States Pharmacopia Convention (Rockville, MD, USA), and 
dissolved in normal saline 0.9% to a concentration of 200 EU/mL. Norepinephrine was retrieved 
from Centrafarm, the Netherlands and dissolved in normal saline. 
Data analyses and statistics
Differences between males and females over time in cytokine levels, inflammation parameters 
and responsiveness of the forearm vessels to norepinephrine were analysed with ANOVA with 
repeated measures. Differences in paired data (within each subject) were tested with paired 
Student’s t-tests. All data are expressed as mean±SEM of n subjects unless otherwise stated. A 
p<0.05 was considered statistically significant.
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results
Demographic data are shown in Table 1. 
Table 1: Demographic data
Males (n=15) Females (n=15) p-value
Age (years) 22.8±0.7 20.7±0.3 0.02420
Height (cm) 183±2 169±2 <0.0001
Weight (kg) 79.7±2.5 65.5±1.6 0.00011
BMI (kg/m2) 23.8±0.5 23.0±0.5 0.34507
FAV (mL) 1158±42 837±36 0.00015
MAP (mmHg) 95±3 98±2 0.529
HR (bpm) 60±3 77±2 <0.0001
Data are expressed as mean ± SEM. BMI, body mass index; FAV, forearm volume measured with water 
displacement method; MAP, mean arterial pressure, measured with i.a. pressure monitoring line, averaged for half 
an hour; HR, heart rate, measured with 3 lead ECG averaged for half an hour.
Differences in inflammatory parameters
At baseline, CRP levels were below the detection limit in all subjects. Female subjects showed a 
more pronounced rise in CRP compared to males (41.8±3.1 vs 28.9±2.7 mg/L at t=22 h (com-
plete curve over time, ANOVA repeated measures, p=0.002) and more leukocyte sequestration 
(leukopenia 1.8±0.1x109/L vs 2.4±0.1x109/L, unpaired Student’s t-test, p=0.003), whereas the 
complete leukocyte curve over time was not significantly different between groups (p=0.095): 
Table 2. 
As illustrated in Figure 1, at baseline, all cytokine levels were below the detection limit in all 
subjects. Females exhibited a more profound pro-inflammatory response after administration 
of endotoxin. TNF-α peak levels in women were more than twice as high as in males (965±193 
vs 411±34.6 pg/mL, p<0.0001), and IL-1β was slightly elevated in females whereas the rise was 
absent in males (12±1.6 pg/mL vs 8±0.1, p=0.005). IFN-γ increased in females to 136±31.7 at 
90 minutes, and in males to 60±10.4 pg/mL (p=0.001). The rise of IL-6 levels was not significantly 
different between sexes as tested by ANOVA repeated measures (p=0.177). 
In contrast to the pro-inflammatory cytokines, the increase in the anti-inflammatory cytokine 
IL-10 was not significantly different between males and females (129±14.6 pg/mL in males vs 
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95±15.3 pg/mL in females, p=0.288). LBP concentrations were higher in females at baseline 
(9.9±1.1 vs 7.0±0.8 pg/mL in males, p=0.042). In females LBP continued to rise until 22 h after 
administration to a maximum of 32.9±4.2 pg/mL, while in males a plateau concentration of 
21.1±1.9 pg/mL was reached at 8 h that remained unchanged at 22 h (21.4±1.8 pg/mL, differ-
ence in increase: p=0.004).
Table 2: Inflammatory parameters
Males (n=15) Females (n=15) p-value
Tbaseline (ºC) 36.3±0.1 36.6±0.1 0.031
Tmax 37.8±0.1 38.2±0.1 0.031
∆Temperature 1.5±0.2 1.5±0.2 0.938
Leukocytes (*109/L) t=0 h 5.9±0.6 5.9±0.4 0.937
t=1 h 2.4±1.1 1.8±0.7 0.003
t=6 h 14.4±0.8 12.5±0.7 0.091
CRP t=0 h <5 <5 1.0
t=12 h 19.3±2.0 25.8±2.6 0.076
t=22 h 28.9 ±2.7 41.8 ± 3.1 0.005
Data are expressed as mean ± SEM. T, body temperature; CRP, C-reactive protein; t, time after endotoxin 
infusion. 
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Figure 1: Cytokine levels
Effects of 2 ng/kg LPS (administered at t=0 h) in the male (●) and the female (○) subjects on TNF-α, IL-6, 
IL-10 and IFN-γ over time. In both groups, administration of 2 ng/kg E. coli LPS resulted in a marked increase in 
TNF-α, IL-6, IFN-γ, and IL-10 concentrations. TNF-α and IFN-γ were significantly higher in the female subjects. 
The difference between groups concerning the release of IL-6 and IL-10 did not reach statistical significance. 
Data are expressed as mean±SEM (n=15+15). P-values in the figure refer to differences between males and 
females tested by ANOVA repeated measures.
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Table 3: Leukocyte count (x109) and differentials (%) during human endotoxemia
t= 0 h t= 1 h t=6 h t=12 h t=22 h
Males Leukocytes 5.9±0.6 2.4±0.1 14.3±0.8 13.7±1.0 8.6±0.7
Neutrophils 52.8±3.3* 51.4±5.3 89.9±2.9 81.9±1.1 69.0±1.8
Lymphocytes 36.3±3.4** 42.9±5.5 4.4±1.8 11.0±0.8 20.5±1.2
Monocytes 8.3±1.0 0.7±0.2 4.3±1.1 6.6±0.7 8.3±1.0
Eosinophils 2.3±0.4 3.9±0.6 0.2±0.1 0.6±0.2 2.2±0.4
Basophils 0.6±0.2 1.0±0.3 0.0±0.0 0.0±0.0 0.1±0.1
Females Leukocytes 5.9±0.4 1.8±0.1 12.5±0.7 13.7±0.8 9.0±0.7
Neutrophils 65.7±1.6* 41.9±3.8 94.7±0.3 86.6±1.1 75.3±2.7
Lymphocytes 25.4±1.6** 53.6±3.7 3.2±0.4 7.7±0.8 16.7±2.2
Monocytes 6.4±0.4 0.6±0.2 2.0±0.3 5.0±0.4 6.4±0.6
Eosinophils 2.0±0.3 3.0±0.6 0.1±0.1 0.2±0.1 1.3±0.30.
Basophils 1±0.1 1.1±0.3 0.0±0.0 0.0±0.0 0.0±0.0
Leukocytes and differentials during the course of endotoxemia. Data are expressed as mean ±SEM. Baseline 
differentials were tested for differences between males and females. Neutrophils were lower in males at baseline 
(p=0.005 whereas lymphocytes were higher (p=0.018). t, time after endotoxin administration.
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Differences in clinical parameters
The onset of flu-like symptoms started approximately 1h after LPS administration and symptoms 
were at their maximum 90 min after LPS infusion (Figure 2). This resulted in a total subjective 
symptom score of 4.5±0.4 for female and 4.7±0.5 for male subjects (difference between groups: 
p=0.85). All symptoms disappeared within 8 hours. In both groups the increase in temperature 
was 1.5±0.2 ºC (p=0.9).
Figure 2: Subjective symptom score
Total subjective symptoms score after 2 ng/kg E. coli endotoxin administration in male (●) and female (○) 
subjects. Subjects were asked to score the severity of nausea, headache, shivering, muscle and back pain on 
a scale from 0 (“symptom not present”) to 5 (“worst ever experienced”) every 30 minutes until 8 hour (h) 
after the endotoxin was administrated and these scores were added up to form a “total symptom score”. All 
subjects experienced a significant rise in symptom score in response to the endotoxin. There was no significant 
difference between the male and female subjects (p=NS, ANOVA repeated measures). Data expressed as 
mean±SEM (n=15+15). 
Differences in cardiovascular parameters
After the administration of LPS forearm blood flow increased from 3.4±0.4 to 7.7±1.0 mL/min/
dL in males, compared to 2.4±0.3 to 6.3±0.6 mL/min/dL in females (both groups p<0.0001, 
difference between groups: p=NS) resulting in a fall in blood pressure and a rise in heart rate.
(Figure 3) Females showed a more pronounced decrease in blood pressure (p<0.0001). The 
LPS-induced rise in heart rate was comparable in males and females (p=0.831, Figure 3).
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Administration of norepinephrine in the absence of endotoxin induced vasoconstriction in both 
groups (p<0.0001), but this tended to be less pronounced in females (p=0.110, Figure 4). The 
sensitivity to norepinephrine was decreased during endotoxemia in male subjects (p=0.002), but 
did not change significantly after the administration of endotoxin in females (p=0.552, Figure 4).
Figure 3: Hemodynamic changes
Effects of 2 ng/kg E. coli endotoxin (administered at t=0 h) on mean arterial pressure (MAP) and heart 
rate (HR) in female (○) and male (●) subjects. MAP was determined using the intra-arterial catheter and 
an arterial pressure monitoring line, heart rate was determined by a 3-lead ECG, both were sampled every 
five minutes throughout the experiments. Endotoxin administration induced a significant fall of MAP in both 
groups (p<0.0001) and heart rate increased in both groups (p<0.0001). MAP significantly decreased more 
in the female subjects (p<0.0001 compared to males), whereas there was no significant difference between 
the groups concerning the increase in heart rate (p=NS) as tested with ANOVA repeated measures. Data 
expressed as mean±SEM (n=15+15).
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Figure 4: Endotoxemia and norepinephrine sensitivity
Dose-reponse curve of intrabrachial norepinephrine (1-3-10-30 ng/min/dL) on forearm blood flow before 
(∆, ) and 4 hours after (○, ■) the administration of 2 ng/kg E. coli LPS in females (open symbols) and males 
(closed symbols). LPS significantly attenuated the vasoconstrictor response to norepinephrine in male subjects, 
whereas this effect was not present in female subjects. The p-values in the figure refer to the statistical difference 
between the dose-response curves within females/males as analyzed with ANOVA repeated measures. 
Percentages of baseline FBF ratio (intervention/control arm) are presented as mean +/- SEM (n=15+15).
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discussion
The present in vivo study is the first to report that females show a more pronounced pro-inflam-
matory response compared to males during systemic inflammation following the administration 
of E. coli endotoxin. Interestingly, the response of the anti-inflammatory cytokine IL-10 was not 
significantly different and even tended to be lower in females, indicating that the pro-anti-inflam-
matory balance demonstrates a clear shift to a more pro-inflammatory pattern in females. This 
pattern was accompanied by a higher baseline level of LBP and a higher rise in LBP in females. The 
more pro-inflammatory pattern in females was not associated with an increase in symptoms or 
a more attenuated vascular response to norepinephrine. In contrast, our study confirms previous 
reports that endotoxemia reduces the sensitivity to vasopressor agents such as norepinephrine in 
males, while this effect was completely absent in female subjects. The augmented innate immune 
response combined with the preserved norepinephrine sensitivity may explain the previously 
observed better outcome of female septic patients.
Male-female differences in innate immunity
A vast amount of animal experiments demonstrate an augmented innate immune response in 
female animals combined with a lower susceptibility to develop endotoxic shock.20,21 Previous 
in vivo human studies have reported a lower1,22,23, similar22, or higher24 proinflammatory cytokine 
response in female surgical and septic patients. Although the male-female differences in incidence 
and outcome of sepsis are clear from large population based studies, the interindividual variability 
of the onset and course of the septic syndrome makes it difficult to compare the innate immune 
response in relatively small groups of septic patients. In contrast, the human endotoxemia model 
offers a standardized systemic inflammatory stimulus suited to examine gender related inflam-
matory differences in vivo. With this model of sepsis the amount and exact moment of purified 
LPS administration are clear, so that a precise and quantitative measure of the innate immune 
response can be obtained to compare different groups.
The influence of sex hormones
The influence of sex hormones on the host innate immune response has been proposed as an 
explanation for the unequal gender distribution in sepsis.25–27 Sex hormone receptors are present 
on immunologically relevant cells28 and correlate with the activity of cytokine-secreting cells in 
vivo 29, for example, estrogens increase TNF-α and IL-6 expression and stimulate the cytokine 
production in response to LPS.30 
In murine models of sepsis, sex hormones exert immunomodulatory effects, as estrogen treat-
ment protects mice from death induced by endotoxic shock 31 and recently a distinct survival 
advantage was reported by the administration of a selective estrogen receptor β-agonist in septic 
rats and mice.32 Human studies concerning estrogen suppletion and innate immunity are sparse. 
One study investigated the innate immune response in post-menopausal women challenged 
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with endotoxin with and without estrogen replacement.33 Replacement therapy resulted in a 
markedly suppressed inflammatory response as reflected by less IL-6, IL1ra and TNF-α produc-
tion. This observation is in contrast with the results obtained in animal experiments 34 and our 
present study, and may be explained by the relatively small number of women studied (n=6) 
and the fact that the study was performed in a paired fashion in which LPS antibody formation 
may have influenced the results.35 
In our study, we found no gender differences in leukocyte differential that could explain the 
differences in cytokine production. The observation that monocyte count was significantly lower 
in females while their systemic cytokine release was higher is in accordance with the notion that 
circulating leukocytes appear not to play a role of importance in systemic cytokine production, 
as LPS-treated leukopenic mice achieve higher cytokine concentrations compared to controls.36 
In contrast, the difference in serum LPS-binding protein between females and males may offer 
an explanation of the observed effects. LBP mediates the transfer of endotoxin to CD14 and 
signaling of TLR4 on leukocytes, leading to the initiation of the immune response and resulting 
in the production of inflammatory cytokines37, resulting in a lower susceptibility to bacterial 
infections. In accordance with this hypothesis LBP-/- mice showed a dramatically reduced survival 
compared to heterozygous controls after the injection of S. tiphimurium38 and in a E. coli peritonitis 
model of sepsis, LBP knock-out mice showed higher mortality, earlier bacterial dissemination 
into the bloodstream and impaired bacterial clearance as compared to the wild-type.39 In the 
present study we found a small but significant difference in baseline LBP levels accompanied by 
a more pronounced increase in LBP in females, which may account for their augmented cytokine 
response. Interestingly, estrogen treatment increases LBP mRNA 40, which provides another link 
between sex hormones and innate immunity. 
Male-female differences in cardiovascular response to LPS
The more pro-inflammatory innate immune response in females was not associated with a more 
pronounced vascular hyporeactivity. During baseline conditions, we confirmed the previously 
reported observation that the norepinephrine-mediated vasoconstriction is less pronounced in 
women, an effect associated with an altered β2-adrenergic function.9,41 The reported increased 
sensitivity to β2-adrenergic receptor stimulation may offset the vasoconstrictive effects of α-adr-
energic receptor stimulation. Also, estrogen replacement therapy reduces the vasoconstrictive 
response to norepinephrine42, possibly due to increased basal NO synthesis.43 These effects may 
play a role in the observed absence of a LPS-induced decrease in norepinephrine sensitivity and 
beneficial hemodynamic response to inflammation in females. 
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Clinical importance
We have previously suggested that with an aggressive initial response to an infection, bacterial 
growth can be contained and controlled in an early stage of the disease, and sepsis is less likely 
to occur.44 However, if the early response to an infection is inadequate, the bacteria have the 
chance to multiply and spread, resulting in disseminated infection and dysregulation of cytokine 
levels. This theory supports the idea of pro-inflammatory cytokines being of benefit, rather than 
being something the patient must be protected from. Thus, a strong initial pro-inflammatory 
response may be an explanation of the lower incidence and mortality of sepsis observed in 
females. Moreover, the vascular sensitivity to norepinephrine during LPS-induced inflammation 
was preserved in female subjects, possibly adding to the observed survival advantage in septic 
women, as refractory shock is the main cause of its mortality.45 Despite these important differ-
ences and the beneficial effects of estrogen treatment in septic animal experiments, this area 
is not yet exploited in human treatment strategies and up to now the treatment for male and 
female septic patients is the same. The immune-modulating effects of androgens and estrogen 
however are undisputed, rendering them a possible future therapeutic target. 
In summary, we have demonstrated that females exert a more pro-inflammatory pattern of 
cytokine release during E. coli endotoxemia compared to males. This difference is associated with 
higher levels of LPS-binding protein in females, which facilitates TLR-4 signaling. In male subjects 
systemic inflammation induces an attenuated vascular sensitivity to norepinephrine, whereas this 
effect is not observed in females. These findings may be relevant in view of the profound and 
incompletely explained differences in incidence and outcome of male and female septic patients.
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abstract
A higher body mass index (BMI) appears to be associated with lower mortality in critically 
ill patients, possibly explained by an altered innate immune response. However, the precise 
relation between BMI and the innate immune response in humans in vivo is unknown. We 
investigated the relation between BMI and the systemic cytokine response during exper-
imental human endotoxemia. Endotoxemia was induced in 112 healthy male volunteers 
by intravenous administration of 2ng/kg E. coli endotoxin. Plasma concentrations of tumor 
necrosis factor (TNF)-α, interleukin( IL)-6, IL-10, and IL-1RA were serially determined. The 
relation between BMI and the cytokines response as well as body temperature was inves-
tigated. The BMIs of the subjects ranged from 18.3 to 33.6 kg/m2, (median: 22.7 kg/m2). All 
subjects showed a marked increase in plasma cytokine levels (median(IQR)) peak levels: 
TNF-α: 509 (353-673) pg/mL, IL-6: 757 (522-1098) pg/mL, IL-10 271 (159-401) pg/mL, 
IL-1RA 4882 (3927-6025) pg/mL) and increase in body temperature (1.8 (1.4-2.2)°C) during 
endotoxemia. No significant correlations were found between BMI and levels of any of the 
cytokines or body temperature. No relation between BMI and the cytokine response was 
found in healthy volunteers subjected to experimental endotoxemia. These data question 
the relationship between BMI and cytokine responses in critical illness.
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introduction
Obesity is an epidemic disease in western society1 and a well-known risk factor for cardiovascular 
diseases, cancer, diabetes and asthma.2–4 However, among critically ill patients mostly beneficial 
effects of obesity have been reported,5–15 named ‘the obesity paradox’16 and a putative immu-
nomodulatory mechanism has been suggested to explain these effects.17,18
Obesity leads to a chronic state of low-grade inflammation. Levels of the pro-inflammatory 
cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β and the pro-inflammatory 
marker C-reactive protein (CRP) increase as the mass of adipose tissue increases,19 while weight 
loss results in reduction of pro-inflammatory markers.20 Interestingly, the profile of both pro- and 
anti-inflammatory cytokines and adipokines in the morbidly obese are generally comparable 
to critically ill patients.21 Possibly, the pre-existing pro-inflammatory state in obesity primes the 
immune system to mount a more pronounced immune response during systemic inflammation 
or sepsis. Accordingly, several animal studies have shown an increased inflammatory response 
during sepsis in obese animals compared to lean controls.22–24 This can partly be explained by the 
fact that fat tissue itself is reactive to exogenous triggering factors like endotoxin. It was shown 
that the intravenous injection of endotoxin in healthy adults results in expression of several 
adipocytokine and chemokine genes in subcutaneous fat tissue.25 However, not only the adipose 
tissue itself may be responsible for the altered immune response in the obese, as blood drawn 
from obese women with a BMI>40 kg/m2 produced twice the amount of TNF-α compared to 
patients with a BMI of 20-25 kg/m2 after in vitro stimulation with endotoxin.26
Considering that an ever increasing number of overweight patients are admitted to the intensive 
care unit, it is of importance to gain more insight into the potential immunomodulatory effects 
of adipose tissue. Existing data are mainly derived from in vitro, ex vivo and murine models of 
systemic inflammation, while human in vivo data are lacking. The experimental human endotox-
emia model, in which a low dose of E. coli endotoxin is administered intravenously to healthy 
volunteers, serves as a standardized way to investigate the innate response in vivo in humans. This 
study aims to investigate the effect of the body mass index on the pro- and anti-inflammatory 
cytokine production in vivo during experimental endotoxemia.
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methods
Design and subjects 
In this study, data and plasma samples of seven double-blind, randomized placebo controlled 
trials were used. These trials were performed in our institution from the year 2005 to 2010. 
All 7 studies (NCT00246714, NCT00513110, NCT00783068, NCT00785018, NCT00916448, 
NCT01349699, NCT01091571) investigated the effect of an intervention on the innate immune 
response elicited by endotoxin administration using the exact same endotoxemia protocol. The 
samples from these studies were reanalyzed for cytokines in one batch for the current study, to 
prevent bias from inter-assay variability. Only the data of subjects that received endotoxin and 
placebo or endotoxin and an intervention that did not influence the immune response were used. 
We only studied male volunteers because of considerable differences in the endotoxin-induced 
cytokine response between males and females and possible effects of hormonal variations due 
to the menstrual cycle.27
The study protocols were approved by the Ethics Committee of the Radboud University Nijme-
gen Medical Centre and complied with the Declaration of Helsinki including current revisions 
and the Good Clinical Practice guidelines. All subjects were carefully screened (height, weight, 
general physical examination, medical history, routine laboratory tests, hepatitis and HIV serology 
and an electrocardiogram in the 14 days preceding the endotoxin administration). Subjects that 
experienced febrile illness in the 4 weeks preceding the test were excluded. Only non-smoking 
individuals were included. The subjects abstained from caffeine and alcohol for 24 hours (h) and 
did not drink or eat for 12 h prior to the start of the experiment. 
Procedures
On the morning of the experiment, subjects were admitted to a research unit on the intensive 
care. Subjects received a 20-gauge arterial catheter (Angiomat, Becton Dickinson, Sandy, UT, 
USA) for continuous blood pressure monitoring and blood sampling. Hemodynamic data were 
continuously monitored for safety. A venous cannula was placed to permit infusion of 1.5 L 
2.5% glucose/ 0.45% NaCl in one hour preceeding LPS infusion (prehydration), followed by 150 
mL/h until 6 hours after LPS infusion and 75 mL/h until the end of the experiment to ensure an 
optimal hydration status. At t=0 h, the subjects received 2 ng/kg U.S. Reference E. coli endotoxin 
intravenously over 1 minute, followed by 5 mL of normal saline. (E. coli O:113, Clinical Center 
Reference Endotoxin, National Institute of Health (NIH), Bethesda, MD, USA). The same batch 
of endotoxin was used for all studies.
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Inflammatory parameters 
EDTA anti-coagulated blood was drawn from the arterial catheter at t=0, 60, 90 minutes and 2, 
4, and 8 h after endotoxin administration, for the measurement of pro-inflammatory cytokines 
TNF-α and IL-6 and the anti-inflammatory IL-10 and IL-1RA. Blood was processed immediately 
by centrifugation at 2000xg at 4˚C for 10 minutes before being stored at -80˚C until further 
analysis. Concentrations of TNF-α, IL-6, IL-1RA and IL-10 were determined using a simultaneous 
Luminex assay, according to the manufacturer’s instructions (Milliplex, Millipore, Billerica, MA, 
USA). As a general clinical measure of inflammation, body temperature was measured every 
half hour.
Data analysis and statistics
For all cytokines, peak levels and area under curve (AUC) values were determined. These values 
were related to the weight, body mass index (BMI), and body surface area (BSA) of the subjects 
using Spearman’s correlation analyses. Also the ratio of the AUCs of TNF-α/IL-10 as a measure 
of pro-anti inflammatory balance was analyzed. To increase the sensitivity to detect a possible 
relation between BMI and cytokine induction, subjects were stratified in three groups according 
to their BMI (<20, 20-25,>25 kg/m2) and systemic cytokine levels were compared between 
the strata. For data analysis, Graphpad Prism 5.0 was used (Graphpad software, San Diego, CA, 
USA). All data are expressed as mean±SEM or median(interquartile range), depending on their 
distribution. A p<0.05 was considered statistically significant. According to methods described 
previously,28 we calculated that with a sample size of 112 subjects and an alpha a 0.05 this study 
had 80% power to detect a correlation between BMI and peak cytokine response with an r of 
0.23 or higher.
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results
Demographic data
112 male subjects, aged 22.2±0.2 years, were enrolled. Subjects had an average height of 184±0.7 
cm and weight of 77.2±0.9 kg resulting in a mean BMI of 22.8±0.2 kg/m2. BMI’s ranged from 
18.3 to 33.6 kg/m2 and were normally distributed. (Figure 1) Thirteen subjects had a BMI <20, 
83 subjects had a BMI of 20-25, and 16 subjects had a BMI>25 kg/m2. Length was not statistically 
different between the strata (185±2.3 cm , 184±0.8 cm and 185±1.5 cm respectively, One-way 
ANOVA p=0.63).
Figure 1: Distribution of BMI’s of the study population
Endotoxemia symptoms
Approximately 1h (t = 1 h) after the administration of LPS, subjects began to show flu-like symp-
toms. The symptoms reached a maximum severity at t = 90 min. Thereafter, symptoms gradually 
declined to normal values at the t = 8 h (data not shown). There was a transient increase in 
body temperature of 1.8 (1.4-2.2) °C. (Figure 2) There were no differences in symptom scores 
and body temperature between the three different BMI strata. 
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Figure 2: Body temperature, mean arterial pressure, heart rate and white blood cell count during 
experimental human endotoxemia. Left panels: Values are depicted as median with interquartile range. Right 
panels: maximal differences compared to baseline. Data were stratified according to BMI. Boxes represent 
interquartile ranges, whiskers represent the 10th and 90th percentile. Differences between groups were analyzed 
with Kruskal-Wallis test for nonparametric data. No significant differences were found between the three 
groups. MAP Mean arterial pressure, HR heart rate, WBC white blood cell count.
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Cytokine response
Endotoxemia led to a marked cytokine response, illustrated in figure 2. TNF-α peaked at t = 1.5, 
while IL-6 was maximally induced at t = 2 h. Peak levels of IL-10 and IL1RA were reached at 
t = 2 and t = 4 h, respectively (peak levels: TNF-α 509 (353-673) pg/mL, IL-6 757 (522-1098) 
pg/mL, IL-10 271 (159-401) pg/mL, IL-1RA 4882 (3927-6025) pg/mL).
Figure 3: Plasma cytokine levels during endotoxemia.
Values are depicted as median with interquartile range
Correlation analyses
Peak plasma cytokine levels and AUCs were calculated and a possible correlation with weight, 
BMI and BSA of the subjects was investigated. We did not find a significant correlation of any of 
the parameters with weight, BMI and BSA (Spearman correlations are listed in Table 1.) 
Furthermore, no significant differences were found between the three aforementioned strata, 
neither in cytokine peak levels (Figure 3), nor in AUCs of the different cytokines, nor in the ratio 
of the AUCs of TNF-α/IL-10. One subject was a statistically significant outlier for IL-10 (peak 
level 3502 pg/mL), and another for IL-1RA (peak level 56399 pg/mL), but they had normal BMI’s 
of 21.5 and 21.7 kg/m2, respectively. In addition, the subject with the highest BMI (33.6 kg/m2) 
had normal peak levels of TNF-α (616 pg/mL), IL-6 (1233 pg/mL), and IL-1RA (6384 pg/mL), 
while peak IL-10 was relatively, but not abnormally low (126 pg/mL).
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Figure 4: Cytokine peak levels stratified according to BMI 
Boxes represent interquartile ranges, whiskers represent the 10th and 90th percentile. Differences between 
groups were analyzed with Kruskal-Wallis test for nonparametric data. No significant differences were found 
between the three groups. AUCs of the cytokine responses stratified according BMI were not shown, but also 
showed no difference.
Table 1: Spearman correlation analyses between indexes of body mass and cytokine levels
TNF-α IL-6 IL-10 IL-1RA TNF-α/IL-10
Peak AUC Peak AUC Peak AUC Peak AUC AUC
Weight -0.02 0.06 0.10 0.11 -0.14 -0.09 0.08 0.08 0.13
BMI -0.00 0.08 0.05 0.04 -0.13 -0.09 0.00 0.02 0.15
BSA -0.03 0.06 0.12 0.13 -0.14 -0.10 0.01 0.09 0.13
Data are expressed and Spearman’s r. No significant correlations were found (p-values not shown). BMI Body 
Mass Index, BSA Body Surface Area, AUC Area Under Curve
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discussion
This is the first study that investigates the relation between body mass index and the innate immune 
response in humans in vivo during systemic inflammation. No correlation was found between BMI 
and the systemic inflammatory cytokine response after the intravenous administration of endotoxin 
to human volunteers. 
The debate on the existence of a beneficial effect of obesity in critically ill patients has been going 
on for decades, including several meta-analyses of which most conclude that obese patients have 
equivalent or improved survival compared to patients with a BMI between 20-25 kg/m2.13–15 The 
findings of these studies have been subject of debate29–31 and the mechanism of action by which 
a higher BMI is associated with a better outcome is unclear. One of the supposed mechanisms 
by which obesity leads to a better prognosis is an altered immune response. In the current study 
we tested this hypothesis in an experimental human endotoxemia model. In contrast to data 
obtained from ICU patients, which are difficult to interpret due to differences in patient charac-
teristics (age, gender, comorbidity, etc) and differences with regard to the inflammatory stimulus 
(type and site of infection, time of onset, disease severity etc), the experimental endotoxemia 
model makes it feasible to test the immune response in a standardized manner in a homogenous 
group of subjects. Our findings in humans do not correspond to the results from previous rodent 
studies of which most,22–24 but not all32 report a pro-inflammatory effect of obesity. In humans, 
apart from more nutritional reserves, higher levels of pro-inflammatory19 and anti-inflammatory 
cytokines,17,18 and the higher cholesterol and lipid levels common in obese patients that bind 
endotoxin during critical illness and provide the precursors for adrenal steroid synthesis33 have 
been related to the beneficial effects of a higher BMI. In addition, neutrophil dysfunction and 
attenuation of acute lung injury,34 and diaphragmatic remodeling due to chronically increased 
weight35 and chronically increased intra-abdominal pressure36 are possibly related to a lower 
acute respiratory distress syndrome incidence in obese patients.37
While our study demonstrates the absence of a clear association between BMI and the cytokine 
response, we acknowledge several limitations. First, we used data of 112 healthy volunteers from 
7 previously conducted endotoxemia trials. Despite this relatively large sample size, our popu-
lation does not comprise a large number of overweight and obese subjects and no massively 
obese subjects with a BMI>35 kg/m2, and therefore any interpretation of the effects of a BMI>30 
kg/m2 is limited, especially when considering that a possible relation may not be linear, but rather 
be dependent on a certain BMI threshold. Nevertheless, ICU mortality has been shown to grad-
ually decrease with increasing BMI, with beneficial effects already found in patients with a BMI 
of 25 to 30 kg/m2,14 suggesting that our sample population was appropriate to detect a possible 
difference. Second, we only measured 4 key cytokines, 2 of which are considered archetypal 
pro-inflammatory cytokines, and 2 that are regarded as classic anti-inflammatory cytokines. All 
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four cytokines are induced relatively early in the inflammatory response. Late cytokines, like e.g. 
IFN-γ, HMGB-1, IL-8 and IL-17 were not measured. Therefore, we cannot rule out the possibility 
that a correlation exists between BMI and one of the unmeasured mediators, however, as early 
pro-inflammatory cytokines orchestrate the subsequent immune response, the panel of markers 
we chose is representative of the general inflammatory cytokine response induced by endo-
toxin administration. In accordance, also no BMI-dependent effects on inflammatory symptoms 
and fever were observed. Finally, BMI is only an indirect measure of obesity, as it assumes that 
overweight is attributed to excess body fat, while in fact well trained muscular subjects with 
low levels of body fat may actually have higher BMI’s. Previous studies have shown that, after 
adjustment for BMI, waist circumference and the waist-to-hip ratio were strongly associated with 
the risk of death for non-hospitalized patients,38 whereas a higher mortality rate was observed 
for adults with a thigh circumference less than 60 cm.39 Unfortunately, these measurements or 
more direct measures of body fat percentage, such as skin fold measurements or bioimpedance 
determinations were not available as the primary aim of the individual trials in which these 
subjects participated was not to investigate the effect of body fat on innate immunity. 
In conclusion, we have studied the effect of BMI on the systemic cytokine response induced 
by endotoxin administration in a large group of healthy young males and found no relation 
between BMI and the cytokine response. Our data suggest that the better prognosis of obese 
patients during critical illness is unlikely to be mediated through an altered cytokine response. 
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abstract
A widely applied method to study the activation of the innate immune system is in vitro 
stimulation of whole blood using lipopolysaccharide (LPS). However, it is unclear if in vitro 
cytokine production relates to in vivo cytokine levels elicited during experimental endotox-
emia or sepsis.
To determine the correlation between in vitro cytokine production and the in vivo inflam-
matory response, blood was obtained from 15 healthy volunteers for in vitro incubation 
with E. coli LPS, immediately followed by experimental E. coli endotoxemia. Correlations of 
in vitro and peak in vivo cytokine concentrations were determined using Pearson correlation 
coefficient.
In stimulated whole blood, tumor necrosis factor ( TNF)-α, interleukin (IL)-1β, IL-6, IL-10 and 
IFN-γ were induced to 279±53, 392±64, 5312±624, 83±20 and 343±85 pg/mL, respectively, 
whereas in vivo cytokine induction led to cytokine levels of 603±123, 11±1, 4999±1228, 
167±25 and 194±40 pg/mL respectively. Correlation coefficients between the in vitro and 
in vivo cytokine concentrations were for TNF-α, IL-1β, IL-6, IL-10 and IFN-γ: -0.10 (p=0.7), 
0.09 (p=0.8), 0.36 (p=0.2), 0.19 (p=0.5) and 0.40 (p=0.1) respectively.
Comparison between in vitro and in vivo stimulation with LPS shows no correlation between 
the amount of cytokines produced. In vitro cytokine production therefore does not predict 
the in vivo inflammatory response.
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introduction
Activation of the cytokine network is of pivotal importance in directing the course of sepsis. In 
patients suffering from sepsis or septic shock, cytokine levels are significantly higher in non-sur-
vivors compared to survivors, supporting increasing evidence that the innate immune response 
directly correlates to early, but not late sepsis mortality.1–3
 Therefore, the quantity and pattern of cytokine production is widely studied in various in vitro and 
in vivo models. In vitro, the pathophysiological pathways of the inflammatory cascade triggered by 
Toll-like receptor-4 are widely studied using stimulation of human whole blood or isolated cells 
with lipopolysaccharide (LPS) derived from Gram-negative bacteria. In comparison, experimental 
endotoxemia represents an in vivo model to investigate the LPS induced inflammatory response.4
This model has improved our understanding of the innate immune response and its subsequent 
effects on e.g. coagulation, cardiac, renal and vascular dysfunction.5–9
However, while monocytes are activated during whole blood stimulation, several animal studies 
have demonstrated that tissue macrophages are crucial for the in vivo cytokine response.10–13
It is unclear to what extent in vitro cytokine production during stimulation experiments resembles 
the in vivo inflammatory response.
The present study compares cytokine production in LPS stimulated whole blood from healthy 
volunteers to their in vivo cytokine production during human experimental endotoxemia and 
examines to what extent the LPS stimulated-whole blood cytokine response predicts the inflam-
matory response in vivo.
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methods
Subjects
After approval of the study protocol by the local ethics committee, 15 (5 female and 10 male) 
healthy volunteers gave written informed consent to participate in this study, which was part 
of a larger trial investigating the pathophysiology of LPS-tolerance (NCT 800246714)14 and 
vascular function during endotoxemia (this study was completed prior to the NCT registration 
obligation).8 Screening of the subjects within 14 days prior to the conduction of the experiments 
revealed no abnormalities in medical history and physical examination. Routine laboratory tests 
and ECG were normal. All subjects tested HIV and Hepatitis B negative. Subjects who had a 
febrile illness in the two weeks preceding the experiments or who were taking prescription drugs 
(except for oral contraceptives) were excluded. Ten hours (h) prior to the LPS administration 
subjects refrained from caffeine, alcohol and food.
Experimental design
All subjects were admitted to our research unit for 24 h. After arrival, an intra-arterial catheter 
(Angiomat, Deseret Medical, Becton Dickinson, Sandy UT, U.S.A.) was inserted to permit blood 
sampling and continuous blood pressure monitoring using an arterial pressure monitoring line 
(Viggo Spectramed, 5269-129). Continuous heart rate monitoring was performed using a 3 lead 
ECG. A canulla was placed in an antecubital vein to permit the administration of endotoxin and 
prehydration as described previously.15
To determine the LPS-induced changes in body temperature an infrared tympanic thermometer 
(Sherwood Medical, ’s-Hertogenbosch, the Netherlands) was used every 30 minutes (min). At 
t=0 h, 2 ng/kg U.S. Standard Reference Endotoxin Escherichia coli O:113 obtained from United 
States Pharmacopia Convention, Rockville, U.S.A. (for study8) and Pharmaceutical Development 
Section NIH, Bethesda, Maryland U.S.A. (for study14) was administered intravenously. Prior to 
the administration of endotoxin, blood for in vitro stimulation as well as baseline determination 
of cytokines was drawn. Afterwards, arterial blood was sampled at 30, 60, and 90 min and 2, 3, 
4 h after endotoxin administration to determine the maximal induced concentration of each 
cytokine per individual. (Figure 1).
For the in vitro stimulation test, blood was sampled using pyrogen free heparinized tubes (Becton 
Dickinson). Directly afterwards 200 μl heparinized blood was incubated combined with 700 
μL RPMI (1% glutamine-1% pyruvate-1% garamycine) and 100 μL E. coli LPS 1 ng/mL during 
24 h at 37°C and 5% CO2. After incubation, blood was centrifuged at 20000 x g during 5 min 
at 20°C . Thereafter plasma was aspirated and stored at -20°C until cytokine measurements. 
Concentrations of tumor necrosis factor(TNF)-α, interleukin(IL)-1b, IL-6, IL-10, and IFN-γ were 
measured using Bioplex (Bio-Rad Laboratories, Hercules, USA) and Luminex assays as described 
previously.16
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Figure 1: Flow chart of blood sampling and cytokine measurements.
At baseline, blood was sampled for in vitro incubation with LPS and for baseline cytokine measurements, 
afterwards, 2 ng/kg E. coli LPS was administered intravenously. Thereafter, blood was sampled at several time 
points (indicated with *).
Calculations and Statistical Analysis
Data are expressed as mean ± SEM unless otherwise specified. In vitro and in vivo cytokine con-
centrations were correlated to assess their relation. To demonstrate the degree of the innate 
immune response within each model correlation of TNF-α-IL-6 concentrations and TNF-α-IL-10 
concentrations were determined. After confirmation of normal distribution using Kolmogor-
ov-Smirnoff analysis, correlations were analyzed by Pearson correlation coefficient. Furthermore, 
Student’s t-test were performed as appropriate. Data expressed for heart rate and mean arterial 
pressure were averaged during the 30 min before endotoxin administration and the period of 
30 min when endotoxin effects were most dominant. A p-value of <0.05 was considered to 
indicate significance.
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results
Age, height and weight of the subjects averaged (mean±SD) 21 ± 2 yrs, 180 ± 9 cm and 76 ± 
10 kg respectively.
Clinical parameters
In vivo LPS administration induced the expected flu-like symptoms after 1 to 2 h. Body temper-
ature increased 1.7 ± 0.1 oC (p< 0.001). Before LPS administration, the average concentration 
of leukocytes was 6.0 ± 0.3 ×109/L. After a decline after 1 h, leukocyte concentrations rose to 
12.1 ± 0.9 ×109/L (p<0.001) at 6 h after LPS administration. Baseline C-reactive protein (CRP) 
concentrations were below the detection limit and increased to 22.5 ± 2.7 mg/L (p<0.001) at 
12 h after LPS administration.Heart rate increased from 65 ± 3 to maximally 95 ± 3 bpm at 3 
h 30 min after LPS administration (p<0.001), mean arterial pressure decreased from 100 ± 5 
to 86 ± 3 mm Hg at 4 h 30 min after LPS (p<0.0001).
In vivo cytokine production
After administration of LPS to our healthy subjects, induction of all measured cytokines was 
observed. Typically for this model, a peak in TNF-α and IL-1β was demonstrated at 90 min after 
LPS administration. For IL-6, IL-10 and IFN-γ peak values were measured after 2 h. Table 1
demonstrates the group averages of the peak values for each cytokine measured.
Table 1: In vitro and in vivo cytokine production.
In vitro
total induction (pg/mL)
In vivo
peak value (pg/mL)
p-value
in vivo vs in vitro
TNF-α 279 ± 53 603 ± 123 <0.05
IL-1β 392 ± 64 11 ± 1 <0.001
IL-6 5312 ± 624 4999 ± 1228 0.82
IL-10 83 ± 20 167 ± 25 <0.001
IFN-γ 343 ± 85 194 ± 40 <0.05
The in vitro data are cytokine concentrations after whole blood incubation with E. coli LPS for 24 hrs. In vivo data 
are averaged maximal values per individual after in vivo LPS administration. Data demonstrated are mean ± SEM.
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In vitro cytokine production
Lipopolysaccharide stimulated whole blood drawn from our healthy subjects prior to systemic 
LPS administration resulted in an increase of all measured cytokines as illustrated in Table 1.
Comparison of in vitro and in vivo results
Figure 2 demonstrates the lack of correlation between in vitro and in vivo levels of all measured 
cytokines. Correlation coefficients of TNF-α, IL-1β, IL-6 and IL-10 were -0.10 (p=0.7), 0.09 
(p=0.8), 0.36 (p= 0.2) and 0.19 (p=0.5), respectively. For IFN-γ the correlation coefficient was 
0.40 with a p- value of 0.1.
Figure 2: Scatter plots of in vitro and in vivo cytokine levels.
Symbols represent the in vitro cytokine levels determined after 24 h incubation with E. coli LPS and in vivo 
cytokine levels maximally induced after administration of 2 ng/kg E. coli LPS to healthy volunteers. The p-values 
were p=0.7 for TNF-α, p =0.8 for IL-1β, p=0.2 for IL-6, p=0.5 for IL-10 and p =0.1 for IFN-γ.
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Within the same model of inflammation (i.e. in vitro or in vivo) correlations of proinflammatory 
cytokines TNF-α and IL-6 and of pro- vs anti-inflammatory cytokines TNF-α and IL-10 were also 
determined. As demonstrated in Figure 3, within the in vitro model, the correlation of TNF-α and 
IL-6 was 0.81 (p<0.001). In vivo the correlation was 0.73 (p=0.002). No significant correlations 
were found for TNF-α and IL-10 in either model (data not shown).
Figure 3: Scatter plots of TNF-α and IL-6 in vitro and in vivo.
Figures A represents the correlation of in vitro levels of TNF-α and IL-6 determined after whole blood 
incubation with E. coli LPS (p<0.001). Figure B represents the in vivo correlation of TNF-α and IL-6 maximally 
induced after administration of 2 ng/kg E. coli LPS to healthy volunteers (p<0.002).
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discussion
The present data demonstrate that cytokine production after whole blood stimulation in vitro 
with LPS does not predict the in vivo cytokine production induced during human experimental 
endotoxemia. This observation is of interest since a large amount of the research studying 
activation of the innate immune system is performed in stimulated whole blood experiments 
as a model for inflammation.
Interestingly, although dosing regimen and timing differ for in vitro and in vivo experiments, the 
cytokine concentrations measured seem to represent a different inflammatory pattern in the 
two models. While TNF-α and IL-10 secretion is highest in the in vivo model, the in vitro model 
demonstrates higher levels of IL-1β and IFN-γ while no differences between IL-6 concentration 
were observed.
 Although cytokine production is thought to be highly dependent on gene polymorphisms17within 
the same model, a significant correlation for proinflammatory cytokines TNF-α and IL-6 could 
be demonstrated indicating that the induction of cytokines within the model is intact. Although 
the demonstrated in vivo correlation is mainly depending on the female participants (the 3 
highest in vivo data points were all of female subjects) who are known to have higher in vivo 
LPS-induced cytokine concentrations18 the data are in agreement with the correlations found 
for other circulating cytokines in blood from septic patients.19
One of the main differences between in vitro and in vivo experiments is the exposure and dosage 
of LPS. During in vivo endotoxemia, the commonly used dosage is 2 or 4 ng/kg resulting in LPS 
plasma concentrations of maximally 0.013 ng/mL which are only detectable in blood during the 
first 15-30 min following administration.20,21However, during in vitro whole blood stimulation tests, 
LPS concentrations used are usually much higher reaching up to 1000 ng/mL.22,23
Moreover, during in vitro experiments, incubation periods of several hours are applied and LPS 
is not cleared as it is in vivo. Therefore, cytokine production measured in supernatants are cumu-
lative values secreted during the incubation time. In our experiments, we deliberately choose a 
relatively low in vitro dose (end concentration of 0.1 ng/mL). In our view, it is unlikely that the 
difference in LPS concentration accounts for the shift in inflammatory pattern because although 
the setup of in vitro experiments can differ greatly, cytokine production has been shown to be 
LPS dose-dependent and reproducible within subjects in subsequent whole blood studies.22,23
Most likely, the differences between in vitro and in vivo cytokine response presented are due to 
the fact that in vivo cytokine production is mainly driven by tissue dwelling cells, either resident 
macrophages or migrating leukocytes.24,25 An important part of the concentrations of cytokines 
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found in blood may be caused by spill-over and has been proposed as being just the ‘tip of the 
iceberg’.10 This notion is illustrated by several animal experiments. First, following LPS infusion 
in mice, expression of tissue mRNA of TNF-α, IL-1β and IL-6 is increased in brain, skeletal 
muscle, liver and lung. In some models, an increased expression of TNF-α mRNA does not 
increase plasma concentrations indicating that the stimulus is only sufficient to increase cytokine 
transcription but not translation or that cytokine synthesis is not enough to increase plasma 
concentrations.26 In addition, in rodents treated with LPS, not only mRNA expression but actual 
TNF-α synthesis occurs in several organs, including kidney, heart, pancreas, spleen, lung, fallopian 
tubes and uterus, but not in other organs.11 Other studies demonstrate LPS-induced IL-1β, 
IL-6 and TNF-α production in kidney, liver, spleen, adrenal gland and peritoneum cells.27,28 Finally, 
in cyclophosphamide-induced neutropenia in mice, cytokine production during endotoxemia is 
not abolished, but aggravated. Interestingly, in vitro, peritoneum derived macrophages of neutro-
penic mice synthesize more cytokines compared to controls. These findings indicate that blood 
dwelling leukocytes are not the driving force for in vivo cytokine production.13
Although concentrations of cytokines measured in blood or plasma appear to mainly result from 
spill-over, their concentrations do correlate to the amount of the insult and the clinical outcome 
in patients suffering diseases associated with the production of large amounts of cytokines, such 
as sepsis.1–3
Nevertheless, the lack of correlation between in vitro and in vivo production of cytokines pre-
sented in this study may explain the discrepancies that are found concerning the amount of 
cytokines produced in vitro and in vivo during certain circumstances. For example, cytokine 
production is higher in females compared to males18 and older vs younger subjects29 during 
experimental endotoxemia, whereas the opposite is was found during stimulated whole blood 
experiments.30
A confounding factor in in vitro experiments are the steps taken to prepare and incubate the 
samples. For instance, in our in vitro experiments as well as many others, heparin is added to 
the blood samples as anti-coagulant but is known to augment the cytokines produced by whole 
blood and isolated cells.31–33 Although whole blood stimulation offers the advantage of the pres-
ence of blood-borne factors and other cells in physiological proportions, in light of the current 
observations, it would be of interest to determine if cytokines produced by isolated monocytes 
stimulated with LPS demonstrate a better correlation to the proposed tissue macrophage 
derived cytokine production. Also, it would be interesting to lower the LPS dose used in vitro 
even more and shorten the exposure time.
While our results demonstrate that the role of circulating cells in the in vivo innate immune 
response is limited, few studies have demonstrated that in very specific situations in vitro cytokine 
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production can predict a clinical outcome measure. In a study performed in newborns undergoing 
cardiac surgery, pre-operative in vitro IL-6 after stimulation with LPS could predict oxygenation 
index during recovery. However no correlation of pre-operative cytokine production and other 
morbidity or mortality could be demonstrated.34
In oncology research, in vitro cytokine production has been explored as a possible marker adding 
to existing tumor markers to predict the risk of metastatic disease. A recent study demonstrated 
that high pre-operative IL-6 production by mononuclear cells after LPS stimulation is associated 
with a poor prognosis in patients undergoing radical surgery for colorectal carcinoma.35 Possibly, 
in extended malignant disease, the immune response, and therefore also the in vitro response to 
LPS, is altered and related to the stage of the disease. Also, in surgical intensive care patients, a 
lower in vitro IL-6 and TNF-α production after LPS stimulation is associated with sepsis and poor 
outcome. This is most likely the effect of immune paralysis as a result of monocyte tolerance 
to endotoxin and an indication of an impaired immune response both in vitro and in vivo.36,37 
Although the in vitro cytokine response to LPS seems of use in these very specific circumstances, 
further research to validate these options is necessary to determine their role in every day 
clinical medicine.
In conclusion, although in vitro stimulated whole blood experiments are a widely used and an 
important model to elucidate the intracellular pathways and intercellular communications of the 
innate immune response, caution should be taken in extrapolating data from the in vitro models 
to clinical in vivo inflammatory states and patients. While in vitro whole blood stimulation can 
reliably determine if a subject is a high or low cytokine responder, it does not predict the degree 
and pattern of cytokine release as it occurs in vivo. This effect is most likely due to tissue derived 
cytokine production with different sensitivity and kinetics.
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abstract
Heme oxygenase (HO)-1 is the inducible isoform of heme degradation, which is up-regu-
lated by multiple stress stimuli. HO-1 has major immunomodulatory and anti-inflammatory 
effects via its cell-type-specific functions in mononuclear cells. 
Contradictory findings have been reported on HO-1 gene regulation by the Toll-like receptor 
(TLR)4 ligand lipopolysaccharide (LPS) in these cells. Therefore, we re-investigated the effect 
of LPS on HO-1 gene expression in human and murine mononuclear cells in vitro and in vivo. 
Remarkably, LPS down-regulated HO-1 mRNA levels in primary human peripheral blood 
mononuclear cells (PBMCs), CD14+ monocytes, macrophages, dendritic cells and granulo-
cytes, but up-regulated HO-1 mRNA levels in murine macrophages and human monocytic 
leukemia cell lines. Furthermore, experiments with human CD14+ monocytes revealed that 
activation of other TLRs including TLR1, 2, 5, 6, 8 and 9 decreased HO-1 mRNA expression. 
LPS-dependent down-regulation of HO-1 was specific, because expression of cyclo-oxy-
genase-2, NADP(H)-quinone-oxidoreductase-1 and peroxiredoxin-1 was increased under 
the same experimental conditions. Notably, LPS up-regulated expression of Bach1, a critical 
transcriptional repressor of HO-1. Moreover, knockdown of this nuclear factor enhanced 
basal and LPS-dependent HO-1 expression in mononuclear cells. Finally, down-regulation 
of HO-1 in response to LPS was confirmed in PBMCs from human individuals subjected to 
experimental endotoxemia. In summary, LPS down-regulates HO-1 expression in primary 
human mononuclear cells via a Bach1-mediated pathway. Since LPS-dependent HO-1 regu-
lation is cell-type- and species-specific, experimental findings in cell lines and animal models 
need careful interpretation.
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introduction 
The heme oxygenase (HO) system has powerful antioxidant and anti-inflammatory effects.1–4 
HO is the rate-limiting enzyme of heme degradation and produces equimolar amounts of carbon 
monoxide (CO), iron, and biliverdin.5 HO-1, the inducible isoform of this enzyme, is up-regulated 
by multiple pro-oxidant and proinflammatory stimuli via the interplay of various transcription 
factors and signaling cascades.6,7 By contrast, the constitutively expressed isoform, HO-2, is not 
regulated by such stimuli.3,8 Anti-inflammatory and immunomodulatory effects of HO-1 have 
been shown in murine and human genetic HO-1 deficiency.9,10 Moreover, targeted induction of 
HO-1 or administration of its effector molecules have been associated with beneficial effects 
in animal models of sepsis and organ transplantation.11–15 In particular, the immunomodulatory 
effects of HO-1 have been linked with its cell-type-specific functions in mononuclear cells.16,17 
Lipopolysaccharide (LPS) is a cell wall component of Gram-negative bacteria and a ligand for 
the cell surface receptor Toll-like receptor (TLR)4, which is a classical activator of the innate 
immune response.18 Moreover, LPS is known to be a central mediator of sepsis and septic 
shock, and is frequently used as an immunostimulator in in vitro and in vivo models.19 Activation 
of mononuclear cells with LPS leads to increased production of reactive oxygen species (ROS), 
nitric oxide (NO) and proinflammatory cytokines.20 In animal models of sepsis, increased HO-1 
gene expression has been found in macrophages of different organs.3,21,22 Moreover, independ-
ent groups have demonstrated that LPS markedly up-regulated HO-1 in various models of 
human and rodent monocytes or leukemic cell lines in vitro.23–26 Conflictingly, HO-1 has also 
been shown to be markedly down-regulated by LPS in primary human monocytes 27 and during 
LPS-dependent maturation of dendritic cells (DCs).28 To reconcile these contradictory findings 
on HO-1 expression, we re-investigated the regulation of HO-1 by LPS in different types of 
mononuclear cells in vitro and in vivo. Moreover, we addressed the role of the nuclear repressor 
Bach129,30, which has recently been shown to be crucial for the immunological functions of HO-1 
in mononuclear cells.31
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methods
All experiments were performed after approval of the local ethics committee and are in agree-
ment with the declaration of Helsinki and Good Clinical Practice guidelines. 
Cell preparation and culture
Mouse macrophages were prepared as described previously.32 Human PBMCs were isolated 
from buffy coats of healthy blood donors by discontinuous Ficoll-Paque density gradient cen-
trifugation and resuspended at a concentration of 1 ×106 cells/mL in standard M’ medium 
(Lonza, Vervies, Belgium) supplemented with 10% human AB serum (C.C.pro, Neustadt/W., 
Germany), as described before.33 Primary monocytes were isolated from the PBMCs using the 
MACS magnetic separation system with a human monocyte isolation kit II (Negative isolation)
(Miltenyi Biotec, Bergisch Gladbach, Germany). CD14+ cells were >95% pure as determined by 
flow cytometry. CD14+ cells were cultured in six-well flat-bottom plates in 1 mL M’ medium.33 
For the generation of human macrophages, isolated CD14+ cells were treated with 800 U/mL 
M-CSF (PeproTech, Hamburg, Germany) for 4 days. The generation of immature human DCs 
was performed as described previously.33 Human neutrophils were isolated from freshly obtained 
peripheral blood of healthy volunteers as previously described.34 In brief, purified neutrophils 
were washed in PBS and then re-suspended in RPMI-1640. Neutrophil purity was typically 90% 
as determined by cytospin, and cell viability was more than 95% according to 0.4% trypan blue 
staining. Monocytic human leukemia cell lines, THP-1 and MonoMac-6 (MM-6) (ATCC, Manassas, 
VA, USA), were also maintained in standard M’ medium. Cell cultures were kept under air/CO2 
(19:1) at 100% humidity. After overnight culture, medium was replaced with medium containing 
TLR ligands and incubated for 18 h. The transcriptional inhibitor actinomycin D (AD)(5 mg/
ml) and protein synthesis inhibitor cycloheximide (CHX) (10 mg/mL) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Cell cultures were pretreated with these two compounds 
for 30 min before treatment with LPS. The various TLR-agonists (Invivogen, Toulouse, France) 
were used at the following concentrations: 1 µg/mL of TLR1/2 agonist Pam3CSK4, 108 freeze-
dried cells of heat killed Listeria monocytogenes (HKLM)/mL for TLR2 activation, 5 μg/ml of 
TLR2-agonist lipoteichoic acid (LTA), 10 μg/ml TLR3-agonist Poly-IC, 1 μg/mL of TLR4-agonist 
LPS (E. coli 0111:B4, Merck Biosciences, La Jolla, CA, USA), 1 µg/mL TLR5-agonist flagellin, 1 µg/
mL TLR2/6-agonist fibroblast stimulating ligand 1 (FSL1), 1 µg/mL of TLR7-agonist imiquimod, 
5 μg/mL TLR8 ligand ssRNA40, 10 μg/mL of TLR9 ligand oligodeoxynucleotide (ODN) 2006. 
Heme (Frontier Scientific, Logan, UT, USA) was applied at a final concentration of 10 µmol/L. 
All other chemicals were purchased from Sigma-Aldrich and Roche Applied Science (Mannheim, 
Germany), unless otherwise indicated.
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Transfection of CD14+ cells with Bach1 siRNA
CD14+ cells (1x106 cells/well) were transfected with Human Monocyte Nucleofector Kit C 
(Amaxa Biosystems, Gaithersburg, MD, USA) according to the manufacturer’s protocol. Equiv-
alent molar concentrations of human Bach1 siRNA and non-targeting negative control siRNA 
(Thermo Fisher Scientific, Waltham, MA, USA) were used to yield a final concentration of 50 
nmol/L. Transfected cells were incubated for 48 h before treatment. To evaluate the efficiency of 
Bach1 knockdown, cells were lysed and subjected to real-time reverse transcription (RT)-PCR 
and Western blot analysis.
Experimental human endotoxemia
All healthy volunteers were participants of a pharmacological intervention study (NCT00785018)35, 
which was approved by the local ethical committee (CMO Arnhem-Nijmegen) under number 
2008-197. The study was also formally announced at the central Dutch medical ethical com-
mission and received approvement (NL 24017.091.08). The experiments were conducted after 
written informed consent and according to the rules of Good Clinical Practice (GCP). Ten 
non-smoking, healthy male volunteers were included, who were not taking any medication and 
did not have a relevant medical history. No abnormalities were present during physical exam-
ination, laboratory tests and electrocardiography. Volunteers were tested negative for HIV and 
hepatitis B and did not suffer from a febrile illness in the 14 days prior to the study. Subjects 
refrained from food 10 h before the start of the experiment. All experiments were performed at 
the Radboud University Medical Centre intensive care research unit. During experiments, heart 
rate (electrocardiogram) and blood pressure (intra-arterially) were monitored continuously. 
Before LPS infusion, prehydration with 1500 mL of 2.5%/0.45% glucose/NaCl was administered 
intravenously. Thereafter, 150 mL/h was infused to maintain an optimal hydration status. At t=0 
h all subjects received LPS (purified LPS dissolved in 0.9% NaCl) in a dose of 2 ng/kg prepared 
from E. coli O:113 (lot Ec-5, Center for Biological Evaluation and Research, FDA, Bethesda, MD, 
USA) intravenously over one min. Subjects were observed for 10 h following LPS infusion with 
serial blood sampling. 
Real-time RT-PCR 
For our in vitro experiments, total RNA was isolated from cells with the RNeasy kit (Qiagen, 
Hilden, Germany) and cDNA was synthesized by reverse transcription using the high-capacity 
cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA). Inventorized TaqMan 
assay mixes (Applied Biosystems) were used for quantification as previously described.36 Human 
TaqMan assays used were: Hs00157965_m1 for HO-1, Hs01573472_g1 for COX-2 (PTGS2), 
Hs00168547_m1 for NAD(P)H-quinone oxidoreductase-1 (NQO1), Hs00602020_mH for 
peroxiredoxin-1 (Prx1), Hs00230917_m1 for Bach1, and 4333764F/4352934E for GAPDH. 
Mouse TaqMan assay Mm00516007_m1 for HO-1 and 4352932E for GAPDH were used. Ampli-
fication was performed using the TaqMan Gene Expression Master Mix on a StepOnePlus™ 
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Real-Time PCR System (Applied Biosystems) according to the manufacturer’s instructions. For 
our in vivo endotoxemia experiments, PAXGene© blood RNA tubes (PreAnalytiX, Qiagen, Venlo, 
The Netherlands) were used for mRNA isolation at baseline, 2 and 4 h after LPS administration 
and stored at -80°C until further processing. RNA was extracted using the whole blood RNA 
kit (Qiagen) according to the manufacturer’s instructions. cDNA synthesis was performed using 
an Omniscript reverse transcriptase kit (Qiagen). cDNA was stored at -20°C until further anal-
ysis. Amplification was performed with the ABI Prism 7000 Sequence Detection System. The 
master mix solution consisted of TaqMan Universal PCR Mastermix, sterile water and probe. The 
primer-probe-sets used were Hs99999905_m1 for glyceraldehyde-3-dehydrogenase (GAPDH), 
Hs00157965_m1 for HO-1, Hs00157969_m1 for HO-2, and Hs01573471_m1 for COX-2 (all 
from Applied Biosystems). The constitutively expressed gene GAPDH, was used for normaliza-
tion of cDNA levels in all experiments. The ΔΔCT method was used to quantify mRNA levels, 
according to the manufacturer’s protocol. 
Western blot
For in vitro experiments, cells obtained from cell cultures were washed twice with 0.9% NaCl. 
300 mL of lysis buffer (2% SDS, 10% glycerol, bromophenolblue, 0.4 M dithiothreitol, 4% protease 
inhibitors) was added, cells were scraped from culture dishes and then homogenized by passage 
through a 25-gauge needle. The homogenate was incubated for 3 min at 95°C and the protein 
content was determined in the supernatant by the Bradford method. Total protein (50 to 100 
μg) was loaded onto a SDS-polyacrylamide gel (NuPAGE 4-12% Bis-Tris gel, Invitrogen) and 
electrophoretically separated under reducing conditions and then transferred to polyvinylidene 
difluoride membranes (Millipore, Bedford, MA, USA) essentially, as described previously.37 Mem-
branes were blocked with PBS containing 5% skim milk or Candor Blocking solution (Candor, 
Wangen im Allgäu, Germany), for 1 h at room temperature (RT). The primary antibodies against 
HO-1 (Enzo Life Sciences, Lörrach, Germany) and GAPDH (Santa Cruz Biotechnology, Heidel-
berg, Germany) were used at a 1:1000 dilution. The primary antibody against Bach1 was from 
Santa Cruz Biotechnology and was used at a 1:750 dilution. Secondary antibodies were goat 
anti-rabbit IgG HRP (Biorad, München, Germany) and anti-mouse IgG HRP (Dako, Glostrup, Den-
mark) and were used at a 1:20,000 and 1:2000, respectively. The ECL chemiluminescent detection 
system (Thermo Fisher Scientific, Schwerte, Germany) was used for detection according to the 
manufacturer’s instructions. The chemiluminescent auto-radiographic signals were visualized and 
quantitated with the Fluorchem FC2 gel documentation system or using GE-X ray films. 
For in vivo experiments, blood was drawn at baseline, 2 and 4 h after LPS administration using 
CPT tubes (Becton-Dickinson, Alphen a/d Rijn, The Netherlands) for isolation of PBMCs accord-
ing to the instructions of the manufacturer. Cells were stored at -80°C after snap freezing until 
analyses. Then, the PBMC pellets were defrosted and lysed for 30 min on ice using lysis buffer (1 
mmol/L EDTA, 1 mmol/L PMSF, 0.5% Triton X-100 and protease inhibitor (Complete Mini, Roche 
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Applied Science, Almere, The Netherlands) in phosphate buffered saline (PBS) 1:100. Cell lysates 
were centrifuged for 2 min at 20,000 x g at 4°C and 10 μL lysate was separated by SDS/PAGE 
using a 12.5% gel. Proteins were blotted onto a nitrocellulose membrane using the BioRad iBlot 
system and the membrane was blocked for 1 h at RT using 5% ELK (milk powder, Albert Heijn, 
The Netherlands) in PBS. The blot was incubated for 1 h at RT with rabbit-anti-HO-1 antibody 
(1:5,000, Stressgen/ITK, Uithoorn, The Netherlands). Mouse-anti-β-actin antibody was simulta-
neously incubated to serve as a protein loading control (1:100,000, Sigma-Aldrich). Antibodies 
were diluted in 2.5% ELK containing 0.1% Tween-20. Afterwards, the membrane was rinsed three 
times with PBS and washed three times for 10 min with PBS containing 0.1% Tween-20. The sec-
ondary antibodies, IRDye800 conjugated anti-mouse IgG (1:10,000, Rockland, Heerhugowaard, 
The Netherlands) and Alexa Fluor 680 goat-anti-rabbit IgG (1:10,000, Molecular Probes), were 
incubated for 45 min at RT in Odyssey Blocking Buffer containing 0.1% Tween-20 and 0.01% SDS. 
After rinsing with PBS three times and washing three times with PBS containing 0.1%Tween-20, 
the membrane was scanned using the Odyssey Infrared Imaging System (LI-COR Biosciences). 
Expression of HO-1 was assessed using channel 700 and β-actin expression at channel 800. 
Intensity of the bands was determined using the Odyssey application software.
Data analysis, calculations and statistics
All data were tested using either paired or unpaired Student’s t-test as appropriate (Prism 5, 
Graphpad Software, La Jolla, USA). All data are expressed as mean ± SEM and p<0.05 was 
considered statistically significant.
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results
LPS-dependent down-regulation of HO-1 gene expression in cell cultures of primary human mononu-
clear cells 
We determined the expression of HO-1 in various types of primary human mononuclear cells 
isolated from healthy volunteer donors. In CD14+ monocytes LPS markedly down-regulated 
HO-1 protein and mRNA expression levels (Figure 1A), whereas the prototypical HO-1 inducer 
heme caused a prominent up-regulation of HO-1. (Figure 1A) In time response studies we 
found that priming with LPS led to a fast (within 3 h) and persistent (+/- 50% lower after 24 
h) down-regulation of HO-1 compared to controls.(Figure 1B) Moreover, the latter effect of 
LPS was dose-dependent. (Figure 1C) Supplementation of LPS-treated CD14+ cells with heme 
restored HO-1 expression to mRNA levels of untreated control cells, indicating that heme can 
compensate for TLR4-mediated down-regulation of HO-1 (data not shown). HO-1 mRNA 
regulation by LPS was also determined in various other primary human cells of mononuclear 
origin, including total PBMCs, monocytes, macrophages, DCs and granulocytes. Although to a 
different extent, LPS priming of mononuclear cells decreased HO-1 gene expression. (Figure 
1D) In contrast to human CD14+ monocytes, HO-1 gene expression was markedly increased 
by LPS in mouse macrophages. (Figure 1E) Notably, in both human and murine mononuclear 
cells, LPS up-regulated production of TNF-α, independent of the differences in HO-1 regulation 
(data not shown). HO-1 gene expression was increased by LPS in two human mononuclear 
cell lines, THP-1 and MM-6, both of leukemic origin. (Figure 1F) Finally, we also investigated the 
effects of TLR ligands, other than LPS, on HO-1 gene expression in human CD14+ monocytes. 
All TLR ligands, except the TLR7 ligand imiquimod, significantly down-regulated HO-1 mRNA 
levels. (Table 1)  Taken together, the findings show that HO-1 expression is down-regulated by 
LPS in primary human mononuclear cells, but not in primary mouse macrophages or human 
leukemia cell lines.
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Figure 1: Effect of LPS and heme on HO-1 gene expression in primary human mononuclear cells and human 
leukemia cell lines
(A) CD14+ monocytes from human peripheral PBMCs were isolated and cultured as described in Methods. The 
effects of LPS (1 μg/ml) and heme (10 μmol/L) on HO-1 expression were examined by Western blot analysis 
after 6 h (left panel) and RT-PCR after 3 h (right panel). Values ± SEM represent the relative HO-1 mRNA 
levels normalized to GAPDH from ten independent experiments. Statistics, Student’s t-test for paired values: *, 
significant differences treatment versus control, p<0.002. (B, C) Human CD14+ monocytes were cultured with 
LPS (1 μg/mL) for the times indicated (B) and at increasing LPS concentrations (0.1 to 10 μg/mL) for 3 h (C), 
after which mRNA expression of HO-1 was determined by RT PCR. Values ± SEM represent relative HO-1 
mRNA levels normalized to GAPDH from three independent experiments. Statistics, Student’s t-test for paired 
values: *, significant differences treatment versus control, p<0.007. (D) Human peripheral blood mononuclear 
cells (PBMC), monocytes (Mono), macrophages (Mac), dendritic cells (DC), and granulocytes (Gran) were 
cultured as described in Methods. Cells were treated with LPS (1 μg/mL) for 3 h and mRNA expression of 
HO-1 was determined by RT-PCR. Values ± SEM represent relative HO-1 mRNA levels normalized to GAPDH 
from three independent experiments. Statistics, Student’s t-test for paired values: *, significant differences 
treatment versus control, p<0.007. (E) Mouse alveolar macrophages were isolated and cultured as described 
in Methods. The effects of LPS (1 μg/mL) and heme (10 μmol/L) on HO-1 expression were examined by 
Western blot analysis after 6 h (left panel) and RT-PCR after 3 h (right panel). Values ± SEM represent the 
relative HO-1 mRNA levels normalized to GAPDH from three independent experiments. Statistics, Student’s 
t-test for paired values: *, significant differences treatment versus control, p<0.002. (F) Human MM-6 and THP-1 
leukemia cell lines were treated for 3 h with LPS (1 μg/mL) or heme (10 μmol/L) and HO-1 mRNA expression 
was determined by RT PCR (n = 3). Values ± SEM represent the relative HO-1 mRNA levels normalized 
to GAPDH from three independent experiments. Statistics, Student’s t-test for paired values: *, significant 
differences treatment versus control, p<0.0001.
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Table 1: Relative change in HO-1 mRNA levels after 3h incubation of human CD14+ monocytes with various TLR 
ligands.
HO-1 SEM p-value
Control 1.00 0.00 NA
TLR1/TLR2 (Pam3CSK4) 0.14 0.01 <0.0001
TLR2 (HKLM) 0.15 0.02 <0.0001
TLR2 (LTA) 0.12 0.01 <0.0001
TLR3 (poly(I:C)) 0.73 0.07 0.02
TLR4 (LPS) 0.07 0.02 <0.0001
TLR5 (flagellin) 0.08 0.02 <0.0001
TLR2/TLR6 (FSL1) 0.12 0.02 <0.0001
TLR7 (imiquimod) 0.95 0.12 NS
TLR8 (ssRNA40) 0.28 0.03 <0.0001
TLR9 (ODN2006) 0.60 0.09 0.01
Concentrations used for incubation were 1 mg/mL Pam3CSK4, 108 freeze-dried cells of heat-killed L. 
monocytogenes/mL (HKLM) for TLR2 activation, 5 mg/mL TLR2 agonist lipoteichoic acid (LTA), 10 mg/mL TLR3 
agonist poly(I:C), 1 mg/mL TLR4 agonist LPS (E. coli 0111:B4), 1 mg/mL TLR5 agonist flagellin, 1 mg/mL TLR2/6 
agonist fibroblast-stimulating ligand 1 (FSL1), 1 mg/mL TLR7 agonist imiquimod, 5 mg/mL TLR8 ligand ssRNA40, 
10 mg/mL TLR9 ligand oligodeoxynucleotide (ODN). Data are expressed as the mean and SEM. Values 
represent relative HO-1 mRNA levels normalized to GAPDH. The p-values were determined using a paired 
Student’s t-test of baseline compared to the values after 3 h. NA, not applicable; NS, not significant.
Down-regulation of HO-1 by LPS but not other stress-inducible genes in human CD14+ monocytes
To determine the specificity of LPS-dependent HO-1 down-regulation in human mononuclear 
cells, we also studied the regulation of the inducible genes COX-2, NQO1 and Prx1, all of 
which have previously been shown to be coordinately up-regulated to HO-1 in mononuclear 
cells.26,32,38,39 In contrast to HO-1, treatment of human CD14+ cells with LPS, but not with heme, 
markedly up-regulated COX-2 expression (Figure 2) and to a lower extent that of the stress-in-
ducible antioxidant genes NQO1 and Prx1. Remarkably, COX-2 mRNA expression was also 
increased by other TLR ligands (Table 2). These findings suggest that down-regulation of HO-1 
by LPS is specific in mononuclear cells. 
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Figure 2: Regulation of COX-2, NQO1, and Prx1 by LPS and heme in comparison to HO-1 in CD14+ monocytes.
CD14+ monocytes from human PBMCs were incubated with LPS (1 μg/mL) and heme (10 μmol/L) for 3 
h, as indicated, and mRNA expression levels of HO-1, COX-2, NQO1 and Prx1 were determined. Values ± 
SEM represent the relative mRNA levels normalized to GAPDH from at least three independent experiments. 
Statistics, Student’s t-test for paired values: *, significant differences treatment versus control, p<0.05.
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Table 2: Relative change in COX-2 mRNA levels after 3h incubation of human CD14+ monocytes with various TLR 
ligands.
COX-2 SEM p-value
Control 1.00 0.05 NA
TLR1/TLR2 (Pam3CSK4) 11.25 1.95 <0.007
TLR2 (HKLM) 121.42 14.72 <0.002
TLR2 (LTA) 89.67 25.22 <0.02
TLR3 (poly(I:C)) 0.92 0.19 NS
TLR4 (LPS) 657.23 162.25 <0.02
TLR5 (flagellin) 1398.49 175.28 <0.003
TLR2/TLR6 (FSL1) 20.28 3.04 <0.004
TLR7 (imiquimod) 1.22 0.11 NS
TLR8 (ssRNA40) 902.93 106.36 <0.002
TLR9 (ODN2006) 1.11 0.11 NS
Concentrations used for incubation were 1 mg/mL Pam3CSK4, 108 freeze-dried cells of heat-killed L. 
monocytogenes/mL (HKLM) for TLR2 activation, 5 mg/mL TLR2 agonist lipoteichoic acid (LTA), 10 mg/mL TLR3 
agonist poly(I:C), 1 mg/mL TLR4 agonist LPS (E. coli 0111:B4), 1 mg/mL TLR5 agonist flagellin, 1 mg/mL TLR2/6 
agonist fibroblast-stimulating ligand 1 (FSL1), 1 mg/mL TLR7 agonist imiquimod, 5 mg/mL TLR8 ligand ssRNA40, 
10 mg/mL TLR9 ligand oligodeoxynucleotide (ODN). Data are expressed as the mean and SEM. Values ± SEM 
represent relative COX-2 mRNA levels normalized to GAPDH. The p-values were determined using a paired 
Student’s t-test of baseline compared to the values after 3 h. NA, not applicable; NS, not significant.
Role of Bach1 in LPS-dependent HO-1 down-regulation 
Bach1 is a transcriptional repressor of HO-1, the activity of which is mainly regulated via intracellu-
lar levels of free heme.29,40 Whereas priming of CD14+ monocytes with LPS increased, exposure 
to heme decreased Bach1 protein and mRNA expression levels (Figure 3A). We also determined 
the effect of the transcriptional inhibitor AD and that of the protein synthesis inhibitor CHX 
on HO-1 and Bach1 mRNA expression in CD14+ monocytes. While pre-incubation with AD 
only partially restored LPS-dependent down-regulation of HO-1 mRNA levels, CHX almost 
completely blunted this effect (Figure 3B). Moreover, AD reduced both basal and LPS-dependent 
up-regulation of Bach1 mRNA levels. In contrast, LPS-mediated induction of Bach1 mRNA was 
blocked by CHX (Figure 3C), which suggests that a pathway involving de novo protein synthesis 
is involved in this regulatory mechanism. 
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Figure 3: Regulation of Bach1 by LPS in CD14+ monocytes. Effects of actinomycin D (AD) and cycloheximide 
(CHX) on LPS-mediated regulation of HO-1 and Bach1 mRNA levels.
(A) CD14+ monocytes were exposed to LPS (1 μg/mL) and heme (10 μmol/L) for 3 h, as indicated, and 
protein (left panel) or mRNA (right panel) expression levels of Bach1 were determined as described in 
Methods. Values ± SEM represent the relative Bach1 levels normalized to GAPDH from three independent 
experiments. Statistics, Student’s t-test for paired values: significant differences treatment versus control: *, 
p<0.05, **, p<0.005. (B) Effects of pretreatment with AD (5 g/mL)(left panel) and CHX (10 mg/mL)(right 
panel) on LPS-dependent regulation of HO-1 mRNA expression levels in CD14+ monocytes. Values ± SEM 
represent the relative HO-1 mRNA levels normalized to GAPDH from three independent experiments. 
Statistics, Student’s t-test for paired values: *, significant differences treatment versus control, p<0.001; **, 
p<0.02. (C) Effects of AD (left panel) and CHX (right panel) on LPS-mediated induction of Bach1 mRNA 
expression in CD14+ monocytes. Values ± SEM represent the relative Bach1 mRNA levels normalized 
to GAPDH from three independent experiments. Statistics, Student’s t-test for paired values: *, significant 
differences treatment versus control, p<0.05.
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To confirm the role of Bach1 in HO-1 regulation by LPS, we also performed knockdown exper-
iments with siRNA directed against Bach1, which decreased levels of Bach1 mRNA and protein 
(Figure 4A and B). In comparison to control cells, Bach1 knockdown cells exhibited markedly 
higher basal and LPS-mediated HO-1 mRNA levels (Figure 4C). In summary, these findings sug-
gest that LPS-mediated down-regulation of HO-1 by LPS is mediated via a Bach1-dependent 
mechanism. 
Figure 4: Role of Bach1 for LPS-dependent HO-1 down-regulation. 
Knockdown of Bach1 in human CD14+ cells (siBach1) was performed as described in Methods. (A) Values 
± SEM represent relative Bach1 mRNA levels normalized to GAPDH from three independent experiments. 
Statistics, Student’s t-test for paired values: *, significant differences treatment versus control, p<0.05. (B) A 
representative Western blot is presented and values ± SEM with relative levels of Bach1 protein normalized 
to GAPDH from three independent experiments are shown. Statistics, Student’s t-test for paired values: *, 
significant differences treatment versus control, p<0.05. (C) LPS-dependent regulation of HO-1 mRNA levels 
in human CD14+ cells after knockdown of Bach1 (siBach1). Values ± SEM represent the relative Bach1 mRNA 
levels normalized to GAPDH from four independent experiments. Statistics, Student’s t-test for paired values: *, 
significant differences treatment versus control, p<0.002; **, significant differences Bach1 siRNA versus control 
siRNA, p<0.002.
HO-1 regulation in mononuclear cells of human individuals subjected to experimental endotoxemia
We next determined HO-1 expression in PBMCs isolated from 10 healthy male individuals with 
endotoxemia induced by infusion of LPS (2 ng/kg body weight). To confirm the proinflammatory 
effects of LPS, various clinical and laboratory parameters were analyzed. Clinical signs of inflam-
mation including headache, muscle pain, nausea, an increase of body temperature of 1.9 ± 0.5°C 
(p<0.001), decreased mean arterial blood pressure (101 ± 8 to 79 ± 8 mmHg; p<0.001) and 
rise in heart rate (66 ± 6 bpm at baseline to 93 ± 7 bpm; p<0.001) after LPS challenge were 
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observed. In addition, we observed a marked increase of leukocyte counts from 4.7 ± 1.9 ×109 
cells/L to 11.3 ± 2.5 ×109 cells/L after 6 h of LPS administration (p<0.001) (data not shown) 
and increased C-reactive protein. (Table 3) Moreover, a number of inducible pro- and anti-in-
flammatory cytokines were up-regulated. (Table 3) Similar to our in vitro findings, HO-1 mRNA 
expression was down-regulated, whereas COX-2 mRNA was up-regulated in PBMCs, which 
were isolated 2 and 4 h after LPS administration. Accordingly, HO-1 protein expression in human 
PBMCs was markedly reduced at 2 and 4 h after LPS infusion. (Figure 5) Taken together, the data 
from this in vivo model of human endotoxemia confirms our in vitro findings on LPS-dependent 
down-regulation of HO-1 gene expression in mononuclear cells.
Table 3: Inflammatory markers after the infusion of LPS (2 ng/kg) to healthy human volunteers.
Time after LPS (h) 0 2 4 24 p-value
IL-6 (pg/ml) 6 ± 0 1521 ± 209 650 ± 237 6±0 <0.001
TNF-α (pg/ml) 20 ± 0 1213 ±187 821 ± 83 20 ± 0 <0.001
IL-1β (pg/ml) 10 ± 0 32 ± 3 34 ± 5 10 ± 0 <0.001
MCP-1 (pg/ml) 44 ± 4 3605 ± 267 6161 ± 1302 62 ± 5 <0.01
IL-10 (pg/ml) 6 ± 0 73 ± 11 47 ± 11 7 ± 1 <0.001
IL-1RA (pg/ml) 61 ± 7 2578 ± 481 31540 ± 2583 82 ± 15 <0.001
CRP (mg/l) 5 ± 0 - - 39 ± 4 <0.001
IL-: interleukin, TNF-α: tumor necrosis factor-α, MCP-1: Monocyte chemotactic protein-1 CRP: C-reactive 
protein, -: not determined at this time point. Data are expressed as mean and SEM. p-values were determined 
using a paired Student’s t-test of baseline compared to the peak values. 
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Figure 5: HO-1 mRNA and protein expression in PBMCs from human individuals after infusion of LPS.
Human PBMCs were isolated before and 2 h or 4 h after LPS infusion to human individuals, as described in 
Methods. (A) Expression of HO-1 and COX-2 mRNA levels at baseline compared to 2 and 4 h after LPS 
infusion was determined by RT-PCR. Values ± SEM represent the relative HO-1 and the relative COX-2 mRNA 
levels normalized to GAPDH from ten individuals. Statistics, Student’s t-test for paired values: *, significant 
differences treatment versus baseline control, p<0.001. (B) HO-1 protein expression at baseline compared to 
2 and 4 h after LPS infusion was determined by Western blotting. Values ± SEM represent the relative HO-1 
mRNA protein levels normalized to β-actin from ten individuals. Statistics, Student’s t-test for paired values: *, 
significant differences treatment versus baseline control, p<0.005. 
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discussion 
HO-1 plays a major immunomodulatory role via its cell-type-specific anti-inflammatory functions 
in mononuclear cells.16,17,41,42The importance of HO-1 in inflammation has been highlighted 
in studies on murine and human genetic HO-1 deficiency, in both of which proinflammatory 
phenotypical features have been observed.9,10,42 In the present study, we demonstrate that LPS 
down-regulates HO-1 gene expression in various primary human mononuclear cells in vitro 
and in vivo. Furthermore, we provide evidence that LPS-dependent down-regulation of HO-1 
is mediated via the transcriptional repressor Bach1. 
Reportedly, HO-1 expression in mononuclear phagocytes is up-regulated by a large variety of 
stress stimuli, including LPS.7,43 Specifically, LPS has been shown to increase HO-1 gene expression 
in rodent peripheral blood mononuclear cells and in the mouse monocyte cell lines RAW264.7 
and J766.4.24,25,44,45 Opposite to these earlier findings, other reports have demonstrated that 
LPS down-regulates HO-1 expression in human mononuclear cells.27,28 Hence, we hypothesized 
that these discrepancies are related to the cell-type used in various experimental models. In 
support of this hypothesis, we found that LPS markedly down-regulates HO-1 gene expression 
in primary human mononuclear cells, including CD14+ monocytes, macrophages, DCs and 
granulocytes. (Figure 1) Moreover, LPS-dependent down-regulation of HO-1 gene expression 
was also observed in mononuclear cells obtained from healthy human individuals exposed to 
experimental endotoxemia. (Figure 5). These data are in agreement with previous findings on 
human monocytes27 and DCs.28 In contrast to primary human mononuclear cells, HO-1 was 
up-regulated in LPS-treated rodent macrophages. (Figure 1E) Thus, the current observations 
together with that of earlier reports on HO-1 regulation by LPS suggest that species-specific 
differences between rodent and human mononuclear cells may be responsible for these discrep-
ancies, which may have various explanations. Rodents not only live in an environment different to 
that of humans, but are also of much smaller size and have significantly shorter lifespans. It has also 
been demonstrated that rodents are more resistant to LPS in comparison to humans indicating 
that their immune systems may have evolved in subtly different ways. For example, inducible 
NO synthase (NOS), which is synonymous with NOS-2, is readily induced by interferon-g and 
LPS in murine, but not in human macrophages.46 Notably, HO-1 induction in mononuclear cells 
by LPS priming is well-documented in animal experiments. For example, HO-1 expression has 
been shown to be markedly increased in heart21, kidney, and, to a lesser extent, in liver, lung and 
brain of LPS-treated rats.22 Moreover, our results demonstrate differences in LPS-dependent 
regulation of HO-1 gene expression between primary human mononuclear cells and human 
leukemia cell lines (Figure 1), which are frequently used for in vitro experiments. Taken together, 
current findings along with those of previous reports indicate, that experimental observations 
on HO-1 regulation in murine cell culture models and in transformed monocyte cell lines cannot 
be directly translated to primary human mononuclear cells. 
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HO-1 down-regulation by LPS in human mononuclear cells involves the transcriptional repressor 
Bach1, which controls HO-1 gene expression via interaction with a Maf recognition site in the 
HO-1 gene promoter.29,47 A critical role of Bach1 in this regulatory pathway is supported by 
the inverse pattern of HO-1 and Bach1 protein and mRNA levels in LPS-treated CD14+ cells 
(Figures 1 and 3) and by HO-1 expression in Bach1 knockdown cells. (Figure 4) In accordance 
with our current findings, Miyazaki and colleagues have shown an up-regulation of Bach1 by LPS 
in human mononuclear cells.27 The mechanism of Bach1-dependent HO-1 regulation in response 
to LPS appears to involve a protein with short half-life, which regulates de novo synthesis of 
Bach1, as indicated by experiments with the protein synthesis inhibitor CHX. (Figure 3) Bach1 is 
a heme-binding protein and intracellular levels of free heme regulate this nuclear repressor.29,30 
Therefore, it is conceivable that free heme levels are involved in LPS-mediated HO-1 regulation 
via Bach1 in mononuclear cells. The marked LPS-dependent up-regulation of the heme-contain-
ing protein COX-2 in parallel to HO-1 down-regulation (Figure 2, Table 2) might suggest that 
incorporation of heme into COX-2 can decrease intracellular free heme levels, which in turn 
leads to Bach1-dependent repression of HO-1. In addition, Nrf2, a master regulator of the induc-
ible antioxidant cytoprotective response,48 has been shown to be involved in HO-1 regulation 
by LPS.49 However, the current data show a differential LPS-dependent up-regulation of the 
Nrf2-inducible genes NQO1 and Prx1 in comparison to that of HO-1 (Figure 2) suggesting a 
key role of Bach1 for LPS-dependent down-regulation of HO-1 in primary human mononuclear 
cells (Figures 3 and 4). Therefore, these findings are similar to those of a recent report on the 
Bach1-specific regulation of HO-1 by electrophilic stimuli in human keratinocytes.49
The Bach1/HO-1 pathway plays a central role for differentiation and immunological functions 
of mononuclear cells, as recently demonstrated in Bach1/HO-1 double knockout mice.31,50 Inde-
pendently, myeloid HO-1 has been shown to have critical immunomodulatory functions in a 
mouse conditional knockout model, in which HO-1 was specifically deleted in mononuclear 
cells.16 Importantly, the opposite regulation of HO-1 by LPS and other TLR ligands in murine 
and human macrophages has clinical implications, because myeloid HO-1 is a potential target 
for therapeutic interventions in various inflammatory disorders such as sepsis51 and malaria.52
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conclusions
In conclusion, the current study demonstrates that the TLR4 ligand LPS specifically down-reg-
ulates HO-1 in human mononuclear cells via the transcriptional repressor Bach1. These results 
implicate that experimental findings on HO-1 gene expression in various species and cell lines 
need careful interpretation, because HO-1 regulation in primary human mononuclear cells is 
different from that in widely used experimental animal models. Further studies are warranted 
to understand the regulation of HO-1 in mononuclear cells of different species. These studies 
may be important for clinical applications, in which myeloid HO-1 serves as a therapeutic target 
for the treatment of inflammation.
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abstract
This translational randomized and vehicle-controlled cross-over study was performed to 
assess the impact of heme arginate (HA) treatment on heme oxygenase-1 (HO-1) induction, 
endothelial function and insulin sensitivity in subjects with the metabolic syndrome (n=14). 
Both treatment periods consisted of 5 days. HA or vehicle (L-arginine) was administered 
intravenously on days 1 and 3. Forearm blood flow in response to acetylcholine and nitro-
glycerin was measured by venous occlusion plethysmography (day 3), insulin sensitivity by 
a hyperinsulinemic clamp procedure (day 5). HA did not improve endothelial function or 
insulin sensitivity but significantly reduced the vasodilator response to nitroglycerin (p<0.01). 
These negative findings are in contrast with preclinical data, which may be due to short-
term and limited HO-1 induction as well as interference by markedly elevated plasma heme 
levels observed after HA treatment (p<0.01). Future studies should pay attention to the 
delicate balance between sufficient dosing and timely normalization of plasma heme levels.
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introduction
Heme oxygenase (HO) is the rate-limiting enzyme in the breakdown of heme into free iron, 
carbon monoxide and biliverdin.1 Biliverdin is then rapidly converted into the antioxidant bilirubin 
by biliverdin reductase. An overwhelming amount of preclinical evidence on the anti-oxidant 
and anti-inflammatory effects of the inducible isoform HO-1 has fuelled speculations about the 
therapeutic use of HO-1 induction in human medicine.2 As the metabolic syndrome (Met-S), 
type 2 diabetes mellitus, and cardiovascular disease are all associated with the presence of oxi-
dative stress and chronic low grade inflammation3-5, these conditions constitute an important 
area for research on the clinical use of HO-1 induction as a novel therapeutic strategy. Indeed, 
many preclinical experiments on HO-1 induction show promising results in models for Met-S 
and type 2 diabetes mellitus.6 HO-1 induction ameliorates Met-S in obese mice7, improves insulin 
sensitivity in insulin-resistant rats8, reduces retroperitoneal adiposity and hyperglycemia in Zucker 
diabetic fatty rats9 and protects against endothelial dysfunction in high-fat-fed LDL-receptor 
knockout mice.10 Interestingly, recent data challenge the supposed beneficial role of HO-1 and 
conversely suggest that in obese settings HO-1 functioning may be disturbed, and, may even 
fuel insulin resistance.11
Both hemin and heme arginate (HA) have been reported to induce HO-1 expression in healthy 
volunteers.12,13 Furthermore, short-term HA treatment has been demonstrated to ameliorate 
experimental ischemia-reperfusion injury in healthy volunteers.14 For the Met-S, type 2 diabetes 
mellitus or cardiovascular disease, translational data on the impact of HO-1 are currently lacking. 
We therefore aimed to induce HO-1 by a short-term HA treatment and subsequently assess its 
effect on insulin sensitivity and endothelial function in subjects suffering from the Met-S.
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methods
Study population
Recruited subjects who met the Met-S criteria15 were invited to an additional and more extensive 
screening visit. Participants had to be at least 18 and no older than 70 years of age and were 
not allowed to have a positive history of drug abuse, active smoking, type 2 diabetes, or cardio-
vascular disease. In addition, subjects were prohibited from using vasoactive medication, statins, 
aspirin, and anti-oxidant vitamin supplements, as these drugs could influence both HO-1 activity 
and endothelial function. Subjects with clinical evidence of cardiac or pulmonary disease or with 
biochemical evidence of renal or hepatic abnormalities (results exceeding twice the upper limit 
of normal range) were excluded. Finally, subjects with unconjugated hyperbilirubinemia (total 
bilirubin level > 10 μmol/L) were excluded to avoid participation of subjects with the Gilbert 
syndrome. All subjects gave written informed consent prior to the first screening visit. The study 
protocol was approved by the local Medical Research Ethics Committee and consistent with 
the Declaration of Helsinki. 
Study design
In a randomized order and with a wash-out period of at least seven weeks in between, subjects 
received both a treatment with HA (Normosang®, Orphan Europe, France; 3 mg/kg with a 
maximum of 250 mg per dose) and a control treatment with equimolar amounts of L-arginine 
(3,2 mg/kg with a maximum of 267 mg per dose) to correct for a potential unintended impact 
of the release of L-arginine upon HA infusion. The time schedule of both treatment periods is 
provided in Figure 1. In brief, the study medication was administered intravenously on days 1 
and 3 of both treatment periods. Prior to the infusion on day 3, we assessed forearm blood flow 
(FBF). On day 5 of each treatment period, we took a fat biopsy and performed an euglycemic 
hyperinsulinemic clamp to assess insulin sensitivity.
During all visits, venous blood was drawn. Hematological parameters were assessed using an 
ADVIA 120 Hemalog (Bayer Diagnostic, Tarrytown, N.Y., USA) and clinical chemistry parameters 
including bilirubin and ferritin were determined using an Aeroset (Abbott Laboratories, Abbott 
Park, IL, U.S.A.). In addition, plasma samples were stored at -80° C for additional measurements 
including the ferric reducing ability of plasma (FRAP) assay and plasma heme levels.
A subcutaneous fat biopsy was taken under local anesthesia (2% Lidocaine HCl) after an over-
night fast. Adipose tissue was aspired from the lateral aspect of the hypogastrium, inferior to 
the umbilicus using a Hepafix Luer Lock syringe (Braun, Melsungen, Germany) and a 2.10 x 80 
mm Braun Medical Sterican needle. The adipose tissue was washed using a 0.9% saline solution, 
snap frozen and stored at -80° C until further analysis.
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Figure 1: Study overview.
HA: heme arginate bolus infusion; LA: L-arginine bolus infusion; Lab: hematology, chemistry and parameters of 
HO activity; FBF: assessment of endothelial function; Fat: fat biopsy; Clamp: hyperinsulinemic euglycemic clamp.
Markers of the HO-1 system
HO-1 was determined on multiple levels including mRNA (peripheral blood and adipose tissue) 
and protein (plasma). In addition, we assessed plasma levels of the HO-1 substrate heme, the 
HO-1 activity product bilirubin and the iron scavenger ferritin. Finally, plasma anti-oxidant capacity 
was assessed by means of the ferric reducing ability of plasma (FRAP) assay.
For the isolation of total RNA from peripheral blood, we used the PAXgene Blood mRNA kit 
(Qiagen Benelux B.V., Venlo, The Netherlands). Samples were handled according to the man-
ufacturers protocol. From adipose tissue, we extracted total RNA using TRIzol Reagent (Life 
Technologies Europe B.V., Bleiswijk, The Netherlands). RNA concentrations were determined 
using the NanoDrop 2000 Spectrophotometer (NanoDrop Products, Wilmington, DE, USA). 
cDNA synthesis was performed using the iScript cDNA Synthesis kit (Bio-Rad Laboratories 
B.V., Veenendaal, The Netherlands). Real-time PCR was performed using the iQ SYBR Green 
Supermix (Bio-Rad Laboratories B.V., Veenendaal, The Netherlands) and the CFX Real-Time 
System and C1000 Thermal Cycler (Bio-Rad Laboratories B.V., Veenendaal, The Nether-
lands). Expression of the heme oxygenase-1 (HO-1) gene was normalized to acidic ribosomal 
phosphoprotein P0 (ARP) gene expression levels. Primer sequences were: ARP, CACCATT-
GAAATCCTGAGTGATGT (sense), TGACAAGCCCAAAGGAGAAG (antisense); HO-1, 
TTTCAGAAGGGCCAGGTG (sense), AGACTGGGCTCTCCTTGTTG (antisense) (Biolegio 
B.V., Nijmegen, The Netherlands). HO-1 protein content of plasma was determined using the 
Immuno Set HO-1 (human) ELISA development kit (Enzo Life Sciences BVBA, Antwerp, Belgium).
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To assess plasma heme levels, 20 μL pure DMSO and subsequently 160 μl of a mixture of 250 
μL HCl (37%) into 10 ml of acetone was added to 20 μL of plasma. After cooling on ice for two 
minutes, the sample was centrifuged. Next, the supernatant was analyzed by reversed-phase high 
performance liquid chromatography. The mobile phase comprised of Solvent A (44% methanol, 
56% 0.1 M ammonium phosphate buffer pH 3.4, v/v) and Solvent B (100% methanol, v/v) using 
the following gradient: Solvent B, 0% at t0 to 100% at 14 minutes; then isocratic to 15 minutes; 
down to 0% at 16 minutes and isocratic to 21 minutes. The UV detector was set at a wavelength 
of 400 nm. The gradient separation of heme was performed on a GraceSmart RP18 column, 
150 x 4,6 mm i.d., 5 μm particle size at a column temperature of 60º C. The FRAP assay was 
performed according to the method of Benzie and Strain.16 FRAP values were obtained using a 
seven-point calibration curve of known amounts of Fe2+ and expressed in μmol Fe2+/L.
Endothelial function
Subjects were instructed to refrain from caffeinated foods and beverages on the day prior to 
the flow experiments. After overnight fasting, flow experiments were performed using venous 
occlusion plethysmography as described previously.17 In brief, FBF was assessed during the suc-
cessive administration of three increasing doses of acetylcholine (0.5, 2 and 8 μg min-1 dL-1 of 
forearm tissue), and nitroglycerin (0.25, 0.5 and 1.0 μg min-1 dL-1). 
Insulin sensitivity
Insulin sensitivity was measured by a 120 minutes hyperinsulinemic euglycemic clamp proce-
dure. These experiments were also performed in the morning after overnight fasting with the 
subjects in supine position in a quiet temperature-controlled room. Glucose and insulin were 
administered in an antecubital vein. Insulin (Novorapid, NovoNordisk, Denmark; diluted in 0.9% 
saline to a concentration of 1 U/mL with the addition of 2 mL of the subject’s blood per 50 mL) 
was infused at a constant rate of 60 mU min-1 m-2 body surface area (360 pmol min-1 m-2). The 
plasma glucose level was monitored at 5 minute intervals by sampling of arterialized blood from 
a cannulated vein on the dorsum of the controlateral hand, which was placed in a warm-air box.18 
Glucose concentrations were measured using a Biosen C_line GP+ (EKF-diagnostic, Barleben, 
Germany). Plasma glucose was clamped at a level of 5.0 mmol/L by variable infusion of a 20% 
glucose solution. Insulin sensitivity (M-value) was calculated from the average glucose infusion rate 
(μmol/min) between 90 and 120 minutes of the euglycemic clamp, divided by body weight (kg).
Statistical analyses
Statistical analysis was performed using the SPSS (version 16.0) and SAS (version 8.2) software 
package. Paired-samples t-test was used to compare Gaussian distributed data. For analysis of 
the FBF measurements, the last five flows of each dose were used. Prior to analysis, logarithmic 
transformation was performed to obtain a Gaussian distribution. The flow data were then aver-
aged per dose and subsequently analyzed in a mixed linear model with random factor subjects 
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and fixed factors treatment and dose. The log-transformed data used for statistical analysis are 
presented in Table 3. The data discussed in the text are medians instead of averages of the original 
flow data to approximate the effect of logarithmic transformation. Statistical significance was 
accepted at the 95% confidence level (p≤0.05).
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results
A summary of the screening, participation and drop out of subjects is provided in Figure 2. 
Sixty-three obese non-smoking subjects with a negative history of cardiovascular disease were 
recruited through local advertisements and gave written informed consent for participation. 
Sixteen of these subjects met the Met-S criteria as well as the additional criteria of our protocol. 
One of these subjects decided to withdraw informed consent prior to the actual enrollment in 
the cross-over study. Of the fifteen subjects that did participate in the study, one experienced 
a severe headache several hours after the first administration of HA. Additional examinations 
including a head CT scan did not reveal any abnormality. Because of the severity of the headache, 
we nevertheless decided to refrain from the second infusion of HA and terminate the partici-
pation of this subject. The results of the remaining fourteen subjects are presented.
Figure 2: Diagram illustrating the screening, participation and drop out of subjects
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Subject characteristics
Characteristics of the final study population are shown in Table 1. This population consisted of 
eight males and six females with an average age of 50.4 years and an average body mass index 
of 34.6 kg/m2. All subjects met the Met-S criteria with regard to elevated waist circumference 
and hypertension.15 Three of fourteen subjects demonstrated an elevated plasma level of fasting 
glucose. Two subjects were using corticosteroids chronically for psoriasis (topical application) 
and chronic obstructive pulmonary disease (inhalation) respectively. In both subjects, no dose 
adjustments were made during participation. A third subject was using small amounts of topical 
corticosteroids for eczema during the first day of his HA treatment. None of the remaining 
subjects suffered from active (auto)inflammatory disease during participation. Three subjects 
were using non-steroidal anti-inflammatory drugs on demand for musculoskeletal pain and on 
our request refrained from taking these drugs during the experiments.
Table 1: Characteristics of study population (n=14)
Sex 8 men, 6 women
Age (years) 50 (13; 25-69)
BMI (kg/m2) 35 (5; 29-44)
Waist circumference (cm) 116 (12; 96-129)
SBP (mm Hg) 145 (14; 131-168)
DBP (mm Hg) 89 (8; 72-100)
Fasting glucose (mmol/L) 5.3 (0.4; 4.5-6.0)
Triglycerides (mmol/L) 2.35 (0.99; 0.89-3.89)
HDL cholesterol (mmol/L) 1.1 (0.2; 0.77-1.37)
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: high-density lipoprotein; 
SD: standard deviation. Data are given as mean (SD; range).
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Markers of the HO-1 system
The outcome on the different markers of HO-1 induction is shown in Table 2. Apart from base-
line, these measures were determined 48 hours after the first and 48 hours after the second dose 
of both HA and control. The data discussed concern the data following HA treatment compared 
to the data following control treatment at the same time point. The plasma heme levels were 
elevated significantly after HA infusion compared to control. On HO-1 mRNA level, fat biopsies 
demonstrated a significant but modest increase (1.27 fold increase of mRNA level, p=0.03) after 
HA treatment, whereas no difference on mRNA levels were observed in the peripheral blood. 
On HO-1 protein level, the HO-1 plasma level increased upon the first HA infusion. Upon the 
second infusion, no difference was found. On the level of HO-effector molecules, plasma ferritin 
levels increased after both HA infusions, but plasma bilirubin levels remained unaffected. Finally, 
HA infusion did not alter the anti-oxidant capacity of plasma as measured by the FRAP assay.
Table 2: Impact of heme arginate at Day 3 and Day 5 on markers of HO-1 induction.
       DAY 3        DAY 5
HA LA p HA LA p
Plasma heme level (μmol/L) 11.7 (0.95) 6.6 (0.84) <0.01 20.7 (1.87) 6.0 (0.89) <0.01
Markers of HO-1 induction
HO-1 mRNA level
Adipose tissue (∆CT) 5.32 (0.20) 5.67 (0.18) 0.03
Blood (∆CT) 4.03 (0.20) 4.37 (0.16) 0.23
HO-1 protein level
Plasma (μg/L) 9.0 (0.85) 4.0 (0.53) <0.01 4.1 (0.63) 4.7 (0.62) 0.55
HO-1 effector molecules
Ferritin (μg/L) 184 (41) 159 (37) <0.01 178 (37) 150 (40) <0.01
Bilirubin (μmol/L) 7.86 (0.54) 8.36 (0.57) 0.25 7.08 (0.68) 7.43 (0.65) 0.21
Therapeutic effect
FRAP (μmol Fe2+/L) 1155 (48) 1182 (44) 0.28 1207 (53) 1224 (66) 0.54
Insulin sensitivity
M value (μmol/min/kg) 7.1 (0.72) 7.3 (0.82 0.54
HO-1: heme oxygenase-1; HA: heme arginate; LA: arginine; p: p-value; mRNA: messenger RNA; FRAP: ferric 
reducing ability of plasma; SEM: standard error of mean. Data are given as mean (SEM). Reported p-values are 
the result of paired t-tests.
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Adverse events
Headache was reported during HA treatment in seven cases and during control treatment in 
five cases. Nearly all subjects reported their headache upon the first but not the second infu-
sion of either HA or control. Only one subject experienced headache upon both the first and 
second infusion of control treatment. In time, two cases of headache were closely related to 
the administration of HA. In one of these cases, participation was ended for the severity of the 
headache. The other subject continued participation and did not experience headache upon the 
second infusion of HA. Besides, phlebitis was noted after HA infusion in three cases and after 
the control infusion in a single case.
Vascular and metabolic effects
The results of the FBF experiments are depicted in Table 3. Baseline flow after control treatment 
was comparable to baseline flow after HA treatment (2,2 and 2,4 mL min-1 dL-1 tissue in the 
intervention arm and 1.8 and 2.2 mL min-1 dL-1 in the control arm respectively). During the FBF 
experiments mean arterial blood pressure was not significantly influenced by HA treatment 
compared to control (103 mm Hg versus 108 mm Hg respectively, NS). Intra-arterial infusion of 
acetylcholine induced an increase in FBF at all three doses after both control and HA treatment. 
The extent of this response was not affected by pretreatment with HA. On average, a non-sig-
nificant increase of 11% (95% CI: -10 to 36%) was observed in the response to the three doses 
of acetylcholine. At the highest dose of acetylcholine, 8 μg min-1 dL-1, FBF amounted to median 
levels of 20.3 and 23.5 mL min-1 dL-1 following control and HA respectively.
Intra-arterial infusion of nitroglycerin induced an increase of FBF at all dosages. Pretreatment with 
HA led to a significant diminution of the vasodilator response to nitroglycerin when compared 
to control. On average, a significant decrease of -7% (95% CI: -11 to -3%) was observed in the 
response to the three doses of nitroglycerin. At the highest dose of nitroglycerin, 1.0 μg min-1 
dL-1, FBF amounted to median levels of 10.6 and 9.7 mL min-1 dL-1 following control and HA 
treatment, respectively. Regarding insulin sensitivity, no difference was observed. (Table 2) The 
average M-values after treatment with HA and control mounted to 7.1 and 7.3 μmol min-1 kg-1, 
respectively (NS). Post hoc analysis yielded similar findings for a subgroup with the highest insulin 
resistance (the seven subjects with the lowest M values after control treatment) and a subgroup 
with the most prominent HO-1 induction (the seven subjects with the highest increase in HO-1 
mRNA level in the adipose tissue).
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Table 3: Forearm blood flow data after logarithmic transformation.
Heme arginate Control p-value
Baseline 0.35 (0.07) 0.31 (0.06) 0.34
ACh 1 0.82 (0.09) 0.82 (0.06)
ACh 2 1.12 (0.07) 1.03 (0.07)
ACh 3 1.34 (0.07) 1.28 (0.05)
Baseline 0.30 (0.07) 0.32 (0.05) <0.0001
NTG 1 0.87 (0.03) 0.90 (0.03)
NTG 2 0.94 (0.03) 0.98 (0.03)
NTG 3 0.98 (0.03) 1.01 (0.03)
ACh 1–3: acetylcholine dosage of 0.5, 2.0 and 8.0 μg/min/dL, respectively; NTG 1–3: nitroglycerin dosage of 0.25, 
0.50 and 1.0 μg/min/dL, respectively. In parenthesis are the standard errors of the mean.
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discussion
This is the first translational study to evaluate the impact of HA administration on HO-1 induc-
tion, insulin sensitivity and endothelial function in subjects suffering from the Met-S. For years, 
an accumulation of preclinical data strongly suggested therapeutic benefit of HO-1 induction 
for both insulin resistance and endothelial dysfunction.2 In contrast to the observed efficacy of 
HO-1 induction by chronic HA treatment in preclinical experiments, short term HA treatment 
in human subjects suffering from the Met-S did not improve insulin sensitivity and endothelial 
function compared to control treatment with L-arginine. Several comments should be made.
HO-1 in metabolic disease
Noteworthy, the dogma of metabolic protection by HO-1 has been challenged recently.11 
Insulin-resistant obese subjects demonstrate increased HO-1 expression in liver and visceral 
fat compartments compared to insulin-sensitive obese subjects. In addition, hepatocyte HO-1 
appears to promote insulin resistance in genetic gain- and loss-of-function models, and mac-
rophage HO-1 knockout mice appear to be protected against metabolic disease upon a high 
fat diet. Finally, cellular assays support a pro-inflammatory role for HO-1 in the development of 
metabolic disease. This discrepancy with previous preclinical studies on HO-1 induction is striking 
and urges to a re-evaluation of data and further research. One of the explanations put forward 
is the limited specificity of metalloprotoporphyrins used for HO-1 induction including cobalt 
protoporphyrin (CoPP), heme and hemin.11,19 As a result, the net positive effects of metallopro-
toporphyrins reported from preclinical experiments may be related to other mechanisms than 
HO-1 induction per se. However, this theory seems inconsistent with the observed abrogation 
of protection by metalloprotoporphyrins when HO-activity is co-inhibited.8 Moreover, it does 
not explain the observed beneficial effects of HO-effector molecules like bilirubin in models of 
the Met-S and diabetes.17,20 An alternate explanation is a possible dysregulation of the HO-1 
system by factors involved in the Met-S, causing a switch from the well-known anti-inflamma-
tory profile to the recently recognized pro-inflammatory role.21 Underlying mechanisms are 
to be clarified and might include a differential induction by pathological stimuli, alterations in 
posttranslational regulation or changes in the subcellular translocation of HO-1.21 In conclusion, 
HO-1 appears to act as a double edged sword having both protective and injurious effects in 
the development of the Met-S.
Study design
Our experiments are amongst the first studies to the therapeutic efficacy of HO-1 induction in 
human disease. Consequently little is known of the optimal design of translational experiments 
on the supposed beneficial impact of HO-1 induction in man. As a result, we cannot exclude that 
either the observed low level or the duration of HO-1 induction obtained by our short-term 
HA treatment is insufficient in view of the lack of therapeutic efficacy.
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The short-term design of our experiments originated from promising data provided by two 
papers demonstrating significant experimental HO-1 induction in healthy volunteers.12,13 Signif-
icant increases of HO-1 mRNA plasma level, HO-1 protein plasma level and ex vivo HO-activity 
in leukocytes were reported 48 hours after a single bolus infusion of either HA13 or hemin.12 
The HA dosage applied in our study (3 mg/kg) equals the highest of three HA dosages applied 
in the first study and the single hemin dosage applied in the second study. Endothelial function 
and insulin sensitivity, our main outcome parameters, were assessed 48 hours after the adminis-
tration of HA, parallel to the reported HO-1 induction in both studies. Suggesting effectiveness 
of short term HA treatment in human translational models on the therapeutic value of HO-1 
induction, others have demonstrated an amelioration of ischemia-reperfusion injury in healthy 
volunteers 24 hours after a single dosage of HA of only 1 mg/kg.14 For insulin sensitivity however, 
it should be noted that a chronic treatment with HO-1 inducers for 4 to 8 weeks was used in 
animal experiments demonstrating an improvement of glucose metabolism.7-9,22 Likewise, a long 
term experiment might have been more effective in subjects suffering from the Met-S. In clinical 
practice however, HA is registered for short term use only with a maximum of four days for acute 
porphyria attacks.23 Chronic once weekly use has been reported in individual porphyria cases23, 
but no data are available on the extent of HO-1 induction associated with a chronic once weekly 
HA treatment regimen in man. Finally, chronic weekly HA treatment is associated with serious 
vascular side effects involving the disappearance of the superficial venous system and the need 
of an indwelling venous access.23 Although more promising based on preclinical experiments, 
we therefore felt that it was inappropriate to perform a long term experiment and overleap 
a short term design with less safety concerns and proven efficacy in terms of HO-1 induction.
The impact of HA treatment on markers of HO-1 induction observed in our subjects is limited. 
It is currently unclear however whether the extent of HO-1 induction observed in translational 
studies relates to the intended clinical effect of treatment with metalloprotoporphyrins. Besides, 
the selection of appropriate markers of HO-1 induction is complicated by the differential impact 
of HO-1 activity on various tissues. As stated, HO-1 activity in the liver and in visceral fat has 
been shown to aggravate instead of ameliorate the Met-S.11 Finally, we have recently demon-
strated that HO-1 induction by lipopolysaccharide in human cells differs from that in widely 
used experimental animal models.24 Potential inter-species differences and cell-type specific 
responses therefore necessitate caution in the adoption of markers of HO-1 induction from 
animal to human experiments. In search for an appropriate marker of HO-1 induction and for 
the central role of adipose tissue in the Met-S4, we included the measurement of HO-1 mRNA 
in subcutaneous adipose tissue. However, the relevance of this marker is also challenged by 
recent data demonstrating that overexpression of HO-1 in adipocytes does not protect against 
insulin resistance.25
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Elevated heme levels
Assessing endothelial function, we observed an unexpected reduced response to nitroglycerin 
48 hours after HA infusion. In theory, this reduced response might be related to changes in 
blood pressure. In animal experiments, lowering of blood pressure upon chronic HO-1 induction 
has been reported in obese mice.7 However, we did not observe significant changes of blood 
pressure after short term HA treatment compared to control. In addition, baseline blood flow 
was unaltered by HA treatment. In our opinion, the reduced response to nitroglycerin is more 
likely related to the elevated plasma levels of heme (11.7 μmol/L on average) at the time we 
performed forearm plethysmography. The heme levels found at this point of time, 48 hours 
after the first administration of HA, correspond to heme levels reported by others.13. Although 
long-term dosing of nitroglycerin involves complex effects26, short term high dosing as used 
in our study is associated with the release of nitric oxide (NO).27 Whereas HO-1 induction is 
expected to increase the bioavailability of NO28, elevated heme levels have been demonstrated 
to trigger the opposite by scavenging NO.29 In fact, heme levels exceeding 6 μmol/L have been 
demonstrated to lower the vasodilator response to sodium nitroprusside, an NO donor, by as 
much as 80 percent.29 In addition, excess of heme is associated with increased oxidative and 
inflammatory stress and endothelial activation in mouse models of hemolytic diseases.30,31 Scav-
enging of free heme by the administration of hemopexin markedly attenuates the observed 
endothelial toxicity induced by heme.30 In contrast to our design, animal experiments on HO-1 
induction in a model of endothelial dysfunction involved a pretreatment HA without exposure 
to heme during the subsequent in vitro assessment of endothelial function.10 As for the vasodi-
lator response to nitroglycerin, the elevated heme levels may have masked a beneficial impact 
of HA treatment on the NO dependent vasodilator response to acetylcholine, our marker of 
endothelial function. Likewise, the pro-inflammatory and pro-oxidant effects of heme31 may have 
counteracted a beneficial impact of HO-1 induction on insulin resistance. In our opinion, our data 
on nitroglycerin therefore reveal an important and general message with regard to the possible 
adverse effects of elevated heme levels upon the use of HA for translational studies on HO-1 
induction. The pharmacokinetics of intravenously administered HA have been published in the 
past32 and should be addressed specifically during the design of future experiments.
Side effects
We observed several well-known side effects of HA, including headache and phlebitis, despite the 
adherence to the instructions of the manufacturer. Both side effects were reported previously by 
others.12-14 Notably, headache was also observed during control treatment and occurred almost 
exclusively upon the first infusion of HA and control, prior to the assessment of forearm blood 
flow. Therefore, alternative causes including abstinence from caffeine must be considered33. Phlebitis 
has been associated with both hemin and HA.23 For the use of hemin, others have been able to 
avoid phlebitis through the dilution in albumin instead of saline.12 Future research should determine 
whether this strategy suits for HA and affects the efficacy of HA.
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Limitations
Limitations of the study include the lack of a healthy control group in our protocol. As a result, 
we cannot substantiate the assumed presence of impaired insulin sensitivity and endothelial dys-
function in our Met-S population at baseline. Second, our study population was characterized by 
a certain degree of diversity in terms of gender and age. Despite the use of a cross-over design, 
gender or age related differences in therapeutic efficacy of HO-1 induction within our study 
population may have flattened the results. Finally, our control treatment consisted of equimolar 
amounts of L-arginine for the fact that the administration of HA is accompanied by the release 
of equimolar amounts of arginate, a well-known substrate of NO. Though in our opinion more 
appropriate than true placebo, we cannot exclude small differences in pharmacological profile 
between L-arginine administered in solution and L-arginate administered as part of HA.
Conclusion
Short term HA treatment only marginally induces HO-1 expression and does not improve insulin 
sensitivity nor endothelial function in subjects suffering from the Met-S. This is in contrast with 
promising results from preclinical studies. Novel studies should unravel the various mechanisms 
by which HO-1 activity and metalloporphyrins affect Met-S. In addition, chronic once weekly HA 
regimens should be examined for their potency to induce HO-1 and subsequently their efficacy 
on clinical endpoints. Finally, the design of translational experiments should be calculated on the 
delicate balance associated with the use of HA and strive for a dosage that is sufficiently high 
to achieve clinical efficacy and at the same time sufficiently low to avoid elevated heme levels 
by the time endpoints are assessed.
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abstract
Rationale: Inflammation-induced free radical release is considered an important factor in the 
pathogenesis of several diseases including atherosclerosis and sepsis. Unconjugated bilirubin 
is a powerful anti-oxidant and elevated levels have beneficial effects in preclinical models 
as well as in human cardiovascular disease. However, its effects during acute inflammation 
in humans are unknown. 
Objective: To investigate the effects of atazanavir-induced (unconjugated) hyperbilirubinemia 
on anti-oxidant capacity, inflammation and endothelial dysfunction in human experimental 
endotoxemia.
Methods and Results: Following double-blinded four-day treatment with atazanavir 2dd300 
mg (or placebo), twenty healthy male volunteers received 2 ng/kg E. coli lipopolysaccha-
ride intravenously. Blood drawn to determine bilirubin levels, anti-oxidant capacity and 
cytokine response demonstrated that, after atazanavir treatment, total bilirubin concentra-
tions increased to maximum values of 4.67 (95%CI 3.91-5.59) compared to 0.82 (95%CI 
0.64-1.07) mg/dL in the control group (p<0.01). Furthermore, the anti-oxidant capacity 
as measured by the ferric reducing activity of plasma was significantly increased with 36% 
in hyperbilirubinemic subjects (p<0.0001) and concentrations correlated strongly to bili-
rubin concentrations (R2=0.77, p<0.001). Hyperbilirubinemia attenuated the release of 
interleukin (IL)-10 from 377 (95%CI 233-609) to 219 (95%CI 152-318) pg/mL (p=0.01), 
whereas release of pro-inflammatory cytokines remained unaltered. In vitro, in the absence 
of hyperbilirubemia, atazanavir did not influence LPS-induced cytokine release. Endothelial 
function was assessed using  forearm venous occlusion plethysmography after intra-arterial 
infusion of acetylcholine and nitroglycerin. Hyperbilirubinemia completely prevented the 
inflammation-associated blunted vascular response to acetylcholine and nitroglycerin. 
Conclusion: Atazanavir-induced hyperbilirubinemia increases anti-oxidant capacity, attenuates 
IL-10 release and prevents vascular hyporesponsiveness during endotoxemia-induced sys-
temic inflammation in humans.
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introduction
Inflammation is the common denominator for numerous diseases and among them are the most 
common causes of death in the developed world, including ischemic heart disease, stroke1 and 
sepsis.2 In cardiovascular diseases, chronic inflammation, oxidative stress and endothelial dys-
function contribute to the formation and progression of atherosclerosis.3 Acute inflammatory 
disorders such as the systemic inflammatory response after trauma, major surgery or during 
sepsis are believed to be driven by the same factors: activation of innate immunity and oxidative 
stress, leading to endothelial dysfunction, organ dysfunction, and, ultimately, death.4 Therefore, 
cardiovascular and infectious diseases research has demonstrated overlap in recent years with 
topics such as the use of statins and their anti-inflammatory and anti-oxidative effects.5,6
While historically considered as a toxic waste product, bilirubin is one of the body’s most pow-
erful endogenous anti-oxidants.7 Bilirubin is known to inhibit nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase8,9 and lipid peroxidation which are both considered crucial for the 
development of atherosclerosis.10,11 Furthermore, it is a known scavenger of reactive nitrogen 
species (RNS) such as nitric oxide and peroxynitrite, both considered central players in the 
development of mitochondrial dysfunction in septic shock.10,12  Indeed, low levels of bilirubin are 
linked to an increased risk for cardiovascular disease13–16, while on the other hand, subjects with 
the common Gilbert syndrome, known for a mild lifelong increase in bilirubin concentrations 
demonstrate lower oxidative stress levels, better endothelium-dependent vasodilation and they 
are protected from myocardial infarction and peripheral artery diseaseas demonstrated in sev-
eral studies.17–20 It must be stated however that others failed to demonstrate these results.21,22 
Animal experiments have also demonstrated beneficial effects of bilirubin (or biliverdin) admin-
istration in endotoxemia which is considered a model for acute inflammatory disorders such 
as sepsis.23–25 
Although bilirubin is currently unavailable for infusion in humans, data from almost 80 years ago 
suggest anti-inflammatory effects of bilirubin infusion on arthritis in humans.26 Furthermore, 
beneficial effects on endothelial function were demonstrated in diabetic patients treated with 
the bilirubin-increasing drug atazanavir.27  Atazanavir, a protease inhibitor used in the treatment 
of human immunodeficiency virus (HIV) infection is known to inhibit uridine diphosphate-5’-glu-
curonosyltransferase A1 (UGT1A1) thereby creating a pharmacologically-induced Gilbert 
syndrome. In the absence of bilirubin for infusion, we used this effect to create hyperbilirubinemia 
in the healthy volunteers that participated in the present study. We modified the dosing regime 
in agreement with a previous study to create sufficient amounts of bilirubin.27 
The human endotoxemia model is known for inducing a predictable inflammatory response 
and vascular dysfunction and therefore, administration of lipopolysaccharide (LPS) to healthy 
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volunteers enables the investigation of possible therapeutical targets in inflammatory disor-
ders.28,29 In the present study we investigated the effects of atazanavir-induced hyperbilirubinemia 
on anti-oxidant capacity, systemic inflammation and endothelial dysfunction elicited by experi-
mental human endotoxemia.
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methods
All study procedures were approved by the local ethical committee and in accordance to 
the declaration of Helsinki. This study was registered at www.clinicaltrials.gov under number 
NCT00916448.
Subjects 
All participating subjects gave written informed consent prior to inclusion.  A screening visit 
within two weeks of the experiments demonstrated no abnormalities in medical history or 
physical examination. Routine laboratory tests as well as an electrocardiogram (ECG) demon-
strated no abnormalities and all subjects tested negative for HIV and Hepatitis B. Total bilirubin 
levels below 0.88 mg/dL (below 15 μmol/L) were obligatory in order to exclude subjects with 
Gilbert syndrome. All subjects were non-smokers and had no signs of previous hypertension 
or cardiovascular disease. Furthermore, no use of (over the counter or prescribed) drugs was 
allowed within two weeks before enrollment until the end of the study. Ten hours before the 
infusion of LPS, subjects refrained from the intake of alcohol, caffeine, and food.
Study design 
In this randomized placebo-controlled parallel study, subjects were treated with atazanavir 300 
mg or placebo twice daily for four consecutive days prior to the LPS infusion in a double-blinded 
fashion. This dosing regimen was used because desired bilirubin values were obtained using this 
dose in diabetic patients.27 Randomization was performed by an independent research nurse 
using sealed envelopes. Per inclusion criterion, all subjects started treatment with bilirubin levels 
below 0.88 mg/dL. After two days into the treatment protocol, bilirubin levels were checked by 
the independent research nurse to ensure that total concentrations would not exceed desired 
values. Given the double-blind placebo-controlled nature of the study, investigators were not 
informed about bilirubin concentrations, however, when bilirubin concentrations exceeded 4.68 
mg/dL (equal to 80 μmol/L) the subject was excluded from further participation by the research 
nurse. Excluded subjects were replaced in the study protocol without unblinding the involved 
investigators. After 4 days of treatment, subjects were admitted to the research intensive care 
unit of the Radboud university medical center. An additional ECG was performed to exclude 
conduction abnormalities as a side effect of atazanavir. After local anesthesia (lidocaine 20 mg/
mL), the brachial artery was cannulated with a 20-gauge catheter connected to an arterial 
pressure monitoring line (Edwards Lifesciences LLC, Irvine CA, USA connected to a Philips 
IntelliVue MP70 monitor, Philips Medical Systems, Eindhoven, The Netherlands) to enable the 
administration of vasodilating drugs, blood sampling and the continuous monitoring of blood 
pressure. A second cannula was placed in an antecubital vein to permit infusion of prehydration 
fluid (1.5 L of 2.5% glucose/0.45% saline solution), LPS,  and the continuous infusion of 150 mL/h 
2.5% glucose/0.45% saline. After determination of the baseline responses to acetylcholine and 
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nitroglycerin, purified LPS (US Standard Reference Endotoxin E. coli O:113) obtained from the 
Pharmaceutical Development Section of the National Institutes of Health (Bethesda, MD, USA) 
was administered at a dose of 2 ng/kg body weight. Thereafter blood was sampled serially and 
body temperature was determined every 30 minutes (Firsttemp Genius 2, Covidien, Dublin, 
Ireland). (Figure 1)
Figure 1: Flowchart of the study protocol. 
After 4 days of taking either placebo (n=10) or atazanavir (n=10), but prior to LPS infusion at 0 h, dose-
response curves to acetylcholine and nitroglycerine were determined. Thereafter, prehydration was infused and 
blood was sampled before LPS infusion and serially thereafter. At 4 h after LPS, dose response curves were 
repeated. FBF indicates forearm blood flow. Dosing of acetylcholine was 0.5-2-8 µg/min/dL forearm volume, 
nitroglycerin was dosed at 125-250-500 ng/min/dL forearm volume.
Laboratory Tests  
All blood samples were drawn from the arterial line, except for samples obtained at t=24 hours 
(h) when blood was sampled using regular vena puncture. Bilirubin was determined before 
and every two hours after LPS infusion in lithium heparin plasma using immunologic detection 
according to the instructions of the manufacturer (Aeroset, Abbott Laboratories, Abbott Park, 
IL, U.S.A.). The ferric reducing ability of plasma (FRAP) assay was performed in duplicate as 
described previously.30 Ferric reducing ability of plasma values were obtained using a 7-point 
calibration curve of known amounts of Fe2+ and expressed in mmol Fe2+/L. The concentrations 
of circulating cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-8, IL-10 and mono-
cyte chemotactic protein (MCP)-1, as well as concentrations of endocan, endothelial (E) and 
platelet (P)-selectin and soluble vascular cell and inter-cellular adhesion molecules (VCAM-1 and 
ICAM-1) were determined in EDTA or lithium heparin plasma obtained immediately before LPS 
administration and serially thereafter (see Figure 1 for details). Measurements of all cytokines and 
of the soluble adhesion molecules VCAM-1 and ICAM-1 were performed by a multiplex assay 
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according to the manufacturer’s instructions (Bio-plex cytokine assay, BioRad, Hercules, CA, USA 
at Luminex 100, Luminex Corporation, The Netherlands). E-and P-selectin were determined 
by Enzyme-Linked Immuno Sorbent Assay (ELISA) (R&D systems, Minneapolis, USA). Endocan 
was measured using a sandwich ELISA  (Lunginnov, Lille, France).
C-reactive protein (CRP) levels were measured just before and at 8 and 24 h after LPS in lithium 
heparin plasma (Aeroset, Abbott Laboratories, Abbott Park, IL, USA). Leukocyte counts were 
determined in EDTA anti-coagulated blood using flow-cytometry (Sysmex XE-2100, Goffin 
Meyvis, Etten- Leur, The Netherlands) just before and serially after LPS infusion.  
In vitro LPS stimulation
To exclude a direct pro- or anti-inflammatory effect of atazanavir unrelated to its induction of 
hyperbilirubinemia, an in vitro experiment incubating whole blood in the presence or absence 
of atazanavir and/or LPS was performed. An atazanavir stock solution of 1 mg/mL was prepared 
as previously described31 and dissolved in DMSO to prevent sedimentation. Further dissolution 
was performed in RPMI 1640 (Sigma-Aldrich, Zwijndrecht, The Netherlands) to reach a final 
concentration of Dimethyl sulfoxide DMSO of 0.1%.  Whole blood of 6 healthy volunteers was 
incubated with atazanavir 0, 1, 5 or 10 μmol/L and LPS 0, 1, 10 ng/mL for 24 h at 37°C under 5% 
CO2. Thereafter, the incubate was centrifuged at 20.000 g for 5 minutes. Plasma was aspirated 
and an ELISA was performed for TNF-α and IL-10 (R&D systems, Minneapolis, USA).
Forearm blood flow measurements 
Forearm blood flow (FBF) was determined using venous occlusion plethysmography (Filtrass, 
Domed, Munich, Germany) as previously described.32,33 Briefly, venous occlusion was achieved 
by inflating the upper arm cuff to 45 mmHg. Strain gauges were placed on the forearm and 
connected to plethysmographs to measure changes in forearm volume in response to inflation 
of the venous-congesting cuffs. FBF and drug administration were normalized to forearm volume 
as measured with the water displacement method and expressed in milliliters per minute per 
deciliter forearm volume (mL/min/dL). After instrumentation, a resting period of 30 minutes was 
kept to ensure stabile forearm blood flow. Thereafter, a dose-response curve to intrabrachial 
infusion of acetylcholine (Miochol, Thea Pharma NV, Zoetermeer, the Netherlands) and nitro-
glycerine (Nitropohl, Pohl-Boskamp, Hoofddorp, The Netherlands) were determined. Baseline 
FBF was determined during five minutes,  thereafter, increasing doses of acetylcholine at 0.5, 2, 
and 8 μg/min/dL forearm volume were infused in equal volumes.  Each dose was administered 
for 5 minutes, measurements of FBF were performed in the last 3 minutes of each dose. After 
a washout period of 15 minutes and after another baseline measurement, nitroglycerin was 
infused in the same fashion at doses of 125, 250 and 500 ng/min/dL. 
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Since infusion of LPS is known to induce vascular hyporeactivity to vasodilators after 4 h and 
until 6 h after administration34,35, we repeated these measurements at t=4 h to determine the 
effects of atazanavir-induced hyperbilirubinemia on LPS-induced vascular hyporeactivity. 
Data Analysis and Statistics. 
Values are expressed as geometric mean (95% confidence interval (CI)) unless described other-
wise. Because of the small sample size, log transformation was performed to ensure a Gaussian 
distribution. Thereafter, a two-way repeated-measures analysis of variance (ANOVA) was used to 
test variation over time, the variation between interventions, and the interaction between time 
and intervention (IBM SPSS statistics 20 software, Amsterdam, The Netherlands). Changes over 
time alone were analyzed by One-way ANOVA (GraphPad Prism version 5.03 for Windows, 
GraphPad Software, San Diego California USA). To compare differences in baseline parameters 
between groups and the difference between baseline and peak values we used Student’s t-test 
(Graphpad) on log transformed data. A p-value<0.05 was considered to indicate significance. 
Given the explorative “proof-of-concept” nature of this study, no formal sample size calculation 
was performed and no subgroup analyses were conducted.
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results
Demographic data and safety
Baseline characteristics are presented in Table 1. There were no significant differences between 
the groups. The study drugs were well tolerated and no side effects were reported by the sub-
jects.  A total of 30 subjects were included in the study, 10 could not complete the study protocol 
for different reasons: five subjects were excluded because of a too steep rise in bilirubin following 
intake of study medication, as measured two days before the planned LPS administration. Two 
subjects experienced a vagal response during the placement of the cannulas, 1 subject was unable 
to plan the experiment, 1 subject made errors in medication intake, and 1 subject had a new 
1st degree atrioventricular block at the morning of the experiment.  All subjects excluded after 
the start of the study medication were replaced to ensure the equal distribution of subjects in 
the two treatment arms. 
Table 1: Baseline Characteristics
Placebo (n=10) Atazanavir (n=10) p-value 
Height, cm 182 (179-185) 182 (177-187) 0.9
Weight, kg 73.7 (68.4-79.4) 76.7 (70.4-83.4) 0.5
Body mass index, kg/m2 22.3 (20.8-23.9) 23.2 (21.4-25.1) 0.3
Age, years 23.0 (21.4-24.7) 21.7 (19.8-23.9) 0.3
Heart rate, bpm 60 (54-66) 63 (57-69) 0.5
Systolic blood pressure, mmHg 121 (112-130) 125 (119-131) 0.5
Diastolic blood pressure, mmHg 74 (70-78) 77 (71-82) 0.4
Forearm Volume, mL 1401 (1324-1482) 1415 (1292-1549) 0.9
Total cholesterol, mmol/L 3.3 (2.8-3.7) 3.2 (2.8-3.6) 0.7
LDL cholesterol, mmol/L 1.9 (1.5-2.3) 1.7 (1.3-2.1) 0.4
HDL cholesterol, mmol/L 0.97 (0.85-1.1) 1.00 (0.88-1.12) 0.7
Non-HDL cholesterol, mmol/L 2.3 (1.9-2.8) 2.1 (1.7-2.6) 0.6
Triglycerides, mmol/L 0.8 (0.6-1.1) 1.0 (0.8-1.2) 0.3
All data are expressed as geometric mean (95% confidence interval). P-values were obtained using an unpaired 
Student’s t-test on log transformed data to ensure normal distribution. No significant differences between 
groups were observed.
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Bilirubin and anti-oxidant capacity
Before the start of atazanavir/placebo treatment, bilirubin averaged 0.54 (95%CI: 0.49-0.58) mg/
dL in subjects using atazanavir versus 0.57 (95%CI: 0.50-0.65) mg/dL in the placebo group (p=0.5). 
After 4 days of treatment bilirubin averaged 3.08 (95%CI: 2.62-3.61) mg/dL in subjects treated 
with atazanavir versus 0.48 (95%CI: 0.37-0.52) mg/dL in subjects treated with placebo (p<0.01).
During experimental endotoxemia, a further increase in bilirubin was observed in both groups. 
In subjects treated with atazanavir levels peaked after 6 h with maximum concentrations of 
4.67 (95%CI: 3.91-5.59) mg/dL while in the placebo group, maximum values of 0.82 (95%CI: 
0.64-1.07) were reached at 4 h after LPS infusion (over time both p<0.001, between groups 
p=0.001). (Figure 2A)
The total anti-oxidant capacity was assessed by measurement of FRAP and was significantly 
increased in subjects treated with atazanavir averaging 1.09 (95%CI: 1.01-1.18) mmol Fe2+/L 
compared to 0.80 (95%CI: 0.72-0.89) mmol Fe2+/L in subjects treated with placebo (p<0.0001) 
and did not change following LPS administration (over time p=0.5 in both the atazanavir group 
and the placebo group). Furthermore, there was a strong correlation between bilirubin and 
FRAP concentrations (Spearman R2: 0.77, p<0.001). (Figure 2B)
Figure 2:
A. Bilirubin concentrations in subjects treated with placebo (●) and atazanavir (ATV) (○) before and serially 
after the administration of 2 ng/kg Escherichia coli LPS. Data are represented as geometric mean and 95% 
confidence interval. P-value was obtained by repeated measures analysis of variance on log transformed data of 
the complete curve.
B. The correlation between bilirubin and FRAP. Values were obtained just before administration of 2 ng/kg E. 
coli LPS. Correlations were determined using Spearman’s rank correlation coefficient.
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Inflammatory effects in vivo and in vitro
As demonstrated in Figure 3, LPS infusion induced an increase in all measured cytokines. Maxi-
mum concentrations for the pro-inflammatory cytokine TNF-α were 578 (95%CI: 443-753) pg/
mL in subjects treated with atazanavir versus 580 (95%CI: 395-852) pg/mL in subjects treated 
with placebo (p-value over time both <0.001, between groups p=0.7). Concentrations of IL-6 
peaked at 1082 (95%CI: 914-1280) pg/mL in hyperbilirubinemic subjects compared to 890 
(95%CI: 683-1160) pg/mL in the placebo group (over time both p<0.001, between groups 
p=0.1). IL-8 and MCP-1 peaked at maximum values of 693 (95%CI: 583-825) and 5828 (95%CI: 
4183-8063) pg/mL in subjects treated with atazanavir versus 590 (95%CI: 444-784) and 6835 
(95%CI: 5224-8943) pg/mL in subjects treated with placebo (all: over time p<0.001, between 
groups IL-8: p=0.2, MCP-1: p= 0.6).
The anti-inflammatory cytokine IL-10 was attenuated in subjects treated with atazanavir : 219 
(95%CI: 152-318) pg/mL versus 377 (95%CI: 233-609) pg/mL in subjects in the placebo group 
(over time both p<0.001, between groups p=0.01). (Figure 3) Furthermore, CRP was increased 
at 24 h following LPS infusion, but did not differ between groups (average concentration of 
39 (95%CI: 33-47) mg/L in the atazanavir-group compared to 35 (95%CI: 29-44) mg/L in the 
placebo group, p=0.3). 
In our in vitro experiments, increasing levels of atazanavir did not induce the release of TNF-αor 
IL-10 during whole blood incubation for 24 hrs neither did atazanavir influence the release of 
TNF-α or IL-10 with increasing doses of LPS. As expected, increasing doses of LPS induced 
increasing concentrations of TNF-α and IL-10. (Figure 4)
Effects on systemic hemodynamic response 
Treatment with atazanavir or placebo did not influence endotoxemia-induced changes in mean 
arterial pressure (MAP) or heart rate. At 4 h after LPS infusion, MAP was decreased by 20% 
in subjects receiving atazanavir versus a decrease of 16% in subjects receiving placebo (Table 
2, over time both p<0.001, no significant difference between groups). Heart rate increased by 
30% in hyperbilirubinemic subjects versus 31% in the placebo group. (Table 2, over time both 
p<0.001, no significant difference between groups). 
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Figure 3: Cytokine concentrations. 
Levels were determined in the absence (n=10 depicted as ●) and presence (n=10, depicted as ○) of atazanavir 
after administration of 2 ng/kg E. coli LPS to healthy volunteers at 0 h. TNF-α: tumor necrosis factor-α (A), IL-6: 
interleukin-6 (B), IL-10: interleukin -10 (C), IL-8: interleukin-8 (D), MCP-1: monocyte chemoattractant protein-1 
(E), CRP: C-reactive protein (F). Data are presented as geometric mean and 95% confidence interval. P-values 
were obtained using repeated measure analysis of variance on log-transformed data of the complete curve.
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Figure 4: In vitro effects of atazanavir and LPS
A: Concentration of tumor necrosis factor-α (TNF-α) after 24 hrs of whole blood incubation (n=6) with 
rising doses of Escherichia coli LPS and/or atazanavir (ATV). Both the doses of LPS significantly increased TNF-α 
concentrations (p<0.001) while increasing doses of atazanavir did not affect TNF-α concentrations. 
B: Concentrations of interleukin (IL)-10 after 24 hrs of whole blood incubation (n=6) with rising doses of 
Escherichia coli LPS and/or atazanavir (ATV). Both the doses of LPS significantly increased IL-10 concentrations 
(p<0.001) while increasing doses of atazanavir did not affect IL-10.  
Whiskers are depicted as minimum and maximum values. P-values were obtained using Student’s t-test on log 
transformed data.
Table 2: Hemodynamic response, temperature and forearm blood flow after 2 ng/kg E. coli LPS infusion.
Before LPS T=4 h p-value 
over time
p-value between 
groups
Heart Rate, bpm Placebo
Atazanavir
70 (62-79)
73 (65-81)
92 (85-100)
95 (87-104)
<0.001
<0.001
0.3
MAP, mmHg Placebo
Atazanavir
93 (87-100)
96 (91-102)
78 (73-84)
77 (72-82)
<0.001
<0.001
0.6
Temperature,°C Placebo 
Atazanavir
36.8 (36.7-37.0)
36.8 (36.6-37.1)
37.8 (37.4-38.3)
38.0 (37.2-38.9)
<0.001
<0.001
0.6
FBF, mL/min/dL Placebo
Atazanavir
3.2 (2.1-4.8)
4.5 (3.0-6.7)
8.1 (6.5-10.1)
6.9 (4.5-10.5)
<0.001
0.2
NS*
MAP: mean arterial blood pressure, FBF: forearm blood flow. Data are expressed as geometric mean and 95% 
confidence interval. P-values were all calculated on log transformed data. Values over time were obtained using 
one-way analysis of variance while p-values between groups were obtained using repeated measures analysis 
of variance or, in case of forearm blood flow using an unpaired Student’s t-test.*NS is used to indicate the non-
significant differences between forearm blood flow in subjects using placebo or atazanavir before LPS (p=0.2) 
and after LPS (p=0.5).
Chapter 8
148
Effects on endothelial dysfunction and activation
FBF assessed by venous occlusion plethysmography increased in both groups after LPS infusion 
as demonstrated in Table 2.  In subjects treated with placebo and before the administration 
of LPS, the highest dose of acetylcholine (8 µg/min/dL forearm tissue) increased flow to 304 
(95%CI: 214-430) % compared to baseline. At 4 h after LPS infusion the response was atten-
uated with a maximum response of 183 (95%CI: 136-246) % compared to baseline measured 
at 4 h. (p=0.02, Figure 5A)
In subjects treated with atazanavir, the attenuated vasodilatory response following LPS infusion 
was not observed. After the highest dose of acetylcholine and before the administration of LPS, 
flow increased to 221 (95%CI: 129-378) % compared to baseline whereas after LPS admin-
istration after 4 h flow increased to 217 (95%CI: 135-347) % after 8 µg/min/dL acetylcholine.
(p=0.8, Figure 5B)
For nitroglycerine, similar effects were found. In subjects treated with placebo, nitroglycerine 
at a dose of 500 ng/min/dL increased flow to maximum values of 251 (95%CI: 185-340) % 
compared to baseline, whereas at 4 h after LPS the maximum response was 169 (95%CI: 143-
198) % (p=0.01). In hyperbilirubinemic subjects the attenuated response following LPS infusion 
was not observed: 226 (95%CI: 162-316) % compared to baseline before LPS and 173 (95%CI: 
142-211) % after LPS infusion. (p=0.2, Figure 5C/D)
Following LPS administration the endothelial biomarkers E-selectin, P-selectin, VCAM-1, ICAM-1 
and endocan were all significantly increased over time (p<0.01). No significant differences could 
be demonstrated between subjects treated with atazanavir or placebo. (Figure 6) 
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Figure 5: Forearm blood flow dose-response curves. 
Responses to acetylcholine (A,B) and nitroglycerin (C,D) before (●) and 4 h after the administration of 2 ng/
kg E. coli LPS (○) to healthy subjects in the absence (A,C) and presence (B,D) of atazanavir. Data are presented 
as % compared to baseline and expressed as geometric mean and 95% confidence interval. P-values were 
obtained using a repeated measures analysis of variance on log transformed data of the complete curve.
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Figure 6: Endothelial biomarkers. 
Platelet(P)-selectin (A), endothelial (E)-selectin (B), vascular cell adhesion molecule (VCAM)-1 (C), intercellular 
adhesion molecule (ICAM)-1 (D) and endocan (E) before and at peak value after administration of 2 ng/kg 
Escherichia coli LPS to healthy volunteers in the absence (grey bars) and presence (white bars) of atazanavir. 
In both treatment arms, LPS induced an increase for all molecules (p<0.01). Data are presented as geometric 
means and 95% confidence interval. P-values between groups were obtained using an unpaired Student’s t-test 
on log transformed data.
Effects of hyperbilirubinemia in human endotoxemia
 151
discussion
The present study demonstrates that atazanavir-induced hyperbilirubinemia indeed increases 
anti-oxidative capacity and decreases IL-10 release. Furthermore, vascular hyporeactivity during 
experimental endotoxemia was completely prevented in subjects with atazanavir-induced hyper-
bilirubinemia. These data indicate that increases in bilirubin in this range exert relevant effects 
on oxidative stress, inflammation and vascular reactivity in humans in vivo.
In the human body, bilirubin is present in three forms: the majority is albumin-bound unconjugated 
bilirubin, a very small fraction is free unconjugated bilirubin, and the remainder is conjugated 
bilirubin. By using atazanavir, the main form of the increased levels of bilirubin will be albu-
min-bound and unconjugated. Its anti-oxidative effects in this form include inhibition of NADPH 
oxidase8,9, reduction of lipid-peroxidation, scavenging of peroxyl radicals and RNS thereby pro-
tecting fatty acids and decreasing the oxidative capacities of hydroxyl, superoxide anion radicals 
and peroxynitrite (extensively described in a review by Stocker7). Besides beneficial effects in 
cardiovascular diseases by prevention of the formation and progression of atherosclerosis and 
vascular dysfunction, these effects could also benefit septic patients since these substances are 
related to mitochondrial dysfunction which is considered important in the development of 
organ dysfunction.10,12 
Clinical data of the inverse correlation between bilirubin concentration and the occurrence of 
cardiovascular disease are abundant. Subjects with Gilbert syndrome have a decreased risk of 
cardiovascular events and ischemic heart disease17,18, whereas a relatively low bilirubin concen-
tration is related to coronary artery calcification and silent cerebral infarction.13–17 Endothelial 
dysfunction is strongly associated with atherosclerosis and cardiovascular disease and increased 
oxidative stress is of utmost importance for its development.36 Our data show that during hyper-
bilirubinemia, inflammation-induced endothelial dysfunction is no longer present. The notion that 
specifically the anti-oxidant effects of bilirubin account for this observation is further supported 
by several other reports elucidating the effects of e.g. the anti-oxidant vitamin C. Both locally 
and systemically administered vitamin C was associated with an improved endothelial function 
using the same experimental human endotoxemia model.37,38
Moreover, it is known that healthy subjects with mild hyperbilirubinemia have significantly 
enhanced endothelium-dependent vasodilation and flow-mediated dilation compared to subjects 
with normal or low bilirubin.20,39 Of interest, similar ameliorating effects on endothelium-de-
pendent vasodilation were demonstrated in type 2 diabetes patients with atazanavir-induced 
hyperbilirubinemia.27 These data indicate that modulation of oxidative stress may be of clinical 
relevance in different groups of patients. 
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The attenuation of the response to the non-endothelium-dependent vasodilator nitroglycerin 
observed in our experiments was not present in some previous studies 35,37, while two other 
studies demonstrated a similar clear and significant attenuation of the response to sodium nitro-
prusside or nitroglycerin during experimental endotoxemia.40,41 It could be speculated that the 
presence of  inducible nitric oxide synthase (iNOS)-derived nitric oxide (NO) after endotoxin 
administration induces a mild tolerance to NO-donors such as nitroglycerin. Since bilirubin is a 
known iNOS inhibitor9,25, it is tempting to speculate that this may explain why the effect is not 
present in subjects treated with atazanavir-induced hyperbilirubinemia.
Beneficial effects of elevated levels of bilirubin on inflammatory markers were demonstrated in 
various inflammation models. In some studies TNF-α secretion was found to be attenuated,23,25 
while in another no effects on cytokine concentrations were observed.8 Nevertheless, pretreat-
ment with bilirubin prior to LPS administration reduces symptoms, attenuates iNOS release and 
improves survival rates in animal models.23,25 Of interest, an average (lifelong) concentration of 
1.14 mg/dL in a human study population with Gilbert syndrome is known to have protective 
effects on cardiovascular disease compared to an average of 0.69 mg/dL in control patients.17 
These data suggest that relatively small changes in bilirubin concentration could already elicit 
beneficial effects. Others have used much higher concentrations in rodents with a single bolus 
that reached peak concentrations of 6 mg/dL.23 We aimed for bilirubin levels around 4 mg/
dL based on a previous study from our own study group also utilizing atazanavir leading to a 
bilirubin concentration of 3.8 mg/dL demonstrating beneficial effects on endothelial function in 
type 2 diabetes.27 Intriguingly, an ancient human study infusing bilirubin and bile salts from 1938 
demonstrated that levels between 4 and 16 mg/dL evoke beneficial effects on inflammatory signs 
and pain perception in arthritis patients.26 Again, we cannot exclude that much lower levels of 
bilirubin may also evoke anti-inflammatory or vascular effects in human inflammatory disorders. 
In our study, endotoxemia itself induced a modest increase of bilirubin in subjects receiving 
placebo. Several mechanisms may explain this effect. LPS administration results in a downregu-
lation of UGT1A1 through nuclear factor (NF)-κB and therefore can increase bilirubin slightly.42 
In addition, TNF-α and IL-6 appear to reduce bilirubin clearance in the liver.43 Furthermore, 
induction of heme-oxygenase that breaks down heme to form bilirubin (most likely occurring 
in the tissues rather than in circulating cells44) cannot be excluded. 
This study was intended as a proof of principle study on the effects of bilirubin in acute inflam-
mation and we have demonstrated that, in the absence of a possibility to administer bilirubin to 
humans, it is feasible to increase endogenous bilirubin concentrations in a controlled manner to 
investigate the effects of increased levels of bilirubin. However, we must acknowledge the fact that 
this ‘pharmacologically-induced Gilbert syndrome’ is currently only useful for research purposes. 
Possible side effects and interactions with the metabolism of other drugs makes atazanavir a 
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poor applicable tool to increase bilirubin levels in patients.
One could argue that the effects found in our study were in fact provoked by atazanavir, rather 
than by bilirubin. Protease inhibitors in HIV patients are known for their disadvantageous effects 
on lipid profiles and their negative effects on endothelial function45,46 and both are considered 
related to the increased risk for cardiovascular disease in HIV patients. However, a study per-
formed in healthy volunteers demonstrated that atazanavir treatment did not influence lipid 
profiles or significantly impact the response to endothelium-dependent vasodilator methacho-
line.46 In accordance, we demonstrated that short term treatment with atazanavir in our study 
does not affect the response to acetylcholine before LPS administration (data not shown) or 
lipid profiles demonstrating that inflammation is the most likely cause for endothelial dysfunc-
tion in our study. However, an effect of atazanavir or its metabolites on endothelial function or 
inflammation after LPS cannot be fully excluded. Nevertheless, additional in vitro experiments 
demonstrated that atazanavir does not influence the release of TNF-α or IL-10 (in the presence 
or absence of LPS) making it less likely that atazanavir itself interfered with our cytokine results.
The strength of the present study includes the fact that the effects of atazanavir-induced hyper-
bilirubinemia were investigated in a well explored and standardized model for inflammation, 
thereby gaining insight into the effects of bilirubin during acute systemic inflammation in humans. 
Naturally, it is a proof of principle study that is limited by the amount of subjects that participated 
and the preclinical model used. Future studies are warranted to explore the effects of bilirubin 
in chronic and acute human inflammatory diseases. 
In conclusion, the present study is the first to demonstrate that hyperbilirubinemia elicited by 
atazanavir improves anti-oxidant status, reduces IL-10 release and prevents endothelial dysfunc-
tion during experimental endotoxemia in humans. Based on these data, further studies utilizing 
possible other techniques to increase bilirubin concentrations are warranted to investigate its 
possible therapeutic applications in patients suffering from inflammatory diseases.
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abstract
Objective: In type 2 diabetes mellitus (T2DM), oxidative stress gives rise to endothelial dys-
function. Bilirubin, a powerful endogenous anti-oxidant, significantly attenuates endothelial 
dysfunction in preclinical experiments. The Gilbert syndrome is accompanied by a mild 
and lifelong hyperbilirubinemia and associated with only a third of the usual cardiovascular 
mortality risk. The hyperbilirubinemia caused by atazanavir treatment closely resembles the 
Gilbert syndrome. We thus hypothesized that treatment with atazanavir would ameliorate 
oxidative stress and vascular inflammation and improve endothelial function in T2DM.
Methods and Results: In a double-blind placebo-controlled crossover design, we induced a 
moderate hyperbilirubinemia by a three day atazanavir treatment in sixteen subjects suffer-
ing from T2DM. On the fourth day, endothelial function was assessed by venous occlusion 
plethysmography. Endothelium-dependent and endothelium-independent vasodilation were 
assessed by intra-arterial infusion of acetylcholine and nitroglycerin respectively. Atazanavir 
treatment induced an increase in average bilirubin levels from 7 μmol/L (0.4 mg/dL) to 64 
µmol/L (3.8 mg/dL). A significant improvement of plasma antioxidant capacity (p<0.001) and 
endothelium-dependent vasodilation (p=0.036) and a decrease of plasma von Willebrand 
factor (p=0.052) were observed.
Conclusions: Experimental hyperbilirubinemia is associated with a significant improvement 
of endothelial function in T2DM. 
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introduction
For years, bilirubin has been recognized as a powerful anti-oxidant in the human body.1,2 As 
atherosclerosis is characterized by a chronic state of low grade inflammation3 and oxidative 
stress of the vascular wall4, its development may be delayed by bilirubin. Preclinical data strongly 
support this hypothesis. Several in vitro experiments for example have demonstrated protection 
against low density lipoprotein (LDL) oxidation by physiological or only mildly elevated bilirubin 
levels.5,6 Moreover, bilirubin attenuates the pro-inflammatory response of vascular endothelial 
cells to oxidized LDL and tumor necrosis factor-α.7 Most importantly, parenteral treatment 
with bilirubin ameliorated the endothelium-dependent vasodilator response of thoracic aortic 
rings of LDL receptor knock-out mice on a high fat diet.7 In line with these robust preclinical 
data, multiple observational studies have demonstrated an inverse relation between bilirubin 
levels and cardiovascular disease in humans.8,9 Striking in this respect, is the fact that subjects 
with a mild lifelong hyperbilirubinemia due to the Gilbert syndrome carry only one third of the 
cardiovascular mortality risk compared to subjects without the syndrome.10
As shown in Figure 1, bilirubin is one of the effector molecules of the cytoprotective enzyme 
heme oxygenase.11 Prior to its excretion into the bile, it is conjugated by UDP glucuronosyl 
transferase 1A1 (UGT1A1). In the Gilbert syndrome, the conjugation and thus excretion of 
bilirubin is hampered as a result of an inactivating TA-repeat polymorphism in the promoter 
region of the gene coding for UGT1A1.12 As reported recently, this polymorphism contributes 
substantially to the variability in bilirubin levels.13 Not surprisingly, UGT1A1 has been suggested 
as an interesting drug target for the prevention of cardiovascular disease.14 Atazanavir is an HIV-1 
protease inhibitor licensed for the treatment of HIV infections and is known to inhibit UGT1A1 
activity.15 As such, treatment with atazanavir closely resembles the Gilbert syndrome.
Figure 1: The heme oxygenase system. 
Bilirubin is one of the effector molecules of heme oxygenase (HO), which breaks down heme into carbon 
monoxide (CO), iron (Fe) and biliverdin. Biliverdin is transformed to bilirubin by biliverdin reductase (BVR). 
Bilirubin is conjugated by UDP glucuronosyl transferase (UGT1A1). Like the Gilbert syndrome, atazanavir 
attenuates UGT1A1 activity.
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Subjects suffering from type 2 diabetes mellitus (T2DM) are particularly prone to the detri-
mental consequences of cardiovascular disease. Endothelial dysfunction can be demonstrated 
even early in the disease and is thought to be crucial in the development of atherosclerosis.16 
As the prevalence of diabetes is increasing worldwide and is expected to double to 366 mil-
lion subjects during the next two decades17 , the prevention of cardiovascular disease in this 
population is of utmost importance. Parallel to the above mentioned observational data, the 
Gilbert syndrome has been associated with a significantly lower risk of cardiovascular disease 
in subjects with T2DM.18 
Despite the strong evidence derived from preclinical and observational data, human experiments 
exploring the beneficial effect of bilirubin on cardiovascular disease have, to the best of our 
knowledge, not been published so far. The aim of this double blind placebo-controlled crossover 
study was to prove the hypothesis that elevation of the serum bilirubin level by experimental 
inhibition of UGT1A1 activity would be accompanied by an improvement of endothelial function 
in subjects suffering from T2DM.
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methods
Subjects with T2DM were recruited through local advertising and were not allowed to have a 
positive history of smoking, drug abuse or macrovascular complications of diabetes. Subjects 
had to be at least 18 and no older than 70 years of age. The body mass index was allowed to 
range from 18 to 35 kg/m2. All hyperglycemia treatment regimens including diet, oral medication 
and insulin therapy were accepted. Subjects were prohibited from using vasoactive medication, 
aspirin or anti-oxidant vitamin supplements, as these drugs could influence endothelial function. To 
avoid pharmacokinetic interactions with atazanavir, any use of gastric acid suppressive medication 
and statins was discontinued during participation starting four weeks prior to the first treat-
ment period. Subjects were enrolled only if they accepted such treatment interruption during 
participation. All subjects gave written informed consent prior to the screening visit. Subjects 
with clinical evidence of cardiac or pulmonary disease and subjects with laboratory evidence 
of renal or hepatic abnormalities were excluded. Finally, subjects were genetically tested for the 
presence of the Gilbert syndrome and excluded if positive. The study protocol was approved 
by the local Medical Research Ethics Committee and consistent with the Declaration of Helsinki. 
In a double-blind and randomized crossover study, subjects received a three day atazanavir treat-
ment (Reyataz®, Bristol-Myers Squibb BV, Woerden, the Netherlands) and a three day placebo 
treatment with a wash out period of at least three weeks in between. To amplify the level of 
hyperbilirubinemia, the regular dose regimen of atazanavir in HIV patients (either 400 mg once 
daily or 300 mg boosted with ritonavir 100 mg once daily) was modified to an alternative reg-
imen of 300 mg twice daily to be taken with food. If reflected by the area under the curve, the 
exposure to atazanavir caused by this dose regimen does not exceed the exposure associated 
with both regular dose regimens.19
On the fourth day of both treatment periods, forearm blood flow (FBF) was assessed by 
venous occlusion strain gauge plethysmography. A time schedule of these flow assessments is 
provided in Figure 2. All experiments were performed in the morning after an overnight fast in 
a temperature-controlled room (23° C) with the subjects in supine position. If needed, dose 
adjustments of hypoglycaemic agents were recommended during the evening and early morning 
prior to the assessments. Capillary glucose levels were monitored. The brachial artery of the 
non-dominant arm was cannulated with a 27-gauge needle (kindly supplied by B. Braun Medi-
cal BV, Oss, the Netherlands) for intra-arterial administration of saline, acetylcholine (Miochol, 
Thea Pharma NV, Zoetermeer, the Netherlands) and nitroglycerine (Nitropohl, Pohl-Boskamp, 
Hoofddorp, the Netherlands). FBF was assessed during the successive administration of three 
increasing doses of acetylcholine (0.5, 2 and 8 μg/min/dL of forearm tissue) and nitroglycerin 
(0.125, 0.25 and 0.5 μg/min/dL). Both series were preceded by a 30 minute pause and started 
with the assessment of baseline FBF during saline infusion. Each dose was administered during five 
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minutes. FBF was recorded simultaneously on both the infusion and the control arm by venous 
occlusion plethysmography using mercury-in-silastic strain gauges (Hokanson EC4, Hokanson, 
Inc., Washington, USA). The upper arm cuffs were inflated using a rapid cuff inflator (Hokanson 
E-20, DE Hokanson). Wrist cuffs were inflated to 220 mm Hg during each series. Immediately 
after completion of FBF assessments, blood pressure in supine position was assessed with an 
aneroid sphygmomanometer.
Figure 2: The vasodilator response to acetylcholine (ACh) and to nitroglycerin (NTG) were consecutively 
assessed. Both vasodilators were administered in three increasing doses. Dosages were adjusted to forearm 
volume (depicted as μg/min/dL forearm volume). A 30 minute pause (equilibration period) was made prior to 
each agent.  S, saline.
Prior to the experiment, venous blood was drawn. Hematological parameters were assessed 
using an ADVIA 120 Hemalog (Bayer Diagnostic, Tarrytown, N.Y., USA) and chemical parameters 
including bilirubin levels were determined using an Aeroset (Abbott Laboratories, Abbott Park, 
IL, U.S.A.). In addition, plasma samples were stored at -80° C for determination of atazanavir 
plasma levels, anti-oxidant capacity and biomarkers of vascular inflammation. Atazanavir plasma 
levels were determined using a modification of a validated HPLC method with UV detection as 
published previously.20 Plasma anti-oxidant capacity was assessed by means of the ferric reducing 
ability of plasma (FRAP) assay, according to the method of Benzie and Strain.21 FRAP values 
were obtained using a seven-point calibration curve of known amounts of Fe2+ and expressed 
in mmol Fe2+/L. The concentrations of soluble vascular cell adhesion molecule-1 (sVCAM-1) 
and soluble intercellular adhesion molecule-1 (sICAM-1) were determined by a multiplex assay 
(Bio-plex cytokine assay, BioRad, Hercules, CA, USA at Luminex 100, Luminex Corporation, the 
Netherlands). The concentration of von Willebrand factor (vWF) was determined by ELISA 
(Progen biotechnik, Heidelberg, Germany and R&D systems, Minneapolis, U.S.A). To enable the 
determination of bilirubin levels after deblinding of the study one additional lithium heparin 
plasma sample was stored at -80°C in a brown Eppendorf tube.
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Statistical analysis was performed using the SPSS (version 16.0) and SAS (version 8.2) software 
package. Paired-samples t-test was used to compare Gaussian distributed data. For analysis of 
the forearm blood flow measurements, the last five flows of each dose were used. Prior to anal-
ysis, logarithmic transformation was performed to obtain a Gaussian distribution. The flow data 
were then averaged per dose and subsequently analyzed in a mixed linear model with random 
factor subjects and fixed factors treatment and dose. In a post-hoc analysis, the atazanavir level, 
the bilirubin level following atazanavir treatment, the baseline level of glycated hemoglobin and 
the duration since diagnosis were included in the model, in order to explore a possible impact 
of these factors on the degree of therapeutic response. Flow data are presented in three ways. 
Figure 3 displays the original data in terms of percentage from baseline. The log-transformed 
data used for analysis are presented in Table 3. The data discussed in the text are medians instead 
of averages of the original flow data to approximate the effect of logarithmic transformation. 
Statistical significance was accepted at the 95% confidence level (p≤0.05).
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results
Eighteen non-smoking subjects with T2DM and a negative history for cardiovascular disease were 
recruited and gave written informed consent. Two of them were excluded during screening, one 
because of a genetically confirmed Gilbert syndrome and the other because of an observed 
tendency towards vasovagal collapse, which would have interfered with the assessment of FBF. 
Based on a data review following completion of the study, one of the sixteen participating subjects 
was excluded because of a highly inaccurate intake of study medication as well as an excep-
tionally low quality of the forearm blood flow assessments. This decision was made prior to the 
deblinding procedure. Based on post hoc analysis, inclusion of this subject would have resulted in 
a higher level of significance. The results presented concern those of the remaining 15 subjects. 
Characteristics of the study population are shown in Table 1. We have examined six males and 
nine females with an average body mass index of 28 kg/m2. The mean history of diabetes was 
5.9 years, the average glycated hemoglobin level 6.8 percent. Three subjects were treated with 
a diet only. The other twelve subjects were treated with either mono or combination therapy 
containing a biguanide, sulphonylurea or insulin. Nine of fifteen subjects were taking statins on 
inclusion and agreed with interruption during participation. As a result of the exclusion criteria, 
none of the subjects was using aspirin or anti-hypertensive medication.
Table 1: Characteristics of study population (n = 15)
Sex 6 men, 9 women
Age (years) 61 (6, 51 – 70)
BMI (kg/m2) 28 (4, 18 – 35)
HbA1c (%) 6.8 (1.1, 5.5 – 9.8)
Treatment regimen: 3 diet only
10 metformin
7 SU
2 insulin
9 statin
Data are given as mean (SD, range), frequency of treatment regimens are given as number of subjects. BMI, body 
mass index; HbA1c, average glycated hemoglobin; SU, sulphonyl urea derivates. 
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Total bilirubin levels after placebo and atazanavir treatment are shown in Table 2. The average 
bilirubin level following placebo treatment amounted to 7 μmol/L (0.4 mg/dL). As anticipated, 
the three day course of UGT1A1 inhibition resulted in significantly elevated bilirubin levels with 
an average of 64 μmol/L (3.8 mg/dL) and a range of 35 to 110 μmol/L (2.1 to 6.4 mg/dL). Due 
to the short term of the atazanavir treatment, significant tissue accumulation and thus clinically 
perceptible jaundice did not occur except in one case. In this subject, jaundice arose on day four 
after completion of the FBF assessments.
When compared with placebo, a significant improvement of anti-oxidant capacity was observed 
following atazanavir treatment (p<0.001). In addition, atazanavir treatment was associated with a 
decrease in plasma vWF (p=0.052). Plasma levels of sVCAM-1 and sICAM-1 were not affected. 
Atazanavir treatment did not influence the plasma levels of fasting glucose and low density 
lipoprotein cholesterol. 
Table 2: Laboratory results after atazanavir and placebo treatment
Placebo Atazanavir p-value
Bilirubin (μmol/L) 7 (1) 64 (21) < 0.01
Glucose (mmol/L) 8.4 (0.6) 8.5 (0.7 0.78
LDL (mmol/L) 3.7 (0.2) 3.6 (0.2) 0.61
FRAP (mmol Fe2+/L) 1.26 (0.06) 1.66 (0.07) < 0.001
vWF  (U/mL) 1.46 (0.13) 1.18 (0.12) 0.05 
sVCAM-1 (pg/mL) 183(10) 191 (8) 0.14 
sICAM-1 (pg/mL) 158 (7) 153 (7) 0.37 
Data are given as mean (SEM). LDL, low-density lipoprotein; FRAP, ferric reducing ability of plasma; vWF, von 
Willebrand factor; sVCAM-1, soluble vascular cell adhesion molecule-1; sICAM-1, soluble interstitial cellular 
adhesion molecule-1. Reported p-values are the result of paired t-tests.
The results of FBF experiments are depicted in Figure 3 and Table 3. Baseline flow after placebo 
treatment was comparable to baseline flow after atazanavir treatment (1.8 and 1.5 mL/min/dL 
tissue in the intervention arm and 1.6 and 1.7 mL/min/dL in the control arm respectively). Nei-
ther acetylcholine infusion nor nitroglycerin infusion affected the blood flow of the contralateral 
forearm (data not shown).
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Intra-arterial infusion of acetylcholine induced an increase in FBF at all three doses after both 
placebo and atazanavir treatment. Compared to placebo, atazanavir treatment was accompanied 
by a significantly enhanced vasodilator response to acetylcholine. At the highest acetylcholine 
dose, 8 μg/min/dL, FBF amounted to median levels of 19.9 and 21.9 mL/min/dL following pla-
cebo and atazanavir treatment respectively. Statistical analysis on the log-transformed flow data 
of all three acetylcholine dosages revealed a relative increase of 12 percent without relevant 
differences between the three acetylcholine dosages. The improvement of acetylcholine response 
was not influenced by the atazanavir level, the bilirubin level following atazanavir treatment, the 
glycated hemoglobin level at baseline or the duration of diabetes prior to inclusion (based on 
post hoc analysis).
Figure 3: Increase of FBF in response to three increasing dosages of acetylcholine (ACh) and nitroglycerin (NTG), 
depicted as percentage from baseline. Error bars indicate standard errors of the mean. Black columns represent 
placebo treatment, white columns atazanavir treatment. Statistical analysis was performed on the log-
transformed data depicted in Table 3.
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Intra-arterial infusion of nitroglycerin also induced a significant increase of FBF at all dosages. 
Contrary to acetylcholine, the extent of vasodilator response to nitroglycerin was not influ-
enced by our intervention with atazanavir. At the highest nitroglycerin dose, 0.5 μg/min/dL, FBF 
amounted to median levels of 7.3 and 7.1 mL/min/dL following placebo and atazanavir treatment 
respectively.
Table 3: Forearm blood flow data after logarithmic transformation
Placebo Atazanavir p-value
Baseline 0.25 (0.04) 0.18 (0.05) 0.036
ACh 1 0.75 (0.07) 0.78 (0.07)
ACh 2 1.01 (0.06) 1.05 (0.06)
ACh 3 1.25 (0.06) 1.33 (0.04)
Baseline 0.25 (0.05) 0.21 (0.04) 0.404
NTG 1 0.64 (0.04) 0.64 (0.04)
NTG 2 0.72 (0.05) 0.73 (0.04)
NTG 3 0.85 (0.04) 0.81 (0.04)
ACh1-3, acetylcholine dosage of 0.5, 2.0 and 8.0 μg/min/dL respectively; NTG1-3, nitroglycerin dosage of 0.125, 
0.250 and 0.500 μg/min/dL respectively. In parenthesis standard errors of the mean. 
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discussion
A multitude of preclinical and observational studies have credited bilirubin with the potential to 
prevent cardiovascular disease. To our knowledge, this is the first study addressing the concept 
of experimental hyperbilirubinemia in humans. Our findings demonstrate, that even a three day 
atazanavir treatment improves endothelial function in subjects with T2DM. Endothelial dysfunc-
tion is strongly related to the development of atherosclerosis and the resulting cardiovascular 
risk.22 Central in the pathogenesis of endothelial dysfunction is the decreased availability of 
endothelial nitric oxide (NO).23 One of the key factors leading to limited NO availability is the 
increase of intracellular oxidative stress. A substantial part of the production of reactive oxygen 
species (ROS) is supposed to stem from NADPH oxidase activity.24
Addressing the mechanistic importance of oxidative stress, several groups have studied the effect 
of anti-oxidant treatment strategies among which intra-arterial infusion of ascorbate. Under-
scoring the fundamental role of oxidative stress, improvement of endothelial function following 
parenteral administration of ascorbate was observed in subjects suffering from various conditions 
like hypercholesterolemia25, hypertension26 and both insulin-independent27 and insulin-dependent 
diabetes mellitus.28 Bilirubin is a powerful endogenous anti-oxidant and its clinical relevance is 
highly suggested by the results of preclinical and observational studies. As such, artificial elevation 
of the serum bilirubin level might be an attractive and for the long term workable approach for 
the prevention of cardiovascular disease.14,29 Our current data on the significant improvement 
of antioxidant capacity and endothelial function observed after a three day atazanavir treatment, 
strongly support the potential of this strategy.
Biomarkers of vascular inflammation like vWF, sVCAM-1 and sICAM-1, have shown to be 
related to the risk of cardiovascular complications in T2DM.30 Besides, bilirubin has been shown 
to attenuate H2O2-induced endothelial leukocyte rolling and adhesion in vivo.31 The observed 
trend towards a decrease of serum vWF is in line with the observed improvement of endothelial 
function and may reflect a decrease of vascular inflammation in our subjects. The limited size of 
our study population and the short duration of atazanavir treatment may account for the fact 
that sVCAM-1 and sICAM-1 did not alter.
Several limitations should be addressed as they may have influenced the outcome of our study. 
At first, there are no data available on the bilirubin levels needed to obtain maximally protective 
anti-oxidant effects in vivo in humans. In our design, we opted for a short term exposure aiming 
at moderately elevated bilirubin levels. The three day treatment regimen resulted in a mean bil-
irubin level of 64 μmol/L (3.8 mg/dL). As we did not observe a relation between bilirubin levels 
and the vasodilator response to acetylcholine, this may indicate that we reached the plateau 
of the concentration – effect curve. Considering the relatively low bilirubin levels and the still 
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marked cardiovascular protection observed in subjects with the Gilbert syndrome, long term 
treatment regimens aiming at bilirubin levels in the subclinical range may be sufficient as well. 
This would favor long term application of a lower dose of atazanavir as our current regimen 
would definitely cause an unacceptable degree of jaundice during prolonged treatment. Further 
research is needed to address this topic.
Secondly, atazanavir itself may have a direct beneficial impact on endothelial function. In a pre-
vious study, 400 mg of atazanavir once daily did not influence endothelial function in healthy 
volunteers.32 In our study however, we administered a different dose. Moreover, we included 
patients with T2DM instead of healthy subjects. Therefore, we do not know whether our dose 
regimen of 300 mg twice daily might affect endothelial function in healthy subjects. Besides, 
bilirubin is obviously not the only substance conjugated by UGT1A1. It is likely therefore, that 
the Gilbert syndrome and atazanavir treatment affect plasma levels of substances other than 
bilirubin. Theoretically, such substances as well as atazanavir itself could cause the observed 
improvement of vascular function ascribed to bilirubin. Nevertheless, UGT1A1 inhibition and 
parenteral administration of bilirubin comparably attenuated oxidative stress and hypertension in 
an angiotensin II-dependent animal model.33 In our opinion, this supports a causal and dominant 
role of bilirubin. A similar approach with parenteral administration of bilirubin in humans may 
provide a definite proof of its beneficial impact on cardiovascular disease.
Finally, HIV protease inhibitors are commonly connoted for their contribution to cardiovascular 
complications in HIV patients.34 In contrast to several other protease inhibitors however, atazana-
vir does not affect glucose tolerance, plasma cholesterol level or endothelial function in healthy 
volunteers at a dosage of 400 mg once daily.32 Consistently, we did not observe changes in 
plasma glucose or plasma cholesterol levels at a twice daily dosage of 300 mg nor did we find a 
relation between atazanavir plasma levels and the observed improvement of endothelial function.
In contrast to the promising data on the parenteral use of ascorbate, clinical trials with orally 
administered exogenous anti-oxidants like vitamin C and E have been generally disappointing.35,36 
Several explanations have been put forward varying from the inability to obtain sufficiently ele-
vated intracellular levels by oral dosing regimens, to the inability of vitamin C and E to compete 
with highly reactive molecules like peroxynitrite.16 Notably, bilirubin is one of the most potent 
scavengers of ROS in nature.37 As our strategy evidently fortifies an endogenous and physiolog-
ically relevant anti-oxidant resource, it may overcome the flaws of previous treatment strategies 
with exogenous anti-oxidants. Besides, bilirubin has shown to inhibit NADPH oxidase activity in 
vitro.38 Given the importance of NADPH oxidase activity in the pathogenesis of diabetes related 
endothelial dysfunction, this property may contribute to the beneficial effects on endothelial 
function observed in our diabetic subjects too.
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In summary, our study is the first to address the concept of vascular protection by experimen-
tal hyperbilirubinemia in humans. Given the overwhelming preclinical and observational data 
on bilirubin and cardiovascular disease, it is in our opinion very likely that the improvement 
of endothelial function and plasma anti-oxidant capacity observed after atazanavir treatment 
should be attributed to the associated hyperbilirubinemia. Indisputable evidence on this should 
be provided by the use of alternative human models for experimental hyperbilirubinemia. Finally, 
optimally protective plasma levels have to be established. If potent at only mildly elevated bilirubin 
levels, long term UGT1A1 inhibition may prove a novel pharmacological approach to prevent 
cardiovascular disease in T2DM.
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abstract
Preclinical studies have demonstrated promising results on the therapeutic potential of 
mild hyperbilirubinemia in type 2 diabetes mellitus and cardiovascular disease. To explore 
the feasibility of a reintroduction of bilirubin for parenteral human use in translational 
experiments, we developed a preparation method that meets current standards of good 
manufacturing practice (GMP) and subsequently performed an explorative pharmacokinetic 
and safety study in eight healthy volunteers. Bilirubin was administered intra-arterially to 
raise the local plasma concentration in the forearm vascular bed and intravenously to raise 
the systemic plasma concentration. A dose-concentration relationship appeared sufficiently 
predictable and the pharmacokinetics of bilirubin could be described best according to a 
two-compartment model. Based on our data and an extensive literature study, we conclude 
that parenteral human use of bilirubin appears safe if produced under GMP conditions and 
applied in its current albumin bound formulation and dosage, aiming for plasma concentra-
tions up to 100 μmol/L.
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introduction
Though commonly seen as a harmful residual product from the breakdown of heme, bilirubin 
was already demonstrated to possess anti-oxidant capacities in 1954.1 Ever since, a wide variety 
of in vitro and animal studies have been published on the protecting anti-oxidant and anti-inflam-
matory effects of both bilirubin and heme oxygenase (HO), the rate-limiting enzyme in bilirubin 
formation.2,3 Numerous observational studies have demonstrated an inverse association between 
bilirubin concentrations and cardiovascular disease in humans.4 Therefore, both the induction 
of a mild hyperbilirubinemia and the enhancement of HO activity have been suggested for the 
treatment of a variety of diseases including type 2 diabetes mellitus and related cardiovascular 
disorders.2,5,6 In case of cardiovascular disease, several well established measures of endothelium 
function can be used as surrogate endpoints to, enable translational research with bilirubin.7 Using 
the perfused forearm technique, we previously succeeded to improve endothelial function and 
plasma anti-oxidant capacity in subjects with type 2 diabetes mellitus by a short-term treatment 
with the plasma bilirubin-increasing drug atazanavir.8 Additional experiments are needed to 
invigorate these promising findings. The availability of a bilirubin formulation that is suitable for 
parenteral human use would significantly facilitate the design of such experiments.
In the past, intravenous administration of bilirubin was commonly applied in human research 
and clinical practice. (Table 4) After 1981, however, no new data on the experimental use of 
bilirubin in humans have been published. Subsequent to an extensive literature study on the 
former preparation and parenteral use of bilirubin, we developed a production method meeting 
current standards of good manufacturing practice (GMP). In addition to the intravenous use of 
the preparation, we also studied its applicability for intra-arterial administration in the perfused 
forearm model. Here, we present the method of preparation, the first intravenous and intra-ar-
terial pharmacokinetics and the safety data in healthy volunteers.
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methods
Preparation
The bilirubin concentrate for infusion was developed and prepared at Radboud university 
medical center (Radboudumc). All procedures were performed according to GMP guidelines. 
As there was no bilirubin available which was certified for human use, bilirubin was purchased 
from Sigma-Aldrich (B4126 Sigma bilirubin ≥98%). Extensive quality control was performed 
to ensure content, chemical purity and nonpyrogenecity by the limulus amebocyte lysate test.
Several formulations of bilirubin in different solvents (sodium carbonate buffer, direct dissolution 
in albumin, sodium hydroxide in different concentrations and hence different pH) were tested 
in order to create a product with an adequate pH for intravenous and intra-arterial infusion. 
The final formulation consisted of bilirubin at 6 mg /mL in 0.1M sodium hydroxide with a pH 
>10. Shortly before administration the product was passed through a 0.2 µm filter and diluted 
with human albumin 200 mg/mL intravenous solution (Albuman®, Sanquin Plasma Products) to 
a concentration of 1.2 mg/mL for intravenous infusion (pH 8.1) and to a concentration of 0.6 
mg/mL for intra-arterial infusion (pH 7.6). Based on the molecular weight of bilirubin (584.66 
g/mol) and albumin (66.5 kg/mol) the molarity for bilirubin and albumin was 2.05 and 2.41 
mmol/L respectively for the intravenous solution and 1.03 and 2.71 mmol/L respectively for the 
intra-arterial solution.
Bilirubin showed signs of degradation after sterilization through heat and gamma radiation. The 
final production therefore consisted of an aseptic preparation and filtration (Sartopore® 2 XLI 
0.35 +0.2 µm) into 10 mL vials under a continuous flow of nitrogen. This was carried out at 
the Department of Pharmacy at the Erasmus Medical Center in Rotterdam, The Netherlands. 
Quality control and release of the product was performed at the Department of Clinical Phar-
macy, Radboudumc, and consisted of identity, content, pH, particle count, microbial count, sterility, 
endotoxins and extractable volume. The 6mg/mL bilirubin concentrate for infusion appeared to 
be stable for at least 12 months stored at -20°C.
Study design
We performed a pharmacokinetic and safety study on the parenteral use of bilirubin in which 
eight healthy volunteers participated. (Figure 1) Subjects had to be at least 18 and no older 
than 65 years of age and were not allowed to have a positive history of smoking, drug abuse 
or liver disease. Women of child bearing potential were included only if adequate contraceptive 
measures had been taken. Except for contraceptives, any use of medication was prohibited. After 
signing informed consent, all volunteers were screened by means of a complete medical history, 
physical examination and a limited laboratory evaluation including blood count, renal function and 
liver enzymes. Subjects with any sign of active disease or laboratory results exceeding twice the 
upper limit of normal range were excluded. To avoid inclusion of subjects with Gilbert syndrome, 
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baseline plasma levels of bilirubin were not allowed to surpass 10 μmol/L (0.58 mg/dL).
The experimental design is depicted in Figure 1. For safety reasons, the study protocol initially 
consisted of a two-stage design. Both stages were separated by a safety evaluation to enable 
adjustment of the second stage protocol if needed. During the experiment, a third stage was 
added to study bilirubin plasma kinetics after a short high-dose intravenous infusion. Intra-arte-
rial and intravenous dose schedules were adjusted to forearm volume and total body weight, 
respectively. In all three stages of the protocol, subjects were studied in succession with at least 
one week in between.
During the first intra-arterial stage of the protocol, we aimed for a local increase in bilirubin 
concentration in the forearm vascular bed without a significant rise of systemic levels. Four 
increasing doses of bilirubin were infused in the brachial artery, each during 20 minutes. Based 
on the assumption of an average brachial artery flow of 2 mL/min per dL of forearm volume, 
the lowest intra-arterial dosage of 1.8 μg/min per dL of forearm volume was estimated to give 
an ipsilateral rise of the plasma bilirubin concentration of 3 μmol/L (0.18 mg/dL). For the highest 
intra-arterial dosage of 30 μg/min per dL of forearm volume we expected an ipsilateral rise of 
the plasma bilirubin concentration of 50 μmol/L (2.92 mg/dL). Venous plasma samples were 
taken every 5 minutes from both the ipsilateral and the contralateral arm to assess local as well 
as systemic changes of bilirubin plasma concentration. 
During the second stage we aimed for a systemic hyperbilirubinemia. Each of the three intra-
venous bolus injections was administered over a period of 5 minutes, followed by a 15 minutes 
pause. Dosages were based on our literature study (see Table 4 for additional details). The lowest 
intravenous dosage of 0.086 μg/kg body weight was estimated to cause a systemic rise of 2.6 
μmol/L (0.15 mg/dL). For the highest intravenous dosage, we expected a rise of 26 μmol/L (1.52 
mg/dL). Every 5 minutes, a plasma sample was taken from the contralateral arm.
During the third phase, we studied the pharmacokinetics of bilirubin upon a single intravenous 
dosage of 2.9 mg/kg body weight administered over 15 minutes. Subsequently, plasma bilirubin 
concentrations were measured frequently over a total period of six hours. The length of interval 
between sampling was increased during observation and varied from 5 minutes immediately 
upon administration to a maximum of 30 minutes from the second hour of observation.
During all three stages, heart rate, blood pressure, respiratory rate and body temperature were 
monitored. All complaints mentioned during participation were listed. After treatment, subjects 
visited the research unit on day 1, 2 and 7 to check for side effects. Two weeks after participation, 
subjects underwent a complete medical screening.
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Hematological parameters were assessed using an ADVIA 120 Hemalog (Bayer Diagnostic, 
Tarrytown, N.Y., USA) and chemical parameters including bilirubin levels were determined using 
an Aeroset (Abbott Laboratories, Abbott Park, IL, U.S.A.). For bilirubin concentrations above 5 
µmol/L, precision of the measurement was characterized by a coefficient of variation (CV) of 
20%. Below 5 μmol/L, which concerned seven samples, the CV was much higher than 20% and 
therefore these results were excluded. 
The initial study protocol and all interim modifications were approved by the local Medical 
Research Ethics Committee and consistent with the Declaration of Helsinki. In addition, we 
appointed an independent safety monitor and scheduled frequent meetings to discuss all safety 
data.
Figure:1 Study design
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Statistics 
In general, descriptive data are presented as mean (± SD). Changes in bilirubin plasma concen-
tration upon intra-arterial or intravenous infusion are depicted as delta. For the intra-arterial 
infusion in the first phase of our experiment, the delta reflects the local rise in plasma bilirubin 
in the forearm vascular bed per dose calculated by the difference between the final venous 
bilirubin concentration in the forearm of administration and the contemporary systemic bili-
rubin concentration in the contralateral forearm vascular bed. For the intravenous infusion in 
the second phase of our experiment, the delta reflects the systemic rise in plasma bilirubin per 
intravenous dose calculated by the difference between the highest plasma bilirubin concentration 
level observed upon each bolus infusion and the baseline bilirubin concentration observed prior 
to the administration of the intravenous bolus infusion. The individual plasma concentration-time 
profiles obtained during the third phase of our experiment are depicted in Figure 2. 
Plasma concentration-time data of bilirubin were analyzed with use of WinNonlin (version 6.3; 
Pharsight, Mountain View, CA) by weighted (1/y) nonlinear regression analysis according to a 
two-compartment model with short intravenous infusion, first-order elimination, and a constant 
endogenous baseline concentration of bilirubin. The following pharmacokinetic parameters were 
obtained (Table 2): total area under the curve (AUC), total area under the first moment curve 
(AUMC), volume of the central compartment (V1), half-life of the distribution phase (t½,α), 
half-life of the elimination phase (t½,β), mean residence time (MRT = AUMC/AUC – Tinf/2, 
where Tinf = infusion time), total plasma clearance (CL = D/AUC), and volume of distribution 
at steady-state (Vss = CL × MRT).
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results
Subject screening
Subjects were recruited on two occasions, prior to the first and the third phase of the study. In 
total, 13 subjects were screened, four of which were excluded because of an elevated plasma 
bilirubin concentration at baseline. The remaining nine subjects were all suitable for inclusion in 
our study. Eight of them actually participated in the experiments. Five subjects (2 male, 3 female) 
participated in the intra-arterial dosing experiment (phase 1) and four of them (1 male, 3 female) 
also participated in the intravenous dosing experiment (phase 2). Subject B was willing but, for 
logistic reasons unable to participate in phase 2. The course of the plasma concentration of bili-
rubin upon a single intravenous bolus infusion (phase 3) was studied in three other subjects (all 
male). All participating subjects were without any active disease. All three female participants used 
oral contraceptive medication. The average age of the subjects was 21.5 years (range 19 – 27).
Intra-arterial (phase 1) and intravenous (phase 2) dosing studies
The local rise of plasma bilirubin concentration in the forearm vascular bed in response to 
intra-arterial administration is depicted in Table 1A. During the first intra-arterial experiments 
we experienced technical difficulties. Because of unsuccessful cannulation of the brachial artery 
during the very first experiment, we decided to administer bilirubin intravenously instead. Con-
sequently, only systemic concentrations and safety data are presented for the first subject. 
Dislocation of the intra-arterial needle (second experiment) and temporary obstruction of 
the sampling system (third experiment) accounted for the remainder of missing values. The 
intra-arterial bilirubin dosage needed to increase the local plasma bilirubin concentration in the 
forearm vascular bed by 1 μmol/L amounted 1.44, 0.75, 0.82 and 0.71 μg/min per dL of forearm 
tissue on average for the four subsequent intra-arterial infusions, respectively. The systemic rise of 
plasma bilirubin concentration in response to intravenous bolus infusion is depicted in Table 1B. 
The intravenous bilirubin dosage needed to increase the systemic plasma bilirubin concentration 
by 1 μmol/L amounted to 0.04 mg bilirubin per kg body weight on average.
Pharmacokinetic parameters (phase 3)
The pharmacokinetic characteristics of bilirubin obtained during the third and final phase of 
our experiments are depicted in Figure 2 and Table 2. The plasma concentration-time curves 
could be described best by an open two-compartment model, taking the endogenous baseline 
concentration of bilirubin into account. Figure 2 displays the fitted individual curves of plasma 
bilirubin concentrations upon the administration of the single intravenous bolus infusion of 2.9 
mg bilirubin per kg body weight. Maximum bilirubin plasma concentrations of 72, 76 and 86 
μmol/L were observed in the three subjects studied, respectively. Pharmacokinetic parameters 
obtained from this analysis are listed in Table 2. 
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Table 1A: Individual bilirubin plasma concentrations during intra-arterial administration
Dose 
(μg/min/dL)
Expected rise 
(μmol/L)
Delta bilirubin 
concentration (μmol/L)
Average delta
(SD; μmol/L)
Increase per 
1 μg/min/dL
Subject A B C D E
FAV (dL) 10 13 11 11 10
Dose 1 1.8 3 1 0 3 1.3 (1.5) 0.7
Dose 2 6 10 5 11 8.0 (4.2) 1.3
Dose 3 18 30 23 18 25 22.0 (3.6) 1.2
Dose 4 30 50 45 27 54 42.0 (13.7) 1.4
The delta resembles the local rise of plasma bilirubin concentration in the forearm per intra-arterial dose 
concentration and is depicted by the difference between the final venous bilirubin concentration in the forearm 
of administration and the contemporary systemic bilirubin concentration in the contralateral forearm. FAV: 
forearm volume.
Table 1B: Individual bilirubin plasma concentrations during intravenous administration
Dose 
(mg/kg)
Expected rise 
(μmol/L)
Delta bilirubin 
concentration (μmol/L)
Average delta
(SD, μmol/L)
Increase per 
1 mg/kg
Subject A C D E
BW (kg) 62 63.5 64 61.5
Dose 1 0.086 2.6 3 2 2 2.3 (0.6) 27.1
Dose 2 0.29 8.8 8 6 7 7 7.0 (0.8) 24.1
Dose 3 0.86 26.4 24 21 22 19 21.5 (2.1) 25.0
The delta resembles the systemic rise of plasma bilirubin concentration per intravenous dose and is depicted 
by the difference between the highest plasma bilirubin concentration observed upon each bolus infusion and 
the baseline bilirubin concentration observed prior to the administration of the intravenous bolus infusion 
concerned. BW: body weight.
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Figure 2: Plasma concentration-time curve of bilirubin after short intravenous infusion of 2.9 mg/kg in three 
healthy male subjects (F, G, and H).
Time is depicted as minutes after infusion.
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Table 2: Computed pharmacokinetic parameters after a single intravenous bolus infusion of 2.9 mg bilirubin per kg 
of body weight
                Individual subjects Mean (SD)
Subject (all male) F G H
BW (kg) 82 87 71
Dosage (μmol) 406 429 351
t inf (min) 15 15 12
Cbaseline (μmol/L) 8 8 8
AUC (μmol*min/L) 1.17×104 0.97×104 1.19×104 1.11 (0.12) ×104
AUMC (μmol*min2/L) 11.0×106 2.41×106 3.72×106 5.71(4.63)×106
V1 (L) 5.8 5.2 4.0 5.0 (0.9)
t½,α (min) 43 34 42 40 (5)
t½,β (min) 280 184 343 270 (80)
MRT (min) 315 204 333 280 (70)
CL (mL/min) 35 44 29 36 (8)
Vss (L) 10.9 9.0 9.8 9.9 (1.0)
Data are presented as mean (SD). BW: body weight; t inf: infusion time; AUC: total area under the plasma 
concentration-time curve, AUMC: total area under the first moment of the plasma concentration-time curve, 
V1: volume of the central compartment, t½,α: half-life of the distribution phase, t½,β: half-life of the elimination 
phase, MRT: mean residence time, CL: total plasma clearance, and Vss: volume of distribution at steady-state.
Safety
In general, the administration of bilirubin was well tolerated. None of the experiments, includ-
ing the one that was complicated by displacement of the intra-arterial needle and consequent 
extravasation of bilirubin, was associated with side effects during the administration. During the 
observation period, several adverse events were noted. An overview of all 13 adverse events is 
provided. (Table 3) The majority of these events was mild, self-limiting and/or clearly unrelated. 
Three events deserve additional attention. First, one of the subjects suffered from a necrotizing 
appendicitis ten days after the intra-arterial administration of bilirubin. The subject underwent 
surgery and fully recovered. The event was considered unrelated to our study by both the 
safety monitor and the independent surgeon. Although the possibility to withdraw informed 
consent was explicitly discussed, the subject decided to continue participation and did not show 
any adverse event during the second phase of the experiments. Second, one of the subjects 
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demonstrated an asymptomatic self-limiting atrial rhythm with a right bundle branch block 
during the post-infusion observation period in the second phase of the study. An independent 
cardiology consultant considered the arrhythmia to be physiologic and unrelated to our study. 
Additional visits did not reveal any sign of side effects. Third, one of the subjects developed a 
rash 50 hours after a single high-dose intravenous bolus injection of bilirubin and albumin. An 
independent dermatology consultant considered the eruption due to atopic eczema and unre-
lated to our study. Additional hematological tests and clinical chemistry did not show any sign 
of systemic side effects. The rash vanished within days after topical application of corticosteroids 
and symptomatic treatment with cetirizine.
Table 3: Safety data
Symptom / diagnosis Frequency Time* Additional information
Vasovagal collapse 1/12 During cannulation, prior to first administration of 
bilirubin
Cardiac arrythmia 1/12 1 hour Atrial rhythm with right bundle branch block. 
Judged physiologic and unrelated to experiments 
by independent cardiologist. No signs of side effects 
during additionally scheduled safety visits
Rash / atopic eczema 1/12 2 hours Judged unrelated to experiments by independent 
dermatologist
Temporary treatment with topical corticosteroids. 
No signs of side effects or inflammation during 
additionally scheduled safety visits and blood tests
Pain in right ankle & wrist 1/12 12 hours Self-limiting, no use of medication
Mild head ache 3/12 12-24 hours Self-limiting in all three cases and responsive to 
intake of food in one case
Light headedness 1/12 12-24 hours Self-limiting
Neck stiffness and myalgia 1/12 24 hours Clearly related to physical activity as judged by 
the volunteer concerned. Self-limiting. No signs 
of side effects or inflammation during additionally 
scheduled safety visits and blood tests
Viral upper airway infection 1/12 4 days Self-limiting
Pain in right foot 1/12 4 days Clearly related to participation in a marathon as 
judged by the volunteer concerned
Sore nipples 1/12 4 days Clearly related to participation in a marathon as 
judged by the volunteer concerned
Necrotizing appendicitis 1/12 10 days Surgery and full recovery
* Interval after administration
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discussion
Promising preclinical and observational reports on bilirubin have inclined to a reintroduction of 
its parenteral human use for the purpose of translational research.6 Our data demonstrate that 
it is feasible to prepare bilirubin solutions for parenteral human use in accordance with GMP 
and good clinical practice (GCP) standards. Due to the exploratory nature of our experiments 
and the associated low number of subjects studied, our results on the pharmacokinetics and 
safety characteristics of parenterally administered bilirubin should be discussed in the context 
of previously reported data. Table 4 provides an overview of all available data on the former 
human use of bilirubin.
Production
The majority of previous publications on the human use of bilirubin report the use of sodium 
carbonate solutions with high alkalinity. In contrast to these reports, we dissolved bilirubin in 
sodium hydroxide and diluted this product in a solution with albumin in excess. Similar procedures 
have been published before for animal experiments and a few human studies.9–17 Apart from 
the beneficial reduction of alkalinity, this strategy matches normal in vivo physiologic conditions 
in which unconjugated bilirubin is tightly bound to albumin.18 In addition, albumin binding has 
shown to augment the anti-oxidant activity of unconjugated bilirubin in vitro.19,20
Pharmacokinetics
In preparation of future translational studies on the supposed beneficial impact of bilirubin, 
we aimed to explore the intra-arterial use of unconjugated bilirubin and verify the previously 
reported pharmacokinetic characteristics of intravenously administered unconjugated bilirubin. 
Our data demonstrate a predictable dose-concentration relationship for both routes of admin-
istration, facilitating the design of future translational studies on the therapeutic use of bilirubin. 
During the third phase of our experiments, we studied the pharmacokinetics of unconjugated 
bilirubin upon a single intravenous bolus infusion. The disposition of unconjugated bilirubin is 
highly determined by its strong capacity to bind albumin, and its exchange between albumin in 
plasma and in interstitial fluid is allowed by a small free fraction, which is estimated to amount only 
1/50.000 of total serum bilirubin.18 The volume of distribution (Vss) found in our experiments 
(Table 2) corresponds to a normal albumin space of 9 L.21 The two phases of the two-com-
partment model that was fitted to the plasma concentration-time curve relate to the initial 
distribution within the albumin space and the true bilirubin clearance by the liver. 
The corresponding half-lives are in agreement with values recently predicted by a theoretical 
model based on the consequences of its strong albumin binding.18 In the past, multiple studies 
on the clearance of intravenously administered bilirubin have been performed using either small 
trace-labeled amounts,9,22 larger non-radioactive dosages23–28, such as in our experiments, or 
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both.29 Both two- and three-compartment models with varying pharmacokinetic characteristics 
have been proposed. Comparison of data is complicated by the fact that the interpretation of 
the disappearance curve and selection of the most appropriate compartment model in these 
reports was hampered by the lack of current insight into bilirubin physiology. Most authors falsely 
assumed the presence of a hepatic bilirubin pool22,23,28 and did not consider the importance 
of the small free fraction of unconjugated bilirubin enabling exchange to albumin within the 
interstitial space. Notably, our experiments were not designed to gain detailed insight into the 
pharmacokinetics of unconjugated bilirubin, but aimed to describe the behavior of parenterally 
administered bilirubin.
Safety
Whereas the actual administration of bilirubin was well tolerated, several adverse events occurred 
during the subsequent observation including an appendicitis, an asymptomatic cardiac arrhythmia 
and a pruritic rash. Although independent clinicians considered these events to be unrelated to 
our experiment, it should be stated that we cannot exclude a causal association between the 
events and the combined administration of bilirubin and albumin. Moreover, the limited size of 
our study does not allow any definite conclusion on safety issues. We therefore performed an 
extensive review of the literature covering over 1600 individual bilirubin infusions during the 
former century. (Table 4) The earliest reports on the human use of bilirubin mentioned the 
occurrence of side effects consisting of transient chills and fever.30,31 Hinting at microbial contami-
nation, these effects could be avoided by a switch to the exclusive use of fresh sterile solutions.30 
Besides, immediate effects like flushing, tachycardia and headache have been mentioned upon 
the combined infusion of bilirubin and bile acids.31 The contemporary use of bile acids obviously 
complicates the definite attribution of the side effects reported in this study. Importantly, no other 
study on the human use of bilirubin has mentioned the occurrence of these immediate effects. 
Finally, the use of large amounts of bilirubin dissolved in an unbuffered alkaline solution has been 
associated with the frequent occurrence of venous thrombosis.32 These authors reported up 
to thirty bilirubin infusions per subject and bilirubin plasma concentrations up to 500 μmol/L. 
Though less severe, others have reported mild soreness at the injection site in a few cases of 
highly dosed bilirubin infusions.25 Notably, the vast majority of reports on the parenteral use of 
bilirubin have not mentioned any side effect related to its infusion. (Table 4) Several of these 
reports explicitly mention the absence of side effects, covering a total of 278 bilirubin infusions 
with bilirubin plasma concentrations up to 150 μmol/L.33–37 In view of the available data, we 
feel confident to state that parenteral use of bilirubin is safe if produced under GMP and GCP 
conditions and applied in its current dosage and albumin bound formulation. Obviously, future 
studies should incorporate a safety monitoring system to guarantee the early detection of side 
effects. It should be noted that bilirubin pigments currently available on the market are purified 
from either porcine or bovine gallstones. In our opinion only products of porcine origin should 
be used to nullify the theoretical risk of prion transmission.
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Limitations 
Several limitations of this study should be mentioned. First, we adjusted the bilirubin dosage to 
forearm volume for intra-arterial administration and to body weight for intravenous adminis-
tration in order to minimize variability. This strategy resulted in fairly predictable and consistent 
bilirubin plasma concentrations. It should be noted though that both the forearm volumes and 
body weights of our subjects were quite similar and within normal range. Additional experiments 
are needed to confirm the applicability of our dose adjustment strategies in a study population 
with a larger inter-individual variability in forearm volume and body weight.
Second, the clearance of bilirubin demonstrates a significant inter-individual variability which 
is related to several genetic polymorphisms.37 Most common is the Gilbert syndrome, which 
is due to a TA-insertion in the UGT1A1 promotor region and accompanied by a significantly 
reduced glucuronidation activity to approximately 30% of normal.38 To avoid outliers as a result 
of the Gilbert syndrome, we excluded subjects with a plasma bilirubin concentration exceeding 
10 μmol/L during the screening visit. Though less sensitive than the assessment of individual 
genetic polymorphisms, this approach sufficiently excludes subjects with the Gilbert syndrome.39 
In view of the relatively high prevalence of the Gilbert syndrome in the general population, the 
avoidance of outliers by the exclusion of subjects with high baseline bilirubin concentrations 
may have caused our clearance data to overestimate the average clearance capacity within the 
general population.
Conclusion 
In conclusion, our study reopens the gate to the human parenteral use of bilirubin for the pur-
pose of translational research. Larger studies are needed to evaluate the usefulness of adjusting 
dose regimens to either forearm volume or body weight and to study the influence of genetic 
variation on the elimination rate of bilirubin from plasma. Nevertheless, it appears feasible to 
verify the promising preclinical and observational data of bilirubin in human disease models. 
As such, our data provide a basis for further experiments on the beneficial anti-oxidant and 
anti-inflammatory effects attributed to bilirubin.
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letter to the editor
In agreement with the recent study by Fazekas and collegues1, an increase in the concentra-
tion of carbon monoxide (CO) has been observed after surgery, cardiopulmonary bypass and 
during sepsis2 While inflammation induces HO and the above mentioned conditions do lead to 
inflammation, a clear association in humans has not been established, underlining the relevance 
of the remarks made by Cove and Pinsky.3 We would like to present data that illustrate that 
inflammation does increase CO in humans in vivo.
During experimental endotoxemia in humans, a controlled immune response is evoked lead-
ing to increased levels of several pro- and anti-inflammatory markers.4 Recent experiments 
demonstrated that in 38 healthy male volunteers infused with US Standard Reference Endo-
toxin obtained from Escherichia coli O:113 at a dose of 2 ng/kg, tumor necrosis factor (TNF)-α 
concentrations increase to maximum values of 610 pg/mL [400-853] (median [IQR] at t = 2 
hours (h) Friedman test p<0.001) and arterial carboxyhemoglobin levels increase with 42% at 
4 h after LPS infusion (Friedman test p=0.0057). (Figure 1) 
During these experiments, subjects breathed ambient air in a climate controlled room making 
an increase of CO due to an increase in inhalation as postulated by Cove and Pinsky unlikely.
Interestingly, the anti-inflammatory effects of CO have also been studied in this model. While CO 
has clear beneficial effects several animal studies, inhaled CO during experimental endotoxemia 
failed to influence the inflammatory response in humans5 making it unclear whether the artificial 
increase of CO could benefit critically ill patients. 
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Figure 1: TNF-α and carboxyhemoglobin levels in arterial blood during experimental human endotoxemia.
 At t=0 hours (h), 38 healthy male subjects were infused with 2 ng/kg E. coli endotoxin. Arterial blood was 
sampled serially to determine carboxyhemoglobin (Siemens Rapidlab 348 blood gas analyzer, Siemens Medical 
Solutions, Germany) and plasma TNF-α concentrations (Bio-plex cytokine assay, BioRad, USA at Luminex 100, 
Luminex Corporation, the Netherlands). Carboxyhemoglobin levels are presented using boxplots with whiskers 
indicating 5-95th percentile. TNF-α is presented as median (black line), for reasons of clarity IQR were omitted. 
Statistical analysis was performed using the Friedman test. Carboxyhemoglobin: p=0.0057, TNF-α: p<0.001.
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abstract
Introduction: Accumulating evidence demonstrates the influence of our genetic blueprint on 
the susceptibility and prognosis of infectious diseases. Bilirubin is one of the most powerful 
anti-oxidants of the human body and its levels are influenced by uridine diphosphate-5’-glu-
curonosyltransferase A1 (UGT1A1). The length of the TA repeat in the UGT1A1 gene 
is associated with decreased glucuronidation and subjects homozygous for UGT1A1*28 
(homozygous carriers of 7 TA repeats) do indeed have higher bilirubin concentrations. 
Most likely related to the anti-oxidative capacities of bilirubin, subjects homozygous for 
UGT1A1*28 appear protected from cardiovascular disorders and in vitro and animal 
experiments have demonstrated protective effects of bilirubin in models for sepsis and 
inflammation. However, bilirubin also sheds effects on bacterial viability and the neutrophil 
oxidative burst possibly leading to either an increased or reduced bacterial killing depending 
on the bacterial species involved. Human data concerning the effects of elevated levels of 
bilirubin in sepsis patients are lacking. In the present study, we aim to investigate the effects 
of homozygosity for UGT1A1*28 on the occurrence, disease severity and outcome during 
human pneumosepsis.
Methods: To determine the effect of UGT1A1*28 on the incidence and severity of pneu-
mosepsis, 281 and 86 controls were included in a prospective cohort study. All were 
genotyped to determine the length of the TA repeat in UGT1A1. Disease severity and 
outcome were recorded for pneumosepsis patients with a follow-up of 28 days. Statistical 
analyses were performed using Cox-regression analysis, Chi-square tests or Student’s t-test 
as appropriate. A p<0.05 is considered statistically significant.
Results: Being homozygous for UGT1A1*28 tended to decrease the susceptibility for the 
development of pneumonia. (OR 0.5 95%CI 0.3-1.1, p=0.07). While the severity of sepsis 
(p=0.5), the APACHE II (p=0.7), SOFA score (p=0.7) and the presence of organ dysfunction 
(p=0.5) were unaffected. Finally, mortality was similar in both groups (38% for homozygous 
pneumosepsis patients versus 33% for other genotypes, OR 1.3, 95% confidence interval: 
0.6-3.0, p=0.5). 
Conclusion: Despite evidence from animal experiments indicating protective effects of bili-
rubin during acute inflammation, no protective effects of the UGT1A1*28, linked to higher 
bilirubin concentrations, could be demonstrated in this cohort of pneumosepsis patients.
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introduction
Despite abundant effort in optimizing care for sepsis patients in recent years, the mortality 
remains unacceptably high. Most infections occur in the lung and pneumosepsis is associated 
with a higher mortality than other sites of infection.1,2 Even within this specific group of patients, 
a large variability of the clinical course of pneumosepsis is observed in day to day clinical prac-
tice. So, besides age, gender, comorbidity and timely and appropriate treatment, other factors 
appear to influence outcome.
In recent years, accumulating evidence demonstrates that our genetic blueprint can influence 
susceptibility to infectious diseases and the course and outcome of disease. For instance, poly-
morphisms in the genes coding for toll like receptor 4 (TLR4), considered pivotal in the activation 
of the innate immune response after an infection, was associated with vulnerability for septic 
shock 3–6 While the polymorphism in the promoter of TNF-α (TNF-308*A) may 3,4 or may not7,8 
be associated with mortality. 
The heme oxygenase (HO) system with HO-1 and its end products bilirubin and carbon 
monoxide is considered to be a potential target for therapeutic interventions in disorders 
related to inflammation and oxidative stress. In many animal and in vitro experiments, induction 
of HO-1 and/or the presence of bilirubin or carbon monoxide exert clear anti-inflammatory 
and anti-oxidative effects.9–12 Variations in the gene coding for HO-1 (HMOX1) are known to 
influence its concentration and are associated with a more pronounced anti-inflammatory status 
and a reduced mortality in septic patients.13,14 The effects of genetic variation influencing HO-1s 
end-products have not been studied in the setting of acute inflammation. However, in cardio-
vascular disorders such as atherosclerosis and stroke, were chronic inflammation is considered 
a main factor,15 effects of mild hyperbilirubinemia have been studied extensively and indeed, an 
inverse correlation between bilirubin concentrations and occurrence of disease was demon-
strated.16–19 In the common Gilbert syndrome, mild hyperbilirubinemia occurs as a consequence 
of a polymorphism in the gene coding for uridine diphosphate-5’-glucuronosyltransferase A1 
(UGT1A1), the enzyme that conjugates bilirubin for its excretion.20 The main polymorphism 
described for this syndrome is UGT1A1*28 and this is characterized by the presence of an 
additional TA repeat in the TATA sequence of the genes promoter.21 Individuals homozygous 
for 7 TA repeats (7/7) have higher serum bilirubin values than heterozygous individuals (6/7) or 
individuals homozygous for the common variant (6/6).22,23 In Caucasian European populations, 
the incidence of the 7/7 genotype is approximately 13-16%.21,24 Indeed, subjects with Gilbert 
syndrome demonstrate lower oxidative stress levels and have a reduced risk of myocardial 
infarction and peripheral artery disease.25,26 These beneficial effects of bilirubin are contributed 
to its anti-oxidative effects which include reducing lipid peroxidation and scavenging of reactive 
nitrogen species (RNS) such as nitric oxide and peroxynitrite.27 These pro-oxidants are consid-
ered to be related to the development of mitochondrial dysfunction in septic shock.28,29 
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However, bilirubin could be a double-edged sword in infectious diseases. On the one hand, bili-
rubin can protect bacteria from the leukocytes neutrophil burst and therefore reduce bacterial 
killing, especially in Gram-negative bacteria, which could lead to an increase in susceptibility for 
infections.30,31 On the other hand, it appears that bilirubin actually interferes with the cell mem-
brane of Gram-positive bacteria, reducing their viability.31 Furthermore, the improved anti-oxidant 
capacity of sepsis patients homozygous for UGT1A1*28 could prevent tissue damage associated 
with sepsis and improve prognosis. This latter hypothesis is supported by animal models of acute 
inflammation were exogenously administered bilirubin has demonstrated beneficial effects on 
outcome.9,32
The aim of the present study is to investigate whether UGT1A1*28 is associated with the 
incidence and outcome of pneumosepsis. We deliberately included only community-acquired 
pneumosepsis patients to increase homogeneity and since the lungs are the most common site 
of infection in sepsis patients in general.
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methods
Sepsis patients
A total of 281 pneumosepsis patients were included in a prospective cohort study in hospitals 
participating in the Hellenic Sepsis Study Group (www.sepsis.gr). Patients were admitted at 
23 departments of Internal Medicine or Intensive Care Units (ICU). The study protocol was 
approved by the Ethics Committees of all participating hospitals and written informed or deferred 
consent was obtained from all patients or first-degree relatives if appropriate.
Inclusion criteria were, age >18 years, the presence of community-acquired pneumonia (CAP) 
and sepsis, severe sepsis, or septic shock according to the definitions stated by ACCP and SCCM 
consensus conference in 1992.33 Exclusion criteria were, the presence of neutropenia (<500 
neutrophils per mm3), HIV infection, and/or oral intake of corticosteroids at a dose ≤ 1 mg/kg 
prednisone (or equivalent dose of another glucocorticoid) for a period greater than 1 month. 
CAP was diagnosed if patients were suffering from at least two of the following signs of lower 
respiratory tract infection: cough, dyspnea, purulent sputum, auscultatory rales and had a new 
consolidation on their chest X-ray without contact with health services in the 90 days prior to 
their diagnosis. 
In all but two patients, follow up was continued until 28 days and the Acute Physiology and 
Chronic Health Evaluation (APACHE) II score, Sequential Organ Failure Assessment (SOFA) 
score, the presence of multi-organ dysfunction syndrome (MODS) defined as the failure of two 
or more organs necessitating intervention and 28-day mortality were registered.
Controls
A total of 86 patients were used as control group to investigate the effect of the UGT1A1*28 
SNP on sepsis susceptibility. They were selected among patients hospitalized at the same time 
as the enrolled patients, with the following characteristics: a) matching for age and sex; b) not 
suffering from an infection.
Molecular analysis
All molecular analyses were performed in a CCKL (Co-ordination Committee for the promotion 
of Quality Control with regard to Laboratory research, http://www.cckl.nl)-accredited laboratory 
at the Department of Human Genetics at the Radboud university medical center in Nijmegen, 
The Netherlands. The investigators involved in the determination of the genotype were blinded 
for the clinical outcome of the patients.
Genomic DNA was extracted from peripheral venous blood using Qiagen Mini Isolation kit 
(Qiagen, Venlo, The Netherlands). The common A(TA)nTAA promoter mutation at the UGT1A1 
locus was determined using primers ordered from Life Technologies Europe BV (Bleiswijk, The 
Netherlands). The forward primer had a fluorescent dye label (VIC), whereas the reverse primer 
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contained a proprietary tail that helps stabilize the amplified product. Semi-automated fluo-
rescent genotyping was carried out using the following protocol. Genomic DNA (25 ng) was 
amplified in a 15 µl reaction using AmpliTaq Gold® 360 Master Mix (Life Technologies) with 0.5 
µl enhancer per reaction, and the specific primers (0.33 mM): CAAGCATGCTCAGCCAGTG 
(forward) and TGAGTATGAAATTCCAGCCAGTT (reverse). Amplification was performed 
using the following PCR protocol: 95⁰C for 12 min followed by 35 cycles of denaturation for 
30 s at 95⁰C, 30 s annealing at 56⁰C, and primer extension at 72⁰C for 1min, followed by a final 
extension at 72⁰C for 10 min. DNA samples with known genotypes were included as positive 
controls in the analysis. 1 µl of 10 times dilution of each amplified product was combined with 
size standard (LIZ-500) before being analyzed on an ABI3730 (Life Technologies). GeneMapper 
v4.0 (Life Technologies) was used to analyze the raw results from the ABI3730; a genotype was 
not considered final until two persons had independently checked the GeneMapper results and 
both individuals were in agreement.
Statistical analysis
Due to the exploratory nature of the study, no formal sample size calculation was performed. 
Statistical analyses were performed using IBM SPSS Statistics version 20.0. Differences in char-
acteristics were tested using Chi-square tests or Student’s-t-tests as appropriate. The association 
of the polymorphism 7/7 with mortality was tested using a uni-and multivariate Cox regression 
analysis. A p-value of <0.05 was considered statistically significant. 
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results
Pneumonia patient characteristics
In total, 281 community-acquired pneumosepsis patients were enrolled in this study. The average 
age of pneumonia patients was 71 ± 19 years and 171 (61%) were male. Average APACHE II 
score was 17.7 ± 9.5 and average SOFA score was 5.7 ± 3.6. Of all pneumosepsis patients, 29% 
developed MODS and 28-day mortality was 33%. 
Genotype frequencies
The genotype distribution of the TA repeat was in Hardy-Weinberg equilibrium for patients 
(p=0.12) and controls (p=0.6). The UGT1A1 7/7 genotype (associated with increased bilirubin 
and Gilbert syndrome) was present in 26 (9%) pneumonia patients and 14 (16%) controls. The 
presence of the different genotypes is depicted in Table 1. These data are in agreement with a 
previous study in a Greek population and also other Caucasian populations.24,34
Table 1: Genotype frequencies in pneumosepsis patients and controls. 
Genotype Pneumosepsis (n=281) Control (n=86) Total (n= 367)
6/6 110 (39.1%) 31 (36.0%) 141 (38.4%)
6/7 144 (51.2%) 40 (46.5%) 184 (50.1%)
7/7 26 (9.3%) 14 (16.3%) 40 (10.9%)
5/6 1 (0.4%) 0 (0.0%) 1 (0.3%)
5/7 0 (0.0%) 1 (1.2%) 1 (0.3%)
Genotype and occurrence of pneumosepsis
To evaluate the possible association of UGT1A1*28 and the susceptibility to develop pneu-
mosepsis, we compared the incidence of the genotype between patients and controls. A trend 
towards a reduced susceptibility in pneumosepsis patients with UGT1A1*28 was found although 
statistical significance was not reached (Odds ratio (OR) of 0.5 (95% confidence interval: 0.3-
1.1), p=0.07. Furthermore, no differences were found in the incidence of allele 7 between both 
groups (OR 0.9 (95% confidence interval 0.5-1.4, p=0.6).
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Genotype and severity of disease and mortality 
In patients suffering from pneumonia, severity of sepsis, APACHE II score, SOFA score and 
incidence of MODS were registered. As demonstrated in Table 2, no statistically significant 
differences were found between UGT1A1*28 (homozygous carriers of the 7 repeat) versus 
other genotypes.
Also, the presence of 7/7 did not affect 28-day mortality in this cohort of pneumosepsis patients 
as calculated using Cox regression (OR 0.8 (95% confidence interval: 0.4-1.6), p=0.5, Figure 1). 
Furthermore, after adjusting for MODS and sepsis category, the genotype 7/7 did not influence 
outcome (p=0.3). Further evaluation of the data demonstrated that this is also the case for 
carriers of at least one allele with 7 TA repeats compared with the other patients (both with 
and without correction for MODS and sepsis category p=0.9 and p=0.6 respectively).
Table 2: Characteristics and disease severity and mortality of pneumosepsis patients
7/7 (n=26) Other (n=255) p-value
Age (yrs): 75 ± 15 70 ± 19 0.3
Males: 14 (54%) 157 (62%) 0.4
Sepsis category:
Sepsis 15 (58%) 116 (45%) 0.5
Severe sepsis 6 (23%) 83 (33%)
Septic shock 5 (19%) 56 (22%)
APACHE II 17.1 ± 8.0 17.8 ± 9.6 0.7
SOFA score 6.1 ± 3.4 5.7 ± 3.7 0.7
Presence of MODS 6 (23%) 75 (30%) 0.5
Mortality 10 (38%) 83 (33%) 0.5
Characteristics and disease severity and mortality of pneumosepsis patients which are either homozygous 
for the 7/7 genotype or have other genotypes for UGT1A1. Statistics were performed using Chi-square or 
Student’s t-test as appropriate. APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, Sequential 
Organ Failure Assessment; MODS, multi-organ dysfunction syndrome
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Figure 1: Kaplan Meier curve for survival in pneumosepsis patients. 
No protective effect of the presence of the 7/7 genotype (associated with higher levels of bilirubin) was found. 
Statistics were performed using a COX regression analysis (p=0.5). Analysis with correction for sepsis category 
and multi-organ dysfunction syndrome showed similar results (p=0.3, data not shown). 
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discussion
Activation of the innate immune system and the presence of oxidative stress are considered 
crucial factors for the development of organ dysfunction in (pneumo)sepsis. While patients with 
UGT1A1*28 are known to have increased levels of bilirubin and therefore have an increased 
anti-oxidant capacity, the present study does not indicate an association of the UGT1A1*28 pol-
ymorphism with severity and mortality of pneumosepsis. Interestingly, a trend towards a reduced 
incidence of community-acquired pneumonia in patients with Gilbert syndrome was observed. 
Bilirubin is considered to have inhibitory effects on many pathways that cause oxidative stress. It 
is effective in preventing lipid peroxidation, inhibiting NADPH oxidase, scavenging of peroxyl radi-
cals and reactive nitrogen species and thereby protecting fatty acids.27,35,36 Furthermore it is known 
to reduce the oxidative capacities of peroxynitrite, hydroxyl and superoxide anion radicals.27 
These anti-oxidative effects are considered relevant in preventing mitochondrial dysfunction 
which is thought to be important in the development of organ failure in sepsis patients.28,29 (For 
a comprehensive review of bilirubins anti-oxidative effects see Stocker 27). We were however 
unable to demonstrate beneficial effects.
A possible explanation for our negative findings could be that exposure to mildly elevated levels 
of anti-oxidants is unable to protect from a sudden and pronounced increase in oxidative stress 
such as observed during the acute inflammatory insult that occurs during sepsis. This could also 
explain the discrepancy found when compared to cardiovascular disease where inflammation is 
of a different magnitude and chronic of nature. Furthermore, the effect that UGT1A1*28 sheds 
on bilirubin concentrations could be outweighed by the body’s response during sepsis where 
different anti-oxidative pathways such as superoxide dismutases (SODs), gluthathion and heme 
oxygenase (also creating an increase in bilirubin) are activated. Therefore, the additional effect 
of the presence of UGT1A1*28 could be very limited and therefore not visible in our patient 
cohort. 
In addition, several attempts in supplementing anti-oxidants in patients suffering from sepsis also 
yielded disappointing results, suggesting that exogenously increasing anti-oxidant capacity does 
not improve outcome. Admittedly, earlier performed studies were subject of debate due to 
small samples sizes, doses, timing and choice of anti-oxidants, as well as selection bias. However, 
a recently performed adequately powered multi-center randomized controlled trial also failed 
to demonstrate beneficial effects.37 One of the hypothesis for these disappointing results is the 
fact that these systemically applied anti-oxidants do not reach an important location where 
oxidative stress is creating its damage: the mitochondrion.29 
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A second explanation for the lack of an association is that the mechanism for the protective 
effect of the 7/7 genotype is influenced by other factors. UGT1A1 also has other effects than 
the conjugation of bilirubin alone. It is involved in the excretion of drugs such as anthracyclines 
(used for chemotherapy in Hodgkin’s disease) and irinotecan (used for metastatic colorectal 
cancer).39,40 Furthermore, the excretion of (carcinogenic) estrogens to the endometrium is 
also mediated by UGT1A1 which may explain the beneficial effect of the polymorphism in 
endometrial cancer.41 Possibly, effects of UGT1A1 on the endocrine system or the change of 
pharmacokinetics of medication used in our patients have interfered with its possible effects on 
oxidative stress in our patient population.
A strength of our study is that we included patients from different hospitals and departments. The 
multicenter approach is thought to prevent selection bias. The fact that we have only included 
patients with a community-acquired pneumonia should also create a more homogenous study 
population. One could however argue that our sample size was too small to demonstrate a 
mortality difference with only 26 pneumonia patients actually possessing the investigated pol-
ymorphism. However, different other studies have demonstrated effects in groups of a similar 
sample size.5,6
Given the effects of bilirubin on bacterial viability and neutrophil burst30,31 we hypothesized 
that the Gilbert syndrome might alter susceptibility for infections. As demonstrated a trend 
towards a reduction in the incidence of pneumonia in subjects with UGT1A1*28 was found. 
It could be hypothesized that in these patients suffering from community-acquired pneumonia, 
Gram-positive bacteria such as S. pneumoniae are the predominant source of infection and that 
increased levels of bilirubin indeed decreased bacterial load in these patients. Unfortunately, 
data concerning the pathogen causing the infection were unavailable for analyses and naturally, 
Gram-negative bacteria such as H. influenza can also very well be the source of infection in 
community-acquired pneumonia. Based on the present data it seems unlikely that a possible 
beneficial effect of UGT1A1*28 on the outcome of pneumosepsis will be demonstrated in a 
larger cohort. In conclusion, the present study indicates that the polymorphism UGT1A1*28 
does not influence the severity and outcome of pneumosepsis patients but a trend toward a 
reduced incidence was demonstrated in this small cohort of patients. 
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In this part of the thesis we will discuss the main findings of the studies presented and we will 
review the results in light of recent findings in the literature. Furthermore, we will elaborate on 
the consequences of our data for current and future research.
In the past decades, sepsis-research has been focusing on the modulation of the systemic immune 
response. While it was initially believed that organ failure in sepsis patients was mainly caused by 
an overwhelming pro-inflammatory response, a plethora of substances targeting this response 
was tested in the last twenty years and the results were highly disappointing.1,2 If there is one 
thing we have learned, it is that plain inhibition of the immune response is not beneficial in sepsis 
patients. We have come to realize that sepsis is in fact a very complex immunological syndrome 
were the interplay between pro- and anti-inflammatory mediators is of key importance to find 
the balance between extinguishing the pathogen on the one side and preventing damage to 
the host on the other. At this time, we still do not fully understand all the mechanisms involved. 
While the focus of immunomodulating therapies was to dampen the immune response, we 
now know that in the later phase of the disease our patients are in fact immunoparalysed and 
may actually need therapies to support their immune system to help them clear pathogens and 
improve their prognosis.3 Clearly, much more research is needed to gain insight in the temporal 
nature of the immune response and to teach us what is needed for which patient at which point 
in time. The data presented in this thesis hopefully add to the enormous amount of knowledge 
gained in recent years. 
The thesis is divided in three different parts. Following an introduction in chapter I, part I describes 
studies that have increased our methodological knowledge on one of the very few human models 
of sepsis. In part II we have investigated the possible induction of HO-1 in humans, since it is 
considered a promising target to prevent inflammation-induced tissue injury. Part III focuses on 
the HO-1-derived end-products CO and bilirubin and their effects in both acute and chronic 
inflammatory disorders.
Part I: Methodological studies in the human experimental endotoxemia model
Following an introduction in chapter 1, in chapter 2 the effect of iso-osmolar prehydration during 
human experimental endotoxemia was investigated. The initiative for this comparison was taken 
after two subjects participating in our endotoxemia studies experienced a vagal response fol-
lowing endotoxin infusion. After analysis of what had happened, it was concluded that relative 
hypovolemia combined with the release of hormonal and inflammatory mediators could have 
triggered vagal afferent nerves in the ventricle.4 In other centers that also use the experimental 
endotoxemia model, fluid administrations are frequently used, but not by protocol. Therefore, 
we changed the protocol and added a (pre)hydration scheme as described. In the subsequent 
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experiments, no vagal responses occurred. Furthermore, and as presented in chapter 2, symp-
toms were attenuated and the cytokine pattern was shifted with a reduced release of tumor 
necrosis factor (TNF)-α, interleukin (IL)-1β and IL-8 while the release of the anti-inflammatory 
IL-10 was unaffected. We speculated that this immunomodulatory effect of fluid administration 
might also have influenced beneficial effects found in the, at that time, published Early Goal-Di-
rected Therapy (EGDT) study.5 In this study, early and aggressive fluid resuscitation demonstrated 
a survival benefit in septic patients. As published later, patients treated according to the EGDT 
protocol demonstrated a similar cytokine pattern as our volunteers suggesting that the inflam-
matory response is also affected by this treatment regimen.6–8 The protocol from this original 
study was used as the basis for the hemodynamic optimization scheme in the original Surviving 
Sepsis Campaign (SSC) protocol.9 
However, three recently published randomized controlled trials, including a total of 4200 patients, 
did not confirm the benefit of EGDT compared to current standard of care leading to an 
adjustment of the resuscitation bundles in the current SSC recommendations.10–13 Of interest, 
the difference between the total amount of volume administered between EGDT groups and 
controls was relatively small (0.5 L), whereas in the original Rivers’ study the difference between 
the amount of volume infused was much larger (1.4 L).5,11 It appears therefore likely that the 
anti-inflammatory effects may not be present if these new studies would be analyzed for inflam-
matory markers. Moreover, an increasing amount of data have become available on the harmful 
effects of excessive fluid loading in sepsis patients as well as other ICU patients.14 Nevertheless, 
our findings are of importance to other researchers using the human experimental endotoxemia 
model. Not only is optimizing hydration status important for the wellbeing of the subjects and 
prevention of vasovagal responses, a standardized fluid protocol is necessary to ensure reliable 
and reproducible examination of the innate immune response in studies using this model to test 
immunomodulatory interventions.
In chapter 3 and 4 the role of gender and body mass index (BMI) on the inflammatory response 
were investigated. As demonstrated in chapter 3, gender clearly influences the immune response 
with males experiencing a less pronounced response of TNF-α and interferon (IFN)-γ compared 
to females, while they demonstrated a decrease in noradrenaline sensitivity following endotoxin 
administration, an effect that was not observed in female subjects. Of interest, animal studies 
have demonstrated the possible therapeutic effects of targeting sex hormones. In rodents, an 
estrogen receptor agonist protects from death in mouse sepsis models.15 On the other hand, the 
blockade of the testosterone receptor can prevent immunosuppression and death in a second 
hit hypovolemic/septic shock model.16 Interestingly, the hormonal precursor dehydroepiandros-
terone (DHEA) for testosterone and estrogen also exerts beneficial effects on survival after 
cecal ligation and puncture.17,18 Indeed, in clinical practice, women seem less vulnerable for the 
development of severe sepsis than men19,20 and our data contribute to the knowledge on the 
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differences between the innate immune response that might (partly) explain these observed 
effects. The exact mechanisms behind the differences demonstrated in these studies however 
remain to be clarified. 
In chapter 4, we demonstrate a lack of correlation between BMI and the induction of TNF-α, IL-6, 
IL-10 and IL-1RA in healthy volunteers infused with endotoxin. The inverse correlation of BMI 
and mortality is observed in different meta-analyses for critically ill patients21–23 and more recently, 
two large studies using nationwide databases demonstrated similar effects.24,25 It was believed 
that this ‘obesity paradox’ was influenced by different factors such as the immunomodulatory 
effects of excess fat tissue and higher cholesterol levels.26,27 Indeed, it has been demonstrated that 
during human experimental endotoxemia, IL-6 is released by adipose tissue.28,29 However, in our 
study, we were unable to demonstrate a relationship between obesity and the innate immune 
response. It must however be stated that despite the relatively large cohort of endotoxemia 
subjects studied (n=112), average BMI was 22.8 kg/m2 and only 16 subjects had a BMI>25 kg/m2 
while in most patient studies, beneficial effects of a higher BMI are usually most clearly present 
in patients with a BMI between 30 and 40 kg/m2. 
Adipose tissue itself rather than BMI might account for the observed clinical effects, as in trauma 
patients higher levels of visceral and subcutaneous fat assessed by CT scan were independently 
associated with the development of acute kidney injury.30 Therefore it seems plausible that, not 
so much BMI, but body composition may influence the outcome of critically ill patients. This may 
also have influenced the lack of correlation found in our study, as it is likely that most healthy 
young males included with a BMI between 25 and 30 in our study have an increase in muscle 
instead of fat tissue. This is in agreement with a previous study demonstrating that in young 
men, BMI seems a very poor predictor of body composition.31 Unfortunately, only body weight 
and length were obtained in these studies, so we cannot analyze the data for body composition. 
Future studies are needed to determine if an increase in adipose tissue may influence the immune 
response and to determine if the immunological activity of the adipocyte is a possible target for 
treatment in both acute (i.e. sepsis, trauma) and chronic (atherosclerosis, diabetes, metabolic 
syndrome) inflammatory disorders.
In chapter 5, we investigated whether in vitro cytokine production after whole blood stimulation 
with endotoxin and the systemic immune response in the same volunteers after endotoxin 
infusion were correlated. The variation in cytokine production between individuals is large, 
both in vitro (endotoxin-stimulated blood or isolated cells) and in vivo (human experimental 
endotoxemia model). As in vitro experiments are easy to perform and frequently reported, we 
were interested to what extent the in vitro response predicts the in vivo cytokine production. As 
presented, no correlations were demonstrated for the cytokines TNF-α, IL-1β, IL-6, IL-10 and 
IFN-γ. The lack of correlation contributes to the notion that not circulating cells (which will be 
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mainly neutrophils when whole blood is used), but tissue resident macrophages are responsible 
for the immune response observed after endotoxin infusion in humans.32 Given the fact that by 
our paired observations, we have excluded inter-personal variations such as gene polymorphisms 
which can influence the immune response, this observation is of great importance and illustrates 
the vulnerability and limitations of frequently used in vitro models. While of importance for 
mechanistic insight in specific cell stimulations and investigations on the activation of intracellular 
pathways, the extrapolation of data to the systemic immune response during health and disease 
has to be performed with great caution. As demonstrated by Seok et al. this is also true for 
rodent endotoxemia as a model for human inflammation where even a correlation with human 
endotoxemia was absent on a genomic level.33 The degree in which the immune response during 
human endotoxemia correlated with human conditions such as trauma and burns was better, 
but still, a gap between the model and ‘the real disease response’ exists. Naturally, one of the 
important limitations of the human endotoxemia model is that it only mimics the initiation of 
the immune response specifically related to the activation of TLR4 and that this pathway is most 
likely only triggered for a very short period of time.34 In septic patients, not only TLR4 but also 
many other pathways are activated (also depending on the type of infectious trigger) and this 
likely occurs for a prolonged period of time. Furthermore, recent data have shown that apart 
from the initial hit, the septic patient might suffer from an immunodepressive state later on.35 In 
this phase, secondary infections such as fungal infections or reactivation of viral infections may 
occur and are related to mortality.36 Furthermore, the clearance of the initial pathogen can be 
hampered as indicated by the fact that in autopsy studies, a persistence of an infectious focus 
was demonstrated in a large amount (approximately 80%) of patients that died from sepsis after 
at least 7 days of antibiotic treatment.37
To further improve the clinical relevance of the human experimental endotoxemia model new 
modes of administration are being explored. Our group will start with an adjusted model in 
which a continuous dose of endotoxin will be administered for 3 hours (cumulative dose of 
4 ng/kg). In this prolonged experimental endotoxemia model, we hope to achieve prolonged 
TLR4 stimulation, which is likely to represent a better surrogate for (Gram-negative) infections 
as they occur in patients. In the past, continuous infusion of endotoxin was performed, but only 
in very low dosages (0.3 ng/kg/h).38
To improve the quality of sepsis research in general, and find specific immunomodulating sepsis 
therapies, other new treatment strategies are necessary. Not only will we need to find animal 
or human models that are more suitable to mimic the cascade of occurrences in the human 
sepsis patient, we also need to readdress the design of sepsis trials, as was eloquently reviewed 
by Cohen and others.2 Not only are there significant problems with the definition of the septic 
patient, the different phases of the immune response could very well imply that a potential drug 
may do harm at one time, while being beneficial a few days or even only hours later. Furthermore, 
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inclusion of patients must be focused on creating a more homogenous patient group to be able 
to evaluate the effects of an intervention in a more meaningful way. The difference between a 20 
year old, otherwise healthy male with urosepsis caused by by pyelonefritis and nefrolithiasis and a 
75 year old woman with various comorbid conditions, such as a preexisting renal impairment, that 
now faces sepsis of abdominal origin after a perforating diverticulitis has not been appreciated in 
many patient trials. Nevertheless, from clinical experience we know that the time course of the 
inflammatory response as well as the prognosis of these patients differs markedly. Therefore, it 
is unlikely that there will be one ‘magic bullet’ to treat all of these patients in the future.2
Part II: The induction of HO-1 in humans 
In this part of the thesis, the regulation and induction of HO-1 was investigated after stimulation 
with two well known HO-1 inducers: endotoxin and heme. In general, HO-1 transcription is 
tightly regulated to be able to respond to oxidative stress. Under normal conditions, transcrip-
tional repressor Bach1 binds to the Maf recognition (MARE) site within the enhancer regions 
of the gene preventing transcription factors such as nuclear factor (erythroid-derived 2)-like 2 
(Nrf2) to activate HO-1s gene transcription.39 
In the presence of heme or under oxidative stress Bach1 is released and exported from the 
nucleus after which the path for HO-1 transcription and translation is cleared.39–41 Endotoxin 
has been widely recognized as an inducer of HO-1 in both murine and human cell lines as well 
as murine and human primary cells in vitro.42–47
In chapter 6, we investigated the in vitro and in vivo effects of endotoxin stimulation on HO-1 
expression in humans. We demonstrated that, HO-1 was not induced, but actually suppressed, 
after stimulation of different human myeloid cells with endotoxin and other TLR-ligands. In con-
trast, but similar to murine cells, the human cell line MM-6 did show a clear increase in HO-1 
after endotoxin stimulation. The in vitro downregulation of HO-1 after endotoxin was repro-
duced in vivo using the human experimental endotoxemia model. HO-1 mRNA levels in whole 
blood and protein concentrations in peripheral blood mononuclear cells (PBMCs) were clearly 
downregulated. Additional experiments demonstrated that the mechanism behind the down-
regulation was most likely controlled by transcriptional repressor Bach1 which is upregulated 
after endotoxin stimulation. The downregulation of HO-1 in human cells stimulated by endotoxin 
in vitro was described previously48,49, but contrasted by data obtained by others.46,47 Human in 
vivo data were unavailable up to our experiments. However, as demonstrated in chapter 8 and 
chapter 11, levels of bilirubin and CO are modestly increased after human endotoxemia and 
demonstrate similar kinetics with peak values at 4 h after endotoxin infusion. This suggests that, 
in contrast to our observations in whole blood and PBMCs, HO-1 activity is in fact increased 
elsewhere in the human body, resulting in the observed increase in these end products. This 
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implies a difference in regulation of HO-1 in these circulating cells and other cells in the body. 
The reason for this difference is unknown. We do know that, in rodents, increased levels of HO-1 
are present in immature dendritic cells and neutrophils and that this is associated with a reduced 
cytokine response and reduced bacterial killing by these immature cells.49,50 It therefore seems 
that maturation and loss of HO-1 is important for leukocytes to reach their potential as first 
line of defense. Possibly, humans are better capable to reduce HO-1 levels in maturing myeloid 
cells and therefore increase their bacterial killing capacities compared to rodents and possibly, 
immature cells are a reservoir of HO-1 activity. Another explanation could be that the increased 
levels of oxidative stress during inflammatory conditions are counteracted at the tissue level by 
an increase in HO-1 to prevent additional collateral damage.51 However, since sampling in human 
research is mainly limited to blood, as tissue sampling is usually too invasive, especially in healthy 
volunteers, this has not been investigated in our human experimental endotoxemia model. 
As mice demonstrate a different regulation of HO-1, it does not seem sensible to try to find the 
answer to this question in mice experiments. Nevertheless, research in other mammals more 
closely related to humans could be of interest. Furthermore, possible sampling of human tissue 
might be feasible, for example during trauma surgery. Sampling during post-mortem autopsy 
of sepsis or severe systemic inflammatory response syndrome (SIRS) patients was considered 
during the writing of this thesis, however, due to the inevitable delay and hypoxia in the tissues 
during the process of dying it was considered an unreliable method to investigate HO-1 tissue 
expression since hypoxia itself is considered to be a trigger for HO-1 induction.52
It must however be stated that in human inflamed patients, circulating monocytes can express 
increased levels of HO-1 and even more so, when monocytes of healthy volunteers are stimu-
lated with inflamed patients plasma, HO-1 levels increase.53 Whether this discrepancy is related 
to other possible stimulatory factors present in inflamed humans, but not during human endo-
toxemia, or to other factors such as prolonged exposure is unknown, but it does suggest that 
circulating monocytes in humans are capable to increase HO-1 levels. Possibly, this can be inves-
tigated in a prolonged experimental endotoxemia experiment as mentioned before.
In chapter 7, we aimed to investigate the effects of HO-1 induction in patients suffering from 
the metabolic syndrome. Naturally, the metabolic syndrome differs markedly from the acute 
inflammatory response evoked after endotoxin infusion, but in this condition, chronic inflam-
mation is crucial to the development of its deleterious effects such as insulin resistance and 
endothelial activation.54,55 To induce HO-1, we used heme arginate, as this is a well-known HO-1 
inducer and since its pharmacological characteristics are well known from its use in porphyria 
patients.56 Endpoints of the study included endothelial function assessed by venous occlusion 
plethysmography and insulin resistance as assessed by euglycemic hyperinsulinemic clamping as 
well as measurements of HO-1 in blood and adipose tissue.
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To ensure adequate exposure to heme arginate and therefore HO-1 induction, patients received 
two doses with a time window of 48 h. As demonstrated, heme arginate only induced HO-1 
protein in plasma after the first, but not the second dosage of heme arginate. Furthermore, only 
a very mild induction of HO-1 in adipose tissue (at 96 h and two dosages of heme arginate) 
was observed. No differences in mRNA expression of HO-1 could be demonstrated after 2 
dosages of heme arginate and 96 h. Furthermore, no increase in bilirubin was observed. These 
data contrasted earlier studies which did demonstrate an increase in HO-1 mRNA and protein 
levels at 24 and 48 h after a single hemin or heme arginate infusion.57,58 However, when scru-
tinizing those data in more detail, the effects of hemin in the previous study differed markedly 
between volunteers: some exhibited a clear increase in HO-1 protein and/or activity while in 
others the response was less pronounced. 
Furthermore, no increase in CO could be demonstrated.58 In the study using heme arginate, 
HO-1 mRNA and protein levels were elevated with mRNA levels rising at 4 h after heme arginate 
infusion and remaining (modestly) elevated after 24 and 48 h. Unfortunately, these authors did 
not describe CO or bilirubin concentrations.57 In this study, the same dose was applied as in our 
study with the main difference that our patients received it twice with a 48 h interval. Possibly, 
this could explain the differences found, since we did observe an increase in HO-1 protein in 
plasma at 48 h but not at 96 h after infusion. Unfortunately, we did not perform measurements 
of HO-1 mRNA levels at 48 h (or before) and therefore cannot completely exclude a rise at 
earlier time points. We did however not find beneficial effects of heme arginate on endothelial 
function, insulin sensitivity and on markers of oxidative stress suggesting a lack of impact on these 
relevant end-points with this dosing regimen. Furthermore, we acknowledge the fact that the 
metabolic syndrome itself might have influenced the effects of heme arginate on HO-1 in our 
study. Interestingly, the response to the vasodilator (and NO-donor) nitroglycerin was reduced 
after exposure to heme arginate. An effect we interpreted as a consequence of increased levels 
of heme itself which induces oxidative stress and can scavenge NO.59 This also illustrates the 
dilemma with the use of heme arginate as an inducer since increased levels of heme will increase 
oxidative stress while we are actually trying to investigate the anti-oxidative potential of HO-1.
Intriguingly, during the writing of this thesis, a paradigm shift has occurred towards the more 
deleterious effects of HO-1. While HO-1 was once widely accepted as a potential beneficial 
enzyme in a plethora of diseases regarding inflammation and oxidative stress, data have become 
available suggesting that HO-1 can actually be harmful under certain circumstances. In obesity 
and the metabolic syndrome, inflammation is considered a cornerstone of the development of 
insulin resistance. In contrast to common expectations, HO-1 levels were found to be strong 
and independent predictors of insulin resistance in mice and humans after being fed a high fat 
diet or in obesity. Furthermore, knockdown of HO-1 actually prevented the deleterious effects 
of high fat diets.60 These data suggest that targeted modulation of HO-1 might prove beneficial 
in obesity and the metabolic syndrome in humans. On the other hand, it could be speculated 
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that the improved outcome of obese septic patients (as described earlier in this discussion) is in 
fact related to the increase of HO-1 in adipose tissue and therefore a possible higher tolerance 
to inflammation in these obese subjects with a BMI> 30 kg/m2. 
In conclusion, endotoxin and heme arginate, both known and powerful inducers of HO-1 in in 
vitro and in animal experiments, demonstrated different or only modest effects in our human 
experiments. Many other possible inducers of HO-1 have not been tested in humans or lack 
specificity.61 Curcumin, which is widely used as food additive in Indian cuisine, sheds clear HO-1 
inducing effects in vitro. However, its effect in vivo appears limited due to poor absorption in the 
digestive tract and lack of measurable HO-1 induction despite high dosing regimens.62 Given 
the data presented in chapter 6 and 7, the targeting of Bach1 release from the promotor site of 
HO-1 or triggering the export from the nucleus by other substances than heme could possibly 
be helpful to exploit the potential benefit of HO-1. Recently, it was demonstrated that also 
gold nanoparticles can cause a shift of Bach1 out of the cellular nucleus.63 Although cytotoxicity 
must be considered, gold injections were once standard treatment for rheumatoid arthritis and 
therefore could be easily applied in other human studies.64 
Inhibition of HO-1 in humans has been applied in the form of tin meso or protoporphyrin in 
the past and it was effective in lowering its activity in for instance neonates with jaundice.65,66 
Side effects such as photo sensibility have precluded wide clinical application and also here, the 
lack of specificity for HO-1 is considered a problem.
Therefore, the clinical application of HO-1 modulation seems far away now we have come to 
realize that its regulation is different between species and even likely between cells and since it 
appears difficult to increase levels of HO-1 with the classical inducers known and applicable in 
humans. Furthermore, recent data suggest that it is also an enzyme with different faces in different 
diseases. Possibly, the inhibition of HO-1 in the metabolic syndrome could prove beneficial but 
more research, preferably in humans or larger animals, is needed before a possible therapeutic 
application of induction or inhibition of HO-1 can be achieved. 
Additionally, there is a great need for inducers and inhibitors which have high specificity for HO-1 
and even elicit their effects only in targeted cells to prevent unwanted effects of manipulating 
this omnipresent enzyme and to improve the quality of HO-1 research in general.
In Part III of the thesis we investigated the HO-1 effector molecules bilirubin and CO
In chapter 8 and 9, the effects of increased levels of bilirubin are described. Bilirubin is considered 
one of the most powerful endogenous anti-oxidants in the human body.67 Oxidative stress is 
considered an important factor in the development of inflammation and organ dysfunction in 
acute inflammatory disorders such as sepsis68,69, but also in diseases associated with chronic 
Chapter 13
226
inflammation such as atherosclerosis and the metabolic syndrome.54,55,70 And indeed, a large 
amount of clinical studies have demonstrated evidence suggesting an inverse relation between 
bilirubin concentrations in cardiovascular disease71–78, although others failed to reproduce these 
results.79,80 On the other hand, the powerful anti-oxidative effects of bilirubin are also associated 
with a decrease in bacterial killing by scavenging neutrophil generated reactive oxygen species 
(ROS)81 and therefore may exert deleterious effects during active infections. Interestingly, it 
was demonstrated that this protective effect of bilirubin for bacteria appears to only exist in 
Gram-negatives such as E. coli. In Gram-positive bacteria such as E. faecalis and S. aureus bilirubin 
actually leads to reduced bacterial viability. Most likely this effect is due to a direct interaction 
with the bacterial membranes.82
In chapter 8, the effects of an atazanavir-induced increase in bilirubin concentrations during 
human endotoxemia are presented. With no bilirubin available for human infusion at that time, 
we used atazanavir, an HIV-1 inhibitor known for its side effect of hyperbilirubinemia to increase 
bilirubin levels. Atazanavir increases bilirubin by inhibition of Uridine glucuronosyltransferase 
1A1 (UGT1A1). This enzyme is involved in the conjugation of bilirubin and its inhibition leads 
to an increase of unconjugated bilirubin in the blood. In approximately 13-16% of the general 
population UGT1A1 holds a mutation which hampers the function of the enzyme leading to 
a lifelong, but mild, increase of bilirubin, a condition commonly known as Gilbert syndrome.83,84 
The majority of unconjugated bilirubin in humans will be bound to albumin. Albumin-bound 
unconjugated bilirubin is known to inhibit oxidative stress in different ways. It inhibits NADPH 
oxidase, reduces lipid peroxidation, scavenges peroxyl radicals and reactive nitrogen species.67,85,86 
These specific markers are considered important in the development of organ dysfunction 
in sepsis and atherosclerosis.68–70 Atazanavir-induced hyperbilirubinemia increased anti-oxidant 
capacity, decreased IL-10 release and prevented hyporeactivity to the vasodilators acetylcholine 
and nitroglycerin after endotoxin infusion. In chapter 9, atazanavir was applied with the same 
purpose in diabetes patients that suffer from a more chronic inflammatory state associated 
with the development of endothelial dysfunction and atherosclerosis.87 Here also, an increase in 
serum bilirubin resulted in an increase in antioxidant capacity and an improvement in endothelial 
function as measured by venous occlusion plethysmography. 
Naturally, the effects of atazanavir itself could have influenced our results in these studies. Although 
research has demonstrated that atazanavir does not negatively impact endothelial function88 and, 
at least in vitro, does not appear to influence the cytokine response to endotoxin (chapter 8), 
one cannot exclude that atazanavir or its metabolites may have influenced our results. Naturally, 
prolonged treatment with atazanavir for chronic inflammatory disorders is not feasible since 
jaundice would occur which is an unwanted side effect for (ambulatory) patients. For patients 
suffering from acute inflammatory disorders such as sepsis, the bilirubin response will likely be 
very unpredictable due to changes in pharmacokinetics and the effects of inflammation itself 
on bilirubin levels. 
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In our studies, atazanavir was used to increase bilirubin purely to be able to test the concept 
of hyperbilirubinemia in the absence of bilirubin available for human administration. After these 
promising results, we aimed to reintroduce bilirubin for infusion to humans, as described in 
chapter 10. As presented here, the infusion of bilirubin was well tolerated and the concentra-
tions achieved were predictable in our small group of healthy volunteers. Unfortunately, due to 
logistical problems, we were unable to create a new batch of bilirubin for further application in 
for instance human endotoxemia studies.
In chapter 12, we investigated the effects of the polymorphism associated with Gilbert syndrome 
(related to endogenously increased bilirubin levels) in patients suffering from pneumosepsis. We 
hypothesized that increased levels of bilirubin could affect susceptibility towards infections by 
depressing the effects of the neutrophil burst and therefore a decreased capacity for bacterial 
killing.81 However, it could also be postulated that bilirubin decreases bacterial viability, especially 
in Gram-positive infections.82 Furthermore, we were interested to see if the improved anti-oxi-
dant capacity of these patients might prevent tissue damage associated with sepsis and improve 
their prognosis. As presented, we demonstrated a trend toward a decreased incidence of pneu-
mosepsis in subjects with Gilbert syndrome. We did not find associations with the severity of 
disease or outcome of patients with pneumosepsis Gilbert syndrome. Naturally, the study has 
several shortcomings. First, we did not have access to bilirubin concentrations of these patients. 
Therefore, although bilirubin concentrations are correlated with the genotype89,90 we cannot 
show that bilirubin concentrations were actually higher in the Gilbert syndrome patients and 
therefore cannot quantify the anti-oxidative effects or correlate them with the different outcome 
measures. Furthermore, the study lacked sufficient power to enable a conclusion regarding the 
effect of Gilbert syndrome on mortality. 
In conclusion, these studies suggest that the targeting of bilirubin in diseases associated with 
chronic or acute inflammation seems a promising strategy. In the future, human studies can be 
performed directly administering bilirubin and it would be very interesting to determine the 
answer to several different questions. When targeting chronic inflammatory disorders such as 
metabolic syndrome and atherosclerosis, it is important to determine what concentration of 
bilirubin can prevent oxidative damage to a sufficient level to prove beneficial, but also to make 
sure that jaundice as an unwanted side effect is avoided. When studying subjects with Gilbert 
syndrome, bilirubin levels are obviously much lower than in our interventionstudies and as 
described, beneficial effects have been demonstrated. However, inhibition of UGT1A1 might 
also have other effects (such as a changed clearance of medications) that might influence the 
results of these studies.91,92
For infectious diseases, it is of utmost importance to look into the effects of bilirubin on bacterial 
viability and neutrophil function in humans. One must exclude the possibility that scavenging of 
ROS can make people more susceptible to infections or influence the course of an infection 
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in a negative manner. However, as presented before, our data in pneumosepsis patients might 
suggest that the contrary is true, possibly due to a decrease in bacterial viability due to bilirubin’s 
interactions with the bacterial membrane in the case of Gram-positive infections.82 Lastly it must 
be determined if an increase in bilirubin indeed increases tolerance to the unwanted collateral 
damage caused by severe infections in humans and if this ultimately leads to an improvement 
in outcome. It must be mentioned that the use of other anti-oxidants has not reached broad 
clinical application due to lack of effect on hard end-points such as mortality.93 
As mentioned previously in this discussion, well designed clinical trials with inclusion of a more 
homogenous patient population and possibly guided by markers indicating the phase of the dis-
ease process would be ideal for this purpose, but are very complicated to achieve in in current 
daily clinical practice.
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In dit deel van dit proefschrift zullen we de belangrijkste conclusies van de gepresenteerde hoofd-
stukken bespreken, en beschouwen in het licht van recente bevindingen in de literatuur. Verder 
zullen we ingaan op de gevolgen van onze studies voor het huidige en toekomstige onderzoek.
 
In de afgelopen decennia is het onderzoek naar sepsis veelal gericht geweest op het beïnvloeden 
van de systemische immuunrespons. Hoewel men aanvankelijk dacht dat orgaanfalen bij sepsis 
patiënten voornamelijk werd veroorzaakt door een (te) sterke pro-inflammatoire respons, bleek 
het remmen van deze respons in een groot aantal studies met diverse middelen in de afgelopen 
20 jaar geen gunstige effecten op te leveren.1,2 
Als er één ding is wat we hebben geleerd, is het dat het algemeen remmen van de immuunreactie 
bij alle sepsis patiënten niet zal werken. We beseffen ons nu dat sepsis een complex immuno-
logisch syndroom is, waarbij de wisselwerking tussen pro- en anti-inflammatoire mediatoren 
van cruciaal belang is voor het evenwicht tussen het uitroeien van het pathogeen enerzijds 
en het anderzijds beperken van orgaanschade. Ook op dit moment begrijpen we de vele 
betrokken mechanismen nog onvolledig. Waar aanvankelijk de focus lag op het remmen van de 
afweerrespons realiseren we ons inmiddels dat in een latere fase van de ziekte onze patiënten 
al immuungecompromitteerd zijn en dat het juist nodig kan zijn om de afweerreactie te onder-
steunen om pathogene micro-organismen uit te schakelen en de prognose te verbeteren.3 Het 
moge duidelijk zijn dat veel meer onderzoek nodig is om inzicht te krijgen in de aard van de 
immuunrespons op verschillende tijdspunten in het ziektebeloop en om ons te leren wat nodig 
is voor welke patiënt op welk punt in de tijd. De in dit proefschrift gepresenteerde data dragen 
hier hopelijk aan bij.
Het proefschrift is onderverdeeld in drie verschillende delen. Na de inleiding in hoofdstuk 1 
worden in deel I de studies beschreven die ons inzicht hebben gegeven in methodologische 
aspecten van een van de weinige humane modellen voor sepsis . In deel II hebben we de 
mogelijkheid van inductie van heme oxygenase (HO)-1 onderzocht bij de mens, omdat dit 
enzym wordt beschouwd als een veelbelovend aangrijpingspunt om ontsteking-geïnduceerde 
weefselschade voorkomen. Deel III richt zich op de HO-1- eindproducten CO en bilirubine en 
hun effecten bij zowel acute als chronische inflammatoire aandoeningen 
Deel I: Methodologische studies in het humane experimentele endotoxinemie model
In hoofdstuk 2 wordt het effect van iso-osmolaire prehydratie tijdens experimentele endo-
toxinemie bij mensen beschreven. De aanleiding voor deze vergelijking werd was dat twee 
proefpersonen die deelnemen aan onze endotoxine studies een vagale reactie meemaakten na 
endotoxine infusie. Na analyse werd geconcludeerd dat relatieve hypovolemie in combinatie met 
de afgifte van hormonale en ontstekingsmediatoren activatie van vagale afferente zenuwbanen 
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in het hart kunnen hebben veroorzaakt.4 In andere centra, die ook het experimentele endotoxi-
nemie model toepassen, worden regelmatig bolussen infusie vloeistof toegediend. Dit gebeurt 
echter op geleide van klachten en niet volgens een vast protocol. Na de vagale reacties pasten 
wij ons protocol aan en voegden een (pre)hydratie toe zoals beschreven. In de daarop volgende 
experimenten traden geen vagale reacties op. Tevens bleek, zoals beschreven in hoofdstuk 2, 
dat de symptomen werden verminderd en de cytokine afgifte wijzigde met een verminderde 
afgifte van tumor necrosis factor (TNF)-α, interleukine (IL)-1β en IL-8, terwijl de afgifte van het 
ontstekingsremmende IL-10 niet werd beïnvloed. We speculeerden dat dit immunomodulerende 
effect van vochttoediening invloed zou kunnen hebben gehad op de, op dat moment net publi-
ceerde, Early Goal Directed Therapy (EGDT) study.5 In deze studie, waarin vroege en agressieve 
vloeistof toediening een verbeterde overleving in septische patiënten gaf, toonden patiënten 
behandeld volgens het EGDT protocol een overeenkomend cytokinepatroon als onze vrijwilli-
gers. Mogelijk is ook bij deze patiënten de ontstekingsreactie beïnvloed door deze behandeling 
en verklaard dit (deels) de gevonden verschillen.6-8 Het protocol van deze EGDT studie werd 
gebruikt als basis voor de hemodynamische optimalisatie in de oorspronkelijke Surviving Sepsis 
Campaign (SSC).9 Echter, drie recent gepubliceerde gerandomiseerde gecontroleerde studies, 
met in totaal 4200 patiënten, konden geen voordeel van EGDT aantonen in vergelijking met 
de huidige standaard van zorg. Dit leidde tot een aanpassing van de resuscitatie bundels in de 
huidige aanbevelingen van de SSC.10-13 Er dient te worden opgemerkt dat de verschillen in de 
totale hoeveelheid toegediend volume tussen EGDT groepen en controles relatief klein waren 
in deze nieuwe studies (0,5 L), terwijl in de oorspronkelijke EGDT-studie het verschil tussen 
de hoeveelheid toegediend volume veel groter was (1,4 L) .5,11 Het lijkt te verwachten dat de 
anti-inflammatoire effecten niet aanwezig zullen zijn als deze nieuwe studies zouden worden 
geanalyseerd t.a.v. de afgifte van ontstekingsmediatoren. Voorts zijn er in de laatste jaren steeds 
meer gegevens beschikbaar over de schadelijke gevolgen van (te) ruime vloeistof toediening bij 
sepsis maar ook bij andere patiënten op de IC.14 Desondanks zijn onze bevindingen relevant 
voor andere onderzoekers die het humane experimentele endotoxinemie model gebruiken. 
Niet alleen is het optimaliseren van de hydratatie-status van belang voor het welzijn van de 
proefpersonen en de preventie van vasovagale reacties, een gestandaardiseerd vloeistof pro-
tocol is noodzakelijk om ervoor te zorgen dat er betrouwbare en reproduceerbare data t.a.v. 
de aangeboren immuunrespons worden verkregen in studies welke met behulp van dit model 
immunomodulatoire interventies pogen te onderzoeken.
In hoofdstuk 3 en 4 zijn de effecten van geslacht en body mass index (BMI) op de ontstekings-
reactie onderzocht. Zoals in hoofdstuk 3 wordt besproken lijkt geslacht de immuunrespons 
duidelijk te beïnvloeden. Mannen hebben een minder uitgesproken respons van TNF-α en 
interferon (IFN)–γ na endotoxine toediening dan vrouwen, terwijl ze wel een verminderde 
response op noradrenaline toonden. Dit laatste effect werd opvallend genoeg niet waargenomen 
in vrouwelijke proefpersonen. In dierstudies zijn de mogelijke effecten van geslachtshormonen 
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reeds aangetoond. Bij knaagdieren beschermde een oestrogeen receptor agonist tegen sterfte 
in modellen voor sepsis.15 Anderzijds voorkomt de blokkade van de testosteron receptor 
immunosuppressie en sterfte in een ‘second hit’ hypovolemische/septische shock model.16 Ook 
de hormonale precursor dehydroepiandrosteron (DHEA) voor testosteron en oestrogeen 
heeft gunstige effecten op overleving na ’cecal ligation and puncture’ (CLP) een model voor 
abdominale sepsis.17,18 
In de klinische praktijk, lijken vrouwen inderdaad minder gevoelig voor de ontwikkeling van 
ernstige sepsis dan mannen.19,20 Onze data geven inzicht in de verschillen tussen de aangeboren 
immuunrespons die de betere uitkomsten voor vrouwen mogelijk (gedeeltelijk) kunnen ver-
klaren. De exacte mechanismen achter de gevonden verschillen verdienen nog nadere analyse.
In hoofdstuk 4 tonen we aan dat er geen correlatie bestaat tussen BMI en de aanmaak van 
TNF-α, IL-6, IL-10 en IL-1 receptor antagonist (RA) in onze gezonde proefpersonen die endo-
toxine kregen toegediend. In diverse meta-analyses is een negatieve correlatie tussen BMI en 
mortaliteit beschreven voor intensive care patiënten.21-23 Daarnaast zijn soortgelijke effecten 
recentelijk aangetoond in twee grote studies die gebruikmaakten van landelijke databases.24,25 
De hypothese is dat deze ‘obesitas paradox’ wordt beïnvloed door verschillende factoren zoals 
de immuunmodulerende effecten van overmatig vetweefsel en hogere cholesterol concentra-
ties.26,27 Tijdens humane experimentele endotoxinemie is aangetoond dat IL-6 wordt aangemaakt 
door vetweefsel.28,29 In onze studie vonden wij echter geen relatie tussen een hoger BMI en 
de aangeboren immuunrespons. Er moet echter worden opgemerkt dat ondanks het relatief 
grote cohort proefpersonen (n = 112), er slechts 16 een BMI> 25 kg / m2 hadden terwijl in de 
meeste patiënten studies de positieve effecten van een hoger BMI het meest uitgesproken zijn 
bij waarden tussen 30 en 40 kg / m2. 
Bij traumapatiënten is beschreven dat een grotere hoeveelheid visceraal en onderhuids vet 
(bepaald middels CT-scan) onafhankelijk geassocieerd is met de ontwikkeling van acute nier-
schade.30 Het lijkt aannemelijk dat niet zozeer BMI, maar met name de lichaamssamenstelling 
de uitkomst van ernstig zieke patiënten beïnvloed. Dit kan ook het gebrek aan correlatie in ons 
onderzoek verklaren, omdat het goed mogelijk is dat de meeste gezonde jonge mannen met 
een BMI tussen 25 en 30 in ons onderzoek een toename van spiermassa hadden, waardoor hun 
hogere BMI niet het gevolg was van overmatig vetweefsel. Dit is in overeenstemming met een 
eerdere studie waaruit blijkt dat bij jonge mannen BMI een slechte voorspeller is van lichaamssa-
menstelling.31 Helaas is alleen het lichaamsgewicht en de lengte gedocumenteerd in deze studies. 
Het is daarom niet mogelijk de lichaamssamenstelling nader te analyseren. Toekomstige studies 
zijn nodig om te bepalen of een toename van vetweefsel de immuunrespons kan beïnvloeden 
en om te bepalen of de immunologische activiteit van adipocyten gebruikt kan worden als een 
mogelijk target voor de behandeling van acute (bijvoorbeeld sepsis en trauma) en chronische 
(atherosclerose, diabetes en metabool syndroom) ontstekingsaandoeningen.
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In hoofdstuk 5 hebben we onderzocht of de in vitro cytokine productie na volbloed stimulatie 
met endotoxine de systemische immuunrespons in dezelfde vrijwilligers na endotoxine toedie-
ning kan voorspellen. 
De variatie in cytokineproductie tussen individuen is groot, zowel in vitro (door endotoxi-
ne-gestimuleerd bloed of endotoxine gestimuleerde geïsoleerde cellen) als in vivo (humane 
endotoxinemie model). In vitro experimenten zijn eenvoudig uit te voeren en worden vaak 
toegepast in de wetenschappelijke literatuur. Zodoende waren wij geïnteresseerd in hoeverre 
de in vitro reactie voorspelt hoe de in vivo cytokine productie zal zijn. Zoals beschreven werden 
geen correlaties aangetoond voor de cytokinen TNF-α, IL-1β, IL-6, IL-10 en IFN-γ. Het ontbreken 
van een correlatie ondersteund het idee dat niet circulerende cellen (wanneer volbloed wordt 
gebruikt voornamelijk neutrofielen), maar weefsel gebonden macrofagen verantwoordelijk zijn 
voor de productie van de gemeten cytokinen na endotoxine infusie in mensen.32 Gezien de 
gepaarde opzet van deze experimenten hebben we uitgesloten dat interpersoonlijke variabelen 
zoals gen polymorfismen de uitslagen hebben kunnen beïnvloeden. Deze waarneming is van 
groot belang en illustreert de kwetsbaarheid en beperkingen van vaak gebruikte in vitro modellen. 
Hoewel in vitro experimenten van grote waarde kunnen zijn voor het verkrijgen van mechanis-
tisch inzicht na specifieke cel stimulaties en om de activatie van intracellulaire pathways te kunnen 
onderzoeken dient de extrapolatie van deze gegevens naar de systemische immuunrespons 
tijdens gezondheid en ziekte, met grote voorzichtigheid te gebeuren. Zoals aangetoond door 
Seok et al. geldt dit ook voor endotoxinemie in knaagdieren als model voor humane ontsteking 
aangezien er zelfs geen correlatie bestaat tussen knaagdier en humane endotoxinemie.33 De 
mate waarin de immuunrespons bij humane endotoxinemie gecorreleerd is aan de humane 
reactie na een trauma of bij brandwonden was beter, maar er lijken duidelijk verschillen tussen 
het model en de afweerreactie tijdens deze ziektebeelden te bestaan. Uiteraard is een van de 
belangrijkste beperkingen van het humane endotoxinemie model dat het alleen de initiatie van 
de immuunreactie door TLR4 nabootst en dat deze route alleen geactiveerd raakt voor een 
korte periode.34 Bij septische patiënten zal niet alleen TLR4 maar zullen ook vele andere inflam-
matoire routes worden geactiveerd (ook afhankelijk van het type verwekker) en dit gebeurt 
waarschijnlijk voor een langere tijdsperiode. Bovendien tonen recente studies aan dat na de 
‘eerste klap’ een septische patiënt in latere fase juist immuungecompromitteerd raakt.35 In deze 
fase kunnen secundaire infecties met opportunisten zoals schimmels of reactivering van virale 
infecties optreden en deze hangen samen met een hogere mortaliteit.36 Bovendien kan de klaring 
van het initiële pathogeen worden gehinderd zoals blijkt uit obductie studies. In circa 80% van de 
patiënten die overleden aan sepsis na ten minste 7 dagen antibiotische behandeling kon alsnog 
het initiële pathogeen worden aangetoond.37
Om de klinische relevantie van het humane experimentele endotoxinemie model te verbe-
teren worden thans nieuwe toedieningswijzen uitgeprobeerd. Onze groep begint met een 
aangepast model waarin een continue dosis van endotoxine wordt toegediend gedurende 3 
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uur (cumulatieve dosis van 4 ng / kg). In deze langdurige experimentele endotoxinemie hopen 
we langduriger TLR4 stimulatie te bewerkstelligen, waarmee we een beter surrogaat denken te 
creëren voor (Gram-negatieve) infecties zoals ze zich voordoen bij patiënten. In het verleden, 
werd reeds continue infusie van endotoxine toegepast maar slechts in zeer lage doseringen 
(0,3 ng / kg / h).38
Om de kwaliteit van sepsis onderzoek in het algemeen te verbeteren, en specifieke immuun-
modulerende sepsis therapieën mogelijk te maken zullen andere strategieën nodig zijn. Niet 
alleen moeten we beter geschikte dier en/of menselijke modellen vinden die de cascade van 
gebeurtenissen in humane sepsis beter nabootsen, ook dient het ontwerp van sepsisstudies te 
worden heroverwogen zoals onder andere beschreven door Cohen et al.2 Er zijn aanzienlijke 
beperkingen aan de tot dusver gebruikte definitie van de septische patiënt. Daarnaast bete-
kenen de verschillende fasen van de immuunrespons dat een potentieel geneesmiddel schade 
kan doen op een bepaald moment, terwijl ze enkele dagen of zelfs enkele uren later gunstige 
effecten zou kunnen sorteren. Bovendien zullen onderzoekers zich er op moeten richten een 
meer homogene patiëntengroep te includeren in studies naar sepsis om de effecten van een 
interventie beter te kunnen evalueren. Het verschil tussen een 20-jarige, verder gezonde man 
met urosepsis veroorzaakt door een pyelonefritis na een nefrolithiasis en een 75-jarige vrouw 
met uitgebreide comorbiditeit, zoals een reeds bestaande verminderde nierfunctie, die nu gecon-
fronteerd wordt met sepsis van abdominale herkomst na een geperforeerde diverticulitis werd 
tot dusver niet erkend in veel patiëntenstudies terwijl op basis van klinische ervaring bekend is 
dat het tijdsverloop van de ontstekingsreactie en de prognose voor deze patiënten aanzienlijk 
verschilt. Daarom is het zeer onwaarschijnlijk dat er een wondermiddel zal worden gevonden 
dat voor alle patiënten die momenteel aan de sepsis definitie voldoen effectief zal zijn.2
Deel II: De inductie van HO-1 bij mensen
In dit deel onderzochten wij de inductie van het enzym HO-1. Dit enzym, betrokken bij het 
opvangen van oxidatieve stress wordt als een belangrijk target gezien voor mogelijke behandeling 
van ontstekingsziekten
Onder normale omstandigheden wordt de transcriptie van HO-1 strak geregu-
leerd zodat adequaat kan worden gereageerd op oxidatieve stress. Hier toe bindt 
transcriptionele repressor Bach1 zich aan de Maf Recognition locatie (MARE) van het gen 
waarmee wordt voorkomen dat transcriptiefactoren zoals Nuclear factor (erythroid-deri-
ved 2)-like 2 (Nrf2) de transcriptie van het HO-1 gen kunnen activeren.39 Wanneer heme 
of andere factoren die oxidatieve stress geven aanwezig zijn komt Bach1 los van het gen en 
wordt weggevoerd uit de celkern waarna de weg vrij is voor HO-1 transcriptie en transla-
tie.39-41 Endotoxine wordt algemeen beschouwd als een inducer van HO-1 in zowel muizen en 
humane cellijnen en daarnaast in dierlijke en menselijke geïsoleerde cellen in in vitro modellen.42-47 
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In hoofdstuk 6 onderzochten we de in vitro en in vivo effecten van endotoxine stimulatie op 
HO-1 expressie bij de mens. We hebben aangetoond dat, HO-1 niet wordt geïnduceerd, maar 
juist onderdrukt wanneer menselijke myeloïde cellen met endotoxine of andere TLR-liganden 
worden gestimuleerd. Echter bleek dat in de menselijke cellijn MM-6 wel duidelijk verhoogde 
concentraties van HO-1 meetbaar waren na endotoxine stimulatie. Dit was vergelijkbaar met de 
effecten die werden gemeten in cellen van knaagdieren. De in vitro gevonden downregulatie van 
HO-1 na endotoxine kon worden bevestigd in vivo met behulp van het humane experimentele 
endotoxinemie model. HO-1 mRNA niveaus in volbloed en eiwitconcentraties in mononucleaire 
cellen afkomstig uit het perifere bloed (PBMCs) waren duidelijk verlaagd. Aanvullende experi-
menten toonden dat het mechanisme achter de downregulatie waarschijnlijk werd gecontroleerd 
door de transcriptionele repressor Bach1 die juist wordt geïnduceerd door endotoxine stimu-
latie. De afname van HO-1 in menselijke cellen die zijn gestimuleerd door endotoxine in vitro 
was reeds beschreven48,49, maar anderen vonden dit effect juist niet.46,47 Tot onze experimenten 
waren er geen in vivo humane data beschikbaar. Zoals besproken in hoofdstuk 8 en hoofdstuk 11, 
zijn de concentraties van bilirubine en CO wel (in bescheiden mate) verhoogd tijdens humane 
experimentele endotoxinemie. Deze volgen een vergelijkbare kinetiek met piekwaarden 4 uur 
na endotoxine infusie. Dit suggereert dat, in tegenstelling tot onze waarnemingen in volbloed 
en PBMCs, HO-1 activiteit elders in het lichaam toeneemt. Dit betekent dat er een verschil 
in regulatie van HO-1 in de circulerende cellen en andere cellen in het lichaam moet zijn. De 
oorzaak van dit verschil is niet bekend. We weten dat bij knaagdieren verhoogde niveaus van 
HO-1 aanwezig zijn in onrijpe dendritische cellen en neutrofielen. Dit is geassocieerd met een 
verlaagde cytokine respons en verminderde bacteriële doding door deze onrijpe cellen.49,50 
Mogelijk is het verlies van HO-1 tijdens de uitrijping van deze cellen belangrijk voor leukocyten 
om hun potentieel als eerste verdedigingslinie bereiken. Mogelijk zijn mensen beter in staat om 
HO-1 niveaus in rijpende myeloïde cellen te verminderen en de bacteriedodende capaciteit te 
vergroten dan knaagdieren. Deze onrijpe cellen kunnen een reservoir zijn van HO-1 activiteit. Een 
andere verklaring is dat de verhoogde oxidatieve stress tijdens ontstekingen op weefselniveau 
schade berokkend en dat dit wordt tegen gegaan door een lokale verhoging van HO-1.51 Om 
dit te onderzoeken zouden samples op weefselniveau moeten worden verkregen. Echter is het 
tijdens onderzoek met gezonde proefpersonen niet verantwoord om dit te verrichten. Derhalve 
kon deze hypothese niet worden onderzocht in onze humane experimentele endotoxinemie 
experimenten.
Aangezien muizen een andere regulering van HO-1 lijken te bezitten lijkt het niet logisch om 
het antwoord op deze vraag in muisexperimenten te zoeken. Wellicht kan onderzoek bij andere 
zoogdieren welke nauwer verwant zijn aan mensen interessant zijn om deze vraag te beant-
woorden. Bovendien zou het interessant zijn om bij mensen weefselonderzoek te verrichten. 
Dit zou bijvoorbeeld haalbaar kunnen zijn tijdens trauma chirurgie. Sampling tijdens obductie 
van sepsis of ernstige ‘systemische inflammatoire respons syndroom’ (SIRS) patiënten werd 
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tijdens dit project overwogen echter vanwege de onvermijdelijke vertraging en hypoxie in het 
weefsel tijdens het stervensproces werd verwacht dat dit een onbetrouwbare methode zou zijn 
om HO-1 concentraties als gevolg van ontsteking te onderzoeken. Dit daar hypoxie zelf wordt 
beschouwd als een trigger voor HO-1 productie.52
Er dient echter te worden opgemerkt dat in patiënten met een ontsteking wel degelijk ver-
hoogde concentraties van HO-1 in circulerende monocyten zijn gevonden. Daarnaast is het zo 
dat wanneer monocyten van gezonde vrijwilligers gestimuleerd worden met plasma van deze 
patiënten, de HO-1 concentratie in deze cellen stijgt.53 Of deze discrepantie is gerelateerd andere 
mogelijke stimulerende factoren aanwezig in dit plasma die niet tijdens humane endotoxinemie 
voorkomen of dat dit gerelateerd is aan andere factoren, zoals langdurige blootstelling is niet 
bekend, maar het suggereert wel dat monocyten bij mensen wel degelijk in staat zijn om HO 
- 1 concentraties te verhogen. Het zou interessant zijn of dit effect ook kan worden gevonden 
tijdens een verlengd endotoxinemie experiment in gezonde vrijwilligers zoals hiervoor reeds 
werd genoemd. 
In hoofdstuk 7, hebben we de effecten van HO-1 inductie bij patiënten met het metabool 
syndroom onderzocht. Uiteraard verschilt het metabool syndroom sterk van de acute ontste-
kingsreactie opgewekt na endotoxine infusie, maar chronische ontsteking is cruciaal voor de 
ontwikkeling van de voor dit syndroom kenmerkende insulineresistentie en endotheel acti-
vatie.54,55 Om HO-1 te induceren, gebruikten we heme arginaat, een bekende HO-1 inducer 
en regulier gebruikt medicijn voor porfyrie patiënten.56 Eindpunten van deze studie waren 
o.a. endotheelfunctie gemeten middels veneuze occlusie plethysmografie en insulineresistentie 
gemeten middels euglycemische hyperinsulinemische ‘clamp’ experimenten. Tevens werd HO-1 
bepaald in het bloed en in vetweefsel.
 
Om een  adequate blootstelling aan heme arginaat te verkrijgen en daarmee HO-1-inductie 
te garanderen, kregen de patiënten twee doses met een interval van 48 uur. Zoals besproken 
induceerde heme arginaat slechts HO-1 eiwit in plasma na de eerste maar niet na de tweede 
dosis heme arginaat. Bovendien werd slechts een lichte inductie van HO-1 in vetweefsel (na 
96 uur en twee doseringen van heme arginaat) waargenomen. Wij vonden geen verschillen 
in mRNA expressie van HO-1 na 2 doseringen heme arginaat (en 96 uur). Voorts werd geen 
toename van bilirubine waargenomen. Deze gegevens spreken eerdere studies tegen welke 
een verhoging van HO-1 mRNA en eiwit niveaus op 24 en 48 uur na één enkele hemine of 
heme arginaat infusie beschreven.57,58 Echter, wanneer men deze studies in meer detail bekijkt 
valt op dat de response op hemine in de vorige studie sterk verschilde per vrijwilliger : som-
mige vertoonden een duidelijke toename van HO-1 eiwit en / of activiteit waar in sommige 
anderen de reactie minder uitgesproken was. Daarnaast vond men geen toename van CO.58 In 
de studie waarin heme arginaat werd gebruikt waren HO-1 mRNA en eiwit niveaus verhoogd 
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waarbij mRNA niveaus reeds stijgen 4 uur na infusie van heme arginaat en deze waarden bleven 
(weliswaar beperkt) verhoogd na 24 en 48 uur. Helaas beschrijven deze auteurs geen CO of 
bilirubine concentraties.57 In deze studie werd dezelfde dosis toegepast als in onze studie met 
als belangrijkste verschil dat onze patiënten tweemaal heme arginaat kregen met een interval 
van 48 uur. Mogelijk kan dit de gevonden verschillen verklaren, aangezien wij ook verhoogde 
HO-1 eiwit concentraties vinden in plasma na 48 uur maar niet na 96 uur na infusie. Helaas 
hebben we geen metingen van HO-1 mRNA niveaus na 48 uur (of eerder) en kunnen daarom 
een eerdere stijging niet volledig uitsluiten. We hebben echter geen gunstige effecten van heme 
arginaat op endotheel functie, insulinegevoeligheid en markers van oxidatieve stress kunnen 
vinden wat suggereert dat dit doseringsschema geen relevante effecten heeft op deze relevante 
eindpunten.Voorts erkennen wij de mogelijkheid dat het metabool syndroom zelf de effecten 
van heme arginaat op HO-1 expressie in ons onderzoek zou kunnen hebben beïnvloed. Interes-
sant is dat de reactie op de vasodilatator (en NO-donor) nitroglycerine juist werd verlaagd na 
blootstelling aan heme arginaat. Een effect dat we interpreteren als een gevolg van verhoogde 
heme concentraties en daarmee verhoogde oxidatieve stress en mogelijk wegvangen van NO.59 
Dit illustreert ook het dilemma bij het gebruik van heme arginaat als inducer aangezien een 
verhoogde heme concentratie de hoeveelheid oxidatieve stress vergroot, terwijl we eigenlijk 
proberen om het anti-oxidatieve vermogen van HO-1 te onderzoeken.
Tijdens het schrijven van dit proefschrift zijn er ook artikelen verschenen welke juist schadelijke 
effecten van HO-1 toonden wat geleidt heeft tot een verschuiving van de verwachtingen van 
dit enzym. Bij obesitas en het metabool syndroom wordt ontsteking beschouwd als voor-
waarde voor de ontwikkeling van insulineresistentie. In tegenstelling tot wat algemeen werd 
verwacht, bleek dat bij muizen en mensen welke werden gevoed met een vetrijk dieet of 
welke leden aan obesitas, de HO-1 concentratie een sterke onafhankelijke voorspeller was 
van insulineresistentie. Bovendien voorkwam uitschakeling (knockdown) van HO-1 de nade-
lige effecten van vetrijke voeding.60 Deze data suggereren dat juist remming van HO-1 nuttig 
zou kunnen zijn bij obesitas en het metabool syndroom. Anderzijds kan worden gespeculeerd 
dat de verbeterde resultaten van obese septische patiënten (zoals eerder beschreven in deze 
discussie) in feite verband houdt met de verhoging van HO-1 in vetweefsel en derhalve een 
mogelijke hogere tolerantie voor ontsteking bij obese patiënten met een BMI> 30 kg / m2. 
Samenvattend, is gebleken dat endotoxine en heme arginaat (deze staan beide bekend 
als krachtige inductoren van HO-1 in zowel in vitro als in dierexperimenten), in onze 
humane experimenten andere of slechts bescheiden effecten op HO-1 expressie hebben. 
Vele andere mogelijke stimuli van HO-1 zijn ofwel nog niet getest bij de mens of het ontbreekt 
aan specificiteit voor HO-1.61 Curcumine, een kruid dat op grote schaal wordt gebruikt in de 
Indiase keuken, heeft duidelijke HO-1-inducerende effecten in vitro. Echter, het effect ervan in 
vivo lijkt beperkt als gevolg van de slechte absorptie in het spijsverteringskanaal en het gebrek 
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aan meetbare HO-1-inductie na het gebruik van een hoge orale dosering.62 Gezien de data uit 
hoofdstuk 6 en 7, zou het vrijmaken van Bach1 van de promotor van HO-1 en het transport van 
Bach1 uit de celkern mogelijk de potentie voor HO-1 inductie kunnen verhogen waarmee de 
potentiële voordelen van HO-1 gemakkelijker kunnen worden benut. Recent werd aangetoond 
dat goud nanodeeltjes een verschuiving van Bach1 uit de celkern kunnen geven.63 Hoewel ook 
potentieel toxisch waren goud injecties ooit standaardbehandeling voor reumatoïde artritis 
en zodoende is er ruime ervaring met dit middel wat de toepassing ervan in humane studies 
vergemakkelijkt.64
 
Remming van HO-1 bij mensen is in het verleden toegepast in de vorm van tin meso of 
protoporfyrine en dit was effectief in het verlagen van HO-1 activiteit in pasgeborenen met 
icterus.65,66 Bijwerkingen zoals lichtovergevoeligheid maakten dat brede klinische toepassing niet 
heeft plaatsgevonden en ook hier is gebrek aan specificiteit voor HO-1 een probleem.
 
Derhalve is de klinische toepassing van HO-1 modulatie ver weg nu men vast moet stellen dat 
de regulering van HO-1 verschilt tussen mens en dier en waarschijnlijk ook tussen cellen onder-
ling. Daarnaast blijkt het induceren van HO-1 middels klassieke inductoren welke bij mensen 
bruikbaar zijn moeizaam. Bovendien suggereren recente gegevens dat dit enzym verschillende 
gezichten heeft in verschillende ziekten. Eventueel zou juist remming van HO-1 in het metabool 
syndroom gunstige effecten kunnen hebben maar dit moet blijken uit aanvullend onderzoek, 
bij voorkeur bij mensen of grotere dieren. Daarnaast is er een grote behoefte aan inducers en 
remmers die een hoge specificiteit hebben voor HO-1 en idealiter zelfs hun effecten alleen in 
doelcellen opwekken om ongewenste effecten van het manipuleren van dit veelvoorkomende 
enzym te voorkomen en de kwaliteit van HO-1 onderzoek in het algemeen te verbeteren.
Deel III: de HO-1 eindproducten bilirubine en CO in preklinische modellen en tijdens ziekte 
In hoofdstuk 8 en 9, worden de effecten van verhoogde bilirubine concentraties beschreven. 
Bilirubine wordt beschouwd als één van de krachtigste endogene anti-oxidanten in het menselijk 
lichaam.67 Oxidatieve stress wordt beschouwd als een belangrijke factor in de ontwikkeling van 
ontsteking en orgaandysfunctie bij acute ontstekingsziekten zoals sepsis68,69, maar ook bij ziekten 
geassocieerd met chronische ontsteking zoals atherosclerose en het metabole syndroom.54,55,70 
Een groot aantal klinische studies hebben aangetoond dat er een negatieve correlatie bestaat 
tussen bilirubineconcentraties en cardiovasculaire aandoeningen.71-78, hoewel anderen deze resul-
taten niet altijd konden reproduceren.79,80 Voorts zijn de anti-oxidatieve effecten van bilirubine 
ook geassocieerd met een afname van bacteriële doding door het wegvangen van door neu-
trofiele granulocyten gegenereerde reactive oxygen species (ROS).81 Zodoende zou bilirubine 
tijdens actieve infecties ook nadelige effecten kunnen genereren. Overigens lijkt dit bescher-
mende effect van bilirubine voor bacteriën slechts aanwezig bij Gram-negatieven zoals E. coli. Bij 
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Gram-positieve bacteriën zoals E. faecalis en S. aureus leidt bilirubine juist tot een verminderde 
bacteriële levensvatbaarheid. Waarschijnlijk is dit het gevolg is van een directe interactie van 
bilirubine met de bacteriële celwand.82
 
In hoofdstuk 8 worden de effecten van een atazanavir-geïnduceerde toename van bilirubine 
concentraties tijdens humane endotoxinemie besproken. Destijds was bilirubine niet beschikbaar 
voor infusie aan mensen en zodoende hebben we gebruik gemaakt van atazanavir, een HIV-1-
remmer welke bekend staat om de bijwerking hyperbilirubinemie. Atazanavir verhoogt bilirubine 
door remming van Uridine glucuronosyltransferase 1A1 (UGT1A1). Dit enzym is betrokken 
bij de conjugatie van bilirubine en remming hiervan leidt tot een toename van ongeconjugeerd 
bilirubine in het bloed. Bij ongeveer 13-16% van de bevolking heeft UGT1A1 een mutatie die 
de functie van het enzym belemmert, en zodoende een milde verhoging van bilirubine geeft, dit 
staat bekend als het Gilbert syndroom.83,84 Het grootste deel van ongeconjugeerd bilirubine bij 
mensen is gebonden aan albumine. Albumine-gebonden ongeconjugeerd bilirubine kan oxida-
tieve stress remmen op verschillende manieren. Het remt NADPH oxidase, verminderd lipide 
peroxidatie, vangt peroxyl radicalen en reactieve stikstof species (RNS).67,85,86 Deze specifieke 
markers zijn belangrijk in de ontwikkeling van orgaanfalen bij sepsis en voor atherosclerose.68-70 
Atazanavir-geïnduceerde hyperbilirubinemie verhoogde in onze studie de anti-oxidant capaciteit, 
verminderde IL-10 afgifte en voorkwam hyporeactiviteit voor de vaatverwijders acetylcholine 
en nitroglycerine na endotoxine infusie. In hoofdstuk 9, werd atazanavir toegepast met hetzelfde 
doel bij diabetes patiënten waarbij sprake is van een milde chronische inflammatie geassocieerd 
met de ontwikkeling van endotheel dysfunctie en het ontstaan van atherosclerose.87 Ook bij 
deze patiënten leidde een toename van het serum bilirubine tot een toename in antioxidatieve 
capaciteit en een verbetering van de endotheelfunctie zoals gemeten door veneuze occlusie plet-
hysmografie.Uiteraaa dkunnen de effecten van atazanavir zelf onze resultaten hebben beïnvloed. 
Hoewel onderzoek heeft aangetoond dat atazanavir,in tegenstelling tot andere HIV-remmers, 
geen negatieve invloed op de endotheel functie heeft88 en in ieder geval in vitro, de cytokine 
reactie op endotoxine niet lijkt te beïnvloeden (hoofdstuk 8), kunnen we niet uitsluiten dat ata-
zanavir zelf of eventuele metabolieten van atazanavir, onze resultaten beïnvloeden. Uiteraard is 
langdurige behandeling met atazanavir voor chronische ontstekingsziekten niet haalbaar gezien 
het feit dat dit zal leiden tot icterus, wat een ongewenst neveneffect zou zijn voor (ambulante) 
patiënten. Voor patiënten met acute ontstekingsziekten zoals sepsis, zal de bilirubine reactie 
waarschijnlijk zeer onvoorspelbaar zijn wegens veranderingen van de farmacokinetiek en directe 
effecten van ontsteking op de bilirubine concentraties.
In onze studies werd atazanavir gebruikt om het principe van hyperbilirubinemie te testen. Na 
deze veelbelovende resultaten, hebben we ons gericht op de herintroductie van bilirubine voor 
infusie voor menselijke toepassing, zoals beschreven in hoofdstuk 10. Zoals hier besproken 
werd de toediening van bilirubine goed verdragen en waren de bereikte concentraties goed 
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voorspelbaar in onze kleine groep van gezonde vrijwilligers. Helaas kon als gevolg van logistieke 
problemen geen nieuwe batch bilirubine worden vervaardigd wat verdere toepassing in bijvoor-
beeld humane endotoxinemie studies in de weg stond.
 
In hoofdstuk 12 onderzochten we het effect van het polymorfisme geassocieerd met het 
syndroom van Gilbert bij patiënten met pneumosepsis. Onze hypothese was dat verhoogde 
concentraties van bilirubine de gevoeligheid voor infecties kunnen vergroten door de effecten 
op neutrofielen en zodoende een verminderd bacteriedodend effect.81 Echter kan echter ook 
worden verondersteld dat bilirubine de bacteriële overleving bemoeilijkt, vooral in het geval van 
Gram-positieve infecties.82 Verder wilden we weten of de verhoogde anti-oxidatieve capaciteit 
bij deze patiënten weefselschade als gevolg van sepsis zou kunnen voorkomen en daarmee de 
prognose zou kunnen verbeteren. Zoals besproken in hoofdstuk 12 vonden wij een trend naar 
een verminderde incidentie van pneumosepsis bij patiënten met het syndroom van Gilbert. We 
hebben geen associaties met de ernst van de ziekte of de overleving van pneumosepsis met het 
syndroom van Gilbert kunnen vinden. Ontegenzeggelijk kent deze studie enkele tekortkomingen. 
In de eerste plaats hebben we geen bilirubine concentraties van deze patiënten kunnen meten. 
Hoewel de bilirubineconcentraties duidelijk gecorreleerd zijn met dit genotype89,90 konden we 
hierdoor niet verifiëren dat de bilirubineconcentraties daadwerkelijk hoger waren bij patiënten 
met het syndroom van Gilbert. Zodoende konden we de antioxidatieve capaciteit niet direct 
correleren aan de diverse uitkomstmaten. Bovendien heeft de studie onvoldoende ‘power’ om tot 
een goede conclusie over het effect van Gilbert syndroom op de mortaliteit te kunnen komen.
 
Concluderend suggereren deze studies dat het verhogen van bilirubine bij aandoeningen 
geassocieerd met chronische of acute ontsteking een veelbelovende strategie zou kunnen 
zijn. In de toekomst kunnen humane studies worden uitgevoerd met bilirubine voor intra-
veneuze infusie waarmee diverse interessante vragen kunnen worden beantwoord. Voor 
chronische ontstekingsziekten zoals het metabool syndroom en atherosclerose, is het van 
belang om te bepalen welke concentratie bilirubine voldoende is om oxidatieve schade te 
verminderen of voorkomen zodat wellicht icterus als ongewenst neveneffect kan worden 
vermeden. Bij het bestuderen van patiënten met het syndroom van Gilbert, zijn de biliru-
bine concentraties uiteraard veel lager dan in onze studies met atazanavir en zoals benoemd, 
zijn hier toch gunstige effecten aangetoond. Er dient te worden opgemerkt dat de ver-
minderde werking van UGT1A1ook andere effecten kan hebben (zoals een veranderde 
klaring van geneesmiddelen) die de resultaten van deze studies kan hebben beinvloed.91,92 
Voor infectieziekten, is het van groot belang om te kijken naar de effecten van bilirubine op de 
bacteriële overleving en op de functie van neutrofielen bij de mens. Men dient zich te realise-
ren dat het wegvangen van ROS mensen vatbaarder zou kunnen maken voor infecties of dat 
dit mogelijk een negatieve invloed kan hebben op het verloop van een infectie. Dit dient te 
worden uitgesloten voor interventiestudies kunnen plaatsvinden. Zoals hiervoor reeds besproken 
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suggereren onze data in pneumosepsis patiënten het tegendeel. Mogelijk is dit het gevolg van 
een afname van bacteriële levensvatbaarheid door interactie van bilirubine met de bacteriële 
celwand bij Gram-positieve verwekkers.82 Tenslotte zal verder onderzoek moeten uitwijzen of 
de overleving van patiënten wordt verbeterd indien bilirubine inderdaad in staat is de onge-
wenste nevenschade veroorzaakt door activatie van het afweersysteem bij ernstige infecties te 
voorkomen. Andere anti-oxidanten zijn in het verleden uitgebreid onderzocht in grote patiënten-
studies maar zij bereikten geen brede klinische toepassing door een gebrek aan effect op harde 
eindpunten zoals mortaliteit.93 Zoals genoemd in deze discussie, zijn goed ontworpen klinische 
studies met een homogene patiëntenpopulatie en zo mogelijk gestuurd door markers die de 
fase van het ziekteproces weergeven ideaal voor dit doel maar erg ingewikkeld te bereiken in 
de huidige dagelijkse klinische praktijk.
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dankwoord
Het is een cliché maar daarom niet minder waar: het schrijven van een proefschrift doe je nooit 
alleen. In de afgelopen jaren hebben talloze mensen een rol gespeeld op mijn weg door de 
wetenschap. Zonder volledig te kunnen zijn wil ik een aantal mensen in het bijzonder noemen.
Allereerst bedank ik de proefpersonen en patiënten die deel hebben genomen aan de studies 
die in dit boekje beschreven zijn. Zonder u allen was dit boekje er niet geweest. U voegde zich 
naar de grillen van deze onderzoekster en vertrouwde mij het belangrijkste toe wat u hebt! 
Dank u wel voor uw deelname!
Geachte prof. dr. Pickkers, beste P(.)(eter), in 2003 zocht jij een student die ‘keihard wilde werken 
en lak had aan kantooruren’ voor een wetenschappelijke stage. Tijdens deze stage mocht ik aan 
jouw hand mijn eerste stappen in de wetenschap zetten en ik heb het nooit ervaren als keihard 
werken. Uiteindelijk heeft een deel van de toen verzamelde data zijn weg gevonden naar dit 
boekje. De afgelopen jaren heb ik onvoorstelbaar veel van je mogen leren. We groeiden allebei op 
de academische ladder: ik van geneeskunde student naar bijna gepromoveerde medisch specialist, 
jij van jonge klare naar internationaal gerespecteerd onderzoeker en hoogleraar. Inmiddels heb 
jij een leesbrilletje en ben ik moeder van 2 kinderen, maar de dynamiek is onveranderd of we 
nu onderzoek doen, borrelen of in de kliniek staan: je (soms wel heel foute) humor en je immer 
klinkende: ‘komt goed!’ maken dat het een feest is om met je te werken. Ik ben ongelofelijk trots 
deel te hebben uitgemaakt van het onderzoek op de Nijmeegse IC en hoop dat de groei van 
de afgelopen jaren zich in de komende jaren verder door mag zetten. Ik heb zoveel aan je te 
danken dat een simpel ‘bedankt’ de lading absoluut onvoldoende dekt maar ik weet niet hoe ik 
het anders zou moeten zeggen. Dus daarom toch: Peter : ontzettend bedankt voor alles!! Ook 
Hillery: bedankt voor alle keren dat we bij jullie thuis welkom waren en voor je interesse in mij, 
achter elke sterke man...
Geachte prof. dr. van der Hoeven, beste Hans: inspirator, motivator, voorbeeld en soms stok achter 
de deur. Je bent een voorbeeld van een alleskunner: geweldig clinicus, inspirerend onderzoeker 
en een opleider uit duizenden! Ik voel me trots om bij de Nijmeegse fellows IC te horen en 
weet hoe jaloers anderen in Nederland soms op ons zijn. Je inspireert me om als onderzoe-
ker en als arts altijd het beste uit mezelf te halen, nooit de binnenbocht te nemen en altijd de 
menselijke maat als uitgangspunt te hebben en houden. Als jonge geneeskunde studente kwam 
ik in 2003 een handje geven om me voor te stellen en in 2006 steunde je mijn sollicitatie voor 
een opleidingsplaats en hadden we het over het vervolg op de IC. Ik vond het spannend om 
aan zo’n 10-jaren plan te gaan beginnen maar realiseerde me ook wat een gouden kans dit was! 
Met hoogtepunten maar ook hobbels op de weg komt het einde van dit traject nu langzaam 
maar zeker in zicht en ik heb geen moment spijt gehad dat ik het ben aangegaan. Het was een 
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geweldig leerzaam avontuur wat me gevormd heeft voor de rest van mijn leven. Ontzettend 
bedankt voor het in mij gestelde vertrouwen en de begeleiding in de afgelopen jaren.
Geachte prof. dr. Smits, beste Paul, ik heb erg veel waardering voor de manier waarop je leiding 
gaf aan de farmacologie-toxicologie en ondanks je drukke schema altijd beschikbaar was om 
mee te denken over mijn onderzoek. Heel veel dank daarvoor! Mede door je transfer naar de 
raad van bestuur ben je als promotor langzaam naar de achtergrond verdwenen. Ik vind het 
daarom een bijzonder grote eer dat je vandaag als plaatsvervangend rector op wilt treden en 
zodoende toch op de eerste rij zit als ik mijn proefschrift verdedig! 
Beste Frank, de aardigste moleculair bioloog en copromotor die ik me in mijn team kon wensen 
en de HO-man van Nijmegen! Ik heb genoten van je energie, je kennis, je ongekende creativiteit 
en je enthousiasme. Ook al was ik groener dan gras in het lab, met jouw uitleg en vertrouwen 
durfde ik het aan! Met dank aan jou kennis over HO en je enorme netwerk in dit onderzoeksveld 
kwamen we tot mooie resultaten. Ontzettend bedankt voor de inkijk die ik heb mogen krijgen 
in de wondere wereld van de moleculaire biologie!
Geachte prof. dr. M. Netea en prof. dr. N. Riksen, ik ben ontzettend vereerd met de namen 
van zulke zwaargewichten voorin mijn boekje. Dank voor de momenten van advies tijdens het 
promotietraject en voor het beoordelen van mijn manuscript. Prof. dr. M. Bauer, thank you very 
much for your appraisal of my manuscript and for your journey to Nijmegen to be present at my 
thesis defense. I am very proud to have an esteemed international investigator in my committee.
Alwin en Bas, de steunpilaren van Frank in het HO-groepje. Jullie waren samen met Frank het 
ideale team om deze dokter aan het pipetteren te krijgen! Jullie kennis en kunde waren de basis 
voor mijn lab ervaring. Hoewel jullie dreigden dat ik mijn artsenbul moest inleveren na mijn 
eerste gelukte qPCR heb ik jullie hulp enorm gewaardeerd! Ook Ab Bilos en Trees Jansen wil ik 
erg bedanken voor hun onmisbare hulp met diverse metingen. 
Douwe, jij liep een stukje op mij voor en daardoor kon ik leren van jouw ervaringen en deze 
voorkennis gebruiken in het endotoxine model. Ik heb erg genoten van de momenten waarop 
we konden sparren over HO, farmacologie en ethische dilemma’s. Hoewel het voor jou nu 
lastiger is om naast je drukke gezin en je drukke baan de laatste puntjes op de i te krijgen heb 
ik er het volste vertrouwen in binnenkort ook jouw boekje in handen te krijgen. Dank je wel 
voor de fijne samenwerking!
Lenny, jij begon als laatste arts-onderzoeker in het HO-groepje maar jouw proefschrift is allang af! 
Heel veel succes met je carrière als reumatoloog en veel dank voor je hulp bij mijn experimenten.
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De research IC: zonder fijne collega’s kan onderzoek doen toch ook een behoorlijk taaie bezig-
heid zijn. Door de fijne club met wie ik heb mogen samenwerken waren mijn onderzoeksjaren 
toch ook vooral heel erg gezellig! Bart, dank voor alle keren dat je het pad voor me effende in 
kliniek en onderzoek. Suzanne, dank voor al je renale input. Matthijs, onderzoeksbeest, dank voor 
je meedenken, gezelligheid en tijd. Lucas, jij vroeg me voor mijn wetenschappelijke stage of ik wel 
wist waar ik aan zou beginnen. Je kreeg gelijk maar wat heeft dat harde werken in die tijd ons 
veel gebracht! Dank je wel voor al je hulp. Mark, dank voor je interesse en gezelligheid met ons 
jonkies op je kamer, ook veel dank voor alle keren dat we mochten komen barbecueën! Met de 
monitor-IC studie heb je denk ik een gouden toekomst voor je, heel veel succes daarmee! Kim, 
na een kortstondig Utrechts avontuur kwam jij ook de kelder bevolken en inmiddels is ook jouw 
boekje af. Dank voor je gezelligheid! Jenneke, collega in Den Bosch en in Nijmegen, dank voor de 
fijne samenwerking en veel succes in je verdere loopbaan bij de vasculaire geneeskunde! Benno, 
Jonne, Lisanne, Lex en Eline, jullie gaven met jullie technische input nieuw elan aan onze afdeling. 
Inmiddels is jullie aanwezigheid onmisbaar geworden. Dank jullie wel! Jelle Zwaag: jij verdient een 
speciale vermelding als ex-student: je hulp bij de atazanavir studie zorgde ervoor dat ik overeind 
bleef. Je was er altijd, ook op de meest onmogelijke uren en verrichtte alle mogelijke klusjes met 
groot enthousiasme. Van tennisballen tot Michael Jackson, ik denk met veel plezier terug aan 
die tijd op H35! Heel veel dank en heel veel succes met je eigen promotietraject! Dorien: onze 
eerste kennismaking was wat bijzonder maar niet minder gezellig! Ik ben blij dat je op de IC bent 
blijven hangen en daar nu prachtig onderzoek doet. Dank voor de fijne samenwerking! Esther en 
Rebecca, ook jullie stoomden door van student naar inmiddels ervaren onderzoeksters, dank 
voor jullie gezelligheid en betrokkenheid en veel succes met de afronding van jullie projecten. 
Marloes, Paul en Annelies, op jullie kamer mocht ik mijn laatste (best heftige) onderzoeksjaar 
doorbrengen. Jullie leefden mee met mijn ups en downs en waren er als het allemaal even 
tegenzat. Heel veel dank daarvoor! Roel en Roger, ook jullie wil ik bedanken voor de fijne 
samenwerking. En last but not least: Jelle Gerretsen: ik moest in het begin even wennen aan de 
keiharde beats uit jouw koptelefoon en de chaos op je bureau, maar wat heb je jezelf onmisbaar 
gemaakt voor onze afdeling! Altijd bereikbaar voor overleg en altijd bereid om op de kortst 
mogelijke termijn alle mogelijke metingen voor ons te doen! Dank je wel! 
Ook de anderen die als student hebben bijgedragen aan mijn onderzoek: Els Rengers, Laura Cox 
en Maaike Fenten wil ik hartelijk bedanken voor hun inzet en gezelligheid.
Onze researchverpleegkundigen verdienen zeker ook een bijzondere vermelding. Tijdens mijn 
stage en mijn promotieonderzoek heb ik mogen samenwerken met jullie team in verschillende 
samenstellingen maar altijd stonden jullie klaar om ons te helpen waar jullie konden. Jullie zijn 
absoluut onmisbaar voor het onderzoek op de IC. Tijn, Olof, Leen, Aarnout, Hetty, Marieke, 
Ingrid, Chantal, Hellen, Noortje en Henk: heel veel dank! Yvonne, jij kwam als secretaresse het 
team ondersteunen en bent een ongeëvenaarde spin in het web geworden: bedankt voor alles!
Dankwoord, C.V., Publicatielijst
 257
Rachel, Sjoukje, Nelly en Jennie, ook jullie weten als geen ander hoe je iemand werk uit handen 
kunt nemen. Veel dank voor jullie inzet!
Dr. Paetrick Netten, dr. Jaap Beutler, dr. Watske Smit,prof. dr. Jacqueline de Graaf, prof. dr. Jan Smit 
en dr. Gerald Vervoort, mijn opleiders bij de interne geneeskunde, ik dank jullie voor de begelei-
ding in de kliniek en de moeite die jullie steeds weer nemen om jonge ambitieuze dokters zoals 
ik de ruimte te geven om onderzoek te kunnen doen. Ook alle andere collega’s bij de interne 
geneeskunde wil ik danken voor de prettige samenwerking.
Stafleden, fellows, arts-assistenten, verpleegkundigen en andere medewerkers van de intensive 
care: jullie inzet is onontbeerlijk voor de goede kwaliteit van onze IC en de fellowopleiding in 
Nijmegen. Dank jullie wel voor de fijne samenwerking in deze ‘intensieve’ tijd. Anne-Miek Broods: 
dank je wel voor je interesse, flexibiliteit en je hulp bij mijn onderzoek en mijn nogal rumoerige 
opleidingsschema! 
Alexander Rennings en Fokko Nagengast wil ik bedanken voor het fungeren als onafhankelijk 
arts bij onze experimenten.
Beste Evelien, jij tekende voor de layout en de kaft. Jouw creatieve vertaling van mijn verhalen 
over onderzoek en kliniek paste voor mij als gegoten! Dank je voor je enorme inzet en flexibiliteit.
Hedwig en José, mijn paranimfen. Vriendinnen van het allereerste blok geneeskunde. Ondanks 
de wat rumoerige start van onze werkgroep zijn we allemaal toch nog redelijk goed terecht 
gekomen! Dank jullie voor jullie vriendschap in de afgelopen jaren en voor jullie hulp in de 
aanloop naar deze promotie. Jullie gingen me reeds voor in het moederschap, het afronden 
van jullie promotie en het afronden van jullie opleiding tot medisch specialist en ik ben dan ook 
supertrots dat jullie vandaag aan mijn zijde staan!
Lieve Haantjes, ondanks dat we in alle windrichtingen zijn uitgevlogen zijn jullie me heel dierbaar. 
Alle avonden in de kroeg, zeilweekendjes, skivakanties en avondjes Guus zorgden ervoor dat de 
boog ook kon worden ontspannen. Dank jullie wel voor alles!
Lieve familie en vrienden, jullie kan ik niet allen bij naam noemen maar ook jullie wil ik graag 
bedanken voor jullie steun en interesse in de afgelopen jaren.
Lieve Mariëtte, wat een geluk heb ik met mijn schoonmoeder! Wat ben ik je dankbaar voor je 
gezelligheid, gastvrijheid en interesse in mij en daarnaast voor alle hulp met ons gezin in de afgelo-
pen jaren. Lieve Jac, ik herinner me de glinstering in je ogen toen ik, gezeten aan je ziekenhuisbed, 
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je uitlegde dat artikelen publiceren ook een soort verkopen is. Je zag er ogenblikkelijk de charme 
van in! Wat vind ik het jammer dat je er niet meer bent maar wat ben ik dankbaar dat ik je heb 
mogen leren kennen en van je kijk op het leven heb kunnen leren.
Lieve Harm, Christel, Guido en Marlies, wat is het een cadeau als je met je partner ook een 
heel gezellige familie erbij krijgt! Hoewel we allemaal heel andere dingen doen waren jullie altijd 
geïnteresseerd in mijn werk en onderzoek. Dank jullie wel daarvoor! 
Lieve papa en mama, dank jullie wel voor alles! Van een couveuzekindje naar wie ik nu ben: jullie 
hebben me gesteund en de ruimte gegeven om me te ontwikkelen op allerlei vlakken. Altijd een 
fijne basis thuis en altijd het vertrouwen dat het me wel zou lukken (ook als anderen het niet 
hadden), maar ook altijd de ruimte om fouten te mogen maken. Het zijn lessen die ik ook mijn 
kinderen hoop mee te geven en die onontbeerlijk waren voor (onder andere) dit boekje. En 
wat is het een feest om jullie nu te zien in de rol van opa en oma! Ook jullie hulp bij de opvang 
van onze kindjes is af en toe goud waard. En papa: jij je elfstedenkruisje, ik mijn proefschrift oké? 
Die 200 km schaatsen is me echt te ver! ;-)
Lieve Joop: broertje! Wij hebben allebei een bijzonder pad afgelegd. Ik ben trots op de soms 
originele keuzes die je maakt en de manier waarop je in je leven je eigen route zoekt. Al je 
avonturen brachten je succes en geluk in de liefde. Ik hoop dat je het avontuur blijft zoeken, ook 
nu je een gezin hebt, omdat het is wie jij bent. Ik wil je bedanken voor je interesse en hoop dat 
onze gezinnen elkaar ondanks de afstanden in de komende jaren toch vaak blijven ontmoeten. 
Lieve Suna, dank je voor de geweldige aanvulling die je bent in onze familie en voor je interesse 
in mijn onderzoek. 
Lieve Thomas en Aimée, van de vele rollen die ik in de afgelopen jaren heb mogen vervullen 
is die van moeder met afstand de allermooiste. Dank jullie wel dat jullie mij leerden wat in het 
leven het allerbelangrijkste is! 
Lieve Gijs, mijn liefste lief, wat ben ik trots op jou, op ons twee en op ons gezin. Jouw rol in de 
totstandkoming van dit proefschrift is groter dan ik in een paar zinnen uit kan drukken. Dank je 
wel voor wie je bent en wat je doet en dankjewel dat je mij de ruimte gunt om dit allemaal te 
doen. Ik hou van je!
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curriculum vitae
Mirrin Dorresteijn werd op 20 maart 1981 geboren in Utrecht. Na haar V.W.O. diploma aan het 
G.S.G. Lingecollege te Tiel werd zij aanvankelijk uitgeloot voor de studie geneeskunde. Hierna 
heeft zij gedurende een jaar met veel plezier in de thuiszorg gewerkt. In het jaar 2000 mocht zij 
alsnog beginnen met de studie geneeskunde in Nijmegen. In 2003 liep zij een facultatieve stage 
op de cardiologische intensive care van het Universiteitsziekenhuis van Charles University in 
Praag, Tsjechië. Hier werd de liefde voor de intensive care geneeskunde geboren. In 2004 werd 
in het kader van de wetenschappelijke stage voor geneeskunde onderzoek verricht bij prof. dr. 
P. Pickkers. Deze stage leidde tot een drietal publicaties waarvan er een in dit proefschrift is 
opgenomen. Met het stageverslag werd onder andere de Universitaire Studieprijs Medische 
Wetenschappen van de Radboud Universiteit Nijmegen gewonnen.
 In 2007 behaalde zij de artsenbul en startte zij met de opleiding tot internist in het Jeroen Bosch 
Ziekenhuis en Radboudumc onder leiding van dr. P. Netten en prof. dr. J. de Graaf. Dankzij het 
verwerven van een AGIKO stipendium van ZonMw kon de opleiding gedurende 3 maal 1 jaar 
worden onderbroken voor het verrichtten van het wetenschappelijk onderzoek zoals beschre-
ven in dit proefschrift. In 2013 startte zij met haar fellowship intensive care geneeskunde onder 
leiding van prof. dr. J.G. van der Hoeven. Medio 2017 zal zij haar opleiding tot internist-intensivist 
voltooien. 
Mirrin woont samen met Gijs Kooijmans en hun twee kinderen Thomas (2013) en Aimée (2015). 
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